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ABSTRACT
Integrins are heterodimeric transmembrane proteins present on virtually every cell,
which maintain and control cell-cell and cell-substratum adhesion. Through this
adhesive property, integrins can govern aggregation, cell polarity and migration.
Several human diseases demonstrate the importance of integrins in normal
physiological function: inappropriate platelet integrin activation is responsible for
myocardial infarctions and cerebral vascular diseases; while leucocytes require
integrin activation for leucocyte migration during inflammation. The understanding
of the function and regulation of integrins therefore has important therapeutic
implications.
Essential to the function of integrins is their ability to modulate the affinity for
binding ligand through conformational change. Platelet aggregation requires prior
activation of the anb(33 integrin to bind fibrinogen. This platelet integrin is a model
for the understanding of the mechanisms regulating affinity modulation. A high
affinity state-specific antibody, PAC1 has facilitated the analysis of oqibP3 activation.
Intracellular signal transduction pathways elucidated through the use of the PAC1
antibody have shown that the integrin cytoplasmic domains are required for affinity
modulation, in a process termed "inside-out signalling".
In this thesis I have sought to understand the mechanism by which H-Ras and its
effectors modulate integrin affinity. H-Ras is a member of the Ras superfamily of
small GTP binding proteins. Expression of the constitutively active variant of H-Ras
(Ras G12V) within an integrin affinity reporter system (aP-py cells) reduced integrin
affinity (suppressed integrin). Ras effector mutants revealed that integrin suppression
is mediated by Raf-dependent and Raf-independent signalling pathways. Raf-
independent signalling pathways activated by Ral-GEFs and PI3-kinase were not
responsible for integrin suppression. An active variant of R-Ras (R-Ras G38V)
reversed integrin suppression by both Raf-dependent and -independent pathways,
indicating that these pathways may converge at a point proximal to the integrin.
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Raf initiates a protein signalling cascade leading to ERK activation that is
responsible for many of the Ras/Raf-dependent biological functions. However, Raf-
dependent integrin suppression was insensitive to MEK inhibition with the
PD098059 compound. A novel Raf mutant (T481A) that fails to bind to MEK was
also capable of mediating integrin suppression in the absence of ERK activation.
Surprisingly, Raf-BxB T481A-mediated integrin suppression was sensitive to
expression of MKP-1. Taken together it is proposed that Raf may mediate integrin
suppression via a MEK-independent pathway that may utilise a member of the MAP
kinase superfamily.
In conclusion, integrin suppression by Ras is mediated by both Raf-independent and
dependent pathways. Signalling by Raf may utilise components other than those
present in the classical Ras to ERK protein cascade.
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INTRODUCTION: CHAPTER 1
Integrins and Integrin Affinity
Integrins are cell surface receptors that bind to extracellular matrix (ECM) proteins.
Much of the initial information regarding integrins was largely a result of studies
performed on three main groups of proteins: the fibronectin receptor on chick
fibroblasts and osteosarcoma cells, platelet glycoprotein GPIIb-IIIa and the leucocyte
antigens (LFA-1, Mac-1 and the VLA antigens). These proteins were shown to be
composed of two non-covalently attached subunits, termed a and (3. Peptide
sequencing and cloning of these receptor subunits revealed sequence homology
between the a and p subunits from these different protein groups. The term
"integrin" was used as a generic term to describe this family of adhesion receptors
and the aP nomenclature adopted to simplify and classify the subunits according to
their sequence identity (Hynes, 1987; Ruoslahti and Pierschbacher, 1987).
1.1 Multiple integrin subunits and ligands
All integrins are composed of an alpha and beta subunit non-covalently attached on
the cell surface. Since the initial reviews relating to integrins in which three P
subunits were described, the number has increased to 18a and 8P subunits.
Sequencing of the human genome suggests that there may be as many as 24a and 9P
subunits. Mathematically, these subunits could associate to produce more than 100
different aP heterodimers. The in vivo pattern of aP heterodimerisation appears to be
much more restricted, with only 24 different receptors identified (Danen and
Yamada, 2001; Plow et al., 2000). Several a subunits, such as anb, associate
exclusively to a single P subunit; in contrast other a subunits such as av are capable
of associating with several p subunits. These aP heterodimers allow the integrins to
be classified into subgroups according to their P subunit interactions (Table 1.1).
The complexity of ap heterodimers is further expanded by alternative splicing of
1
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integrin subunits. Splice variants have been described for both a and p subunits, with
changes in both the extracellular and the intracellular domains (de Melker and
Sonnenberg, 1999).
Many of the integrins were described prior to the a.p nomenclature classification of
integrins. The platelet integrin anbP3 is often referred to as GPIIb-IIIa and several Pi
integrins have either a platelet glycoprotein (GP) nomenclature or are known as VLA
(very late after activation) antigens. Only the P2 integrins are routinely referred to in
the literature by their earlier names: (XlP2- lymphocyte function associated antigen-1
(LFA-1) and o,mP2 - macrophage-1 receptor (Mac-1) (see Table 1.1).
Integrins are expressed on virtually every mammalian cell and expression profiles of
integrins are just as complex as their heterodimer interactions. The Pi integrins are
the most broadly expressed, whereas P2 integrin expression is restricted to leucocytes
(Springer, 1990). Of the P3 integrins; anbP3 is primarily found on platelets, but
expression has also been observed in cells of the megakaryocyte lineage and some
tumours; while avP3 has a much broader expression profile including platelets,
endothelial cells and monocytes (Smyth et al., 1993).
1.1.1 Evolution of integrins
Integrin subunits have been identified in several organisms ranging from sponges,
corals, nematodes and echinoderms to mammals (Hynes and Zhao, 2000). The
process of integrin-mediated adhesion therefore appears to be evolutionarily
conserved. Studies performed in C. elegans, Drosophila and vertebrates show that
each has a basic set of ECM-binding integrins, one laminin-specific and one
recognising an Arg-Gly-Asp (RGD) motif, that have been preserved throughout
evolution. Expansion from this basic set of integrins and evolution of new integrins
has occurred in vertebrates giving rise to the large integrin number within the human
genome (Brown, 2000).
2
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Table 1.1 Integrin heterodimers and their ligands.
Subunits Previous Names Fn Lam Coll Fg Vn Other
Pi Integrins
a,Pi VLA-1, CD41a/CD29 X X
a2p. VLA-2, CD41b/CD29 X X X Thr
a3p. VLA-3, CD41c/CD29 X X X VCAM-I
a4Pi VLA-4, CD4Id/CD29 X
a5p. VLA-5, CD41e/CD29 X X X






avPi CD51/CD29 X X
p2 Integrins
C*LP2 LFA-1, CDlla/CDI8 ICAM 1-5
aMp2 Mac-1, CD1 lb/CD18 X ICAM-1,
Fx, C3bi
axp2 P150/95, CD1 lc/CD18 X C3bi
CDP2 VCAM-1
P3 Integrins
0tlIbP3 GPIIIb/IIa, CD41/CD61 X X X X
Disintegrins,
vWF, Thr










X denotes an interaction. Abbreviations: Fn - fibronectin; Lam - laminin; Coll -
collagens; Fg - fibrinogen; Vm - vitronectin; Thr - thrombospondin; Fx - factor X;
vWF - von Willebrand factor; BM - basement membrane and Bs - bone sialoprotein
(de Melker and Sonnenberg, 1999; Hynes, 1992; Plow et al., 2000).
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1.1.2 Integrin ligands
Integrins were initially described by their ability to bind to extracellular matrix
proteins (fibronectin, laminin, collagen and vitronectin) and mediate cell-substratum
adhesion. Other ligands such as fibrinogen, a soluble plasma protein and integral
membrane proteins (ICAM-1/2 and VCAM-1) mediate cell-cell adhesion.
Similar to the a,p heterodimer interactions, individual integrins can bind multiple
ligands and individual ligands are recognised by several integrins. Put simply this
allows a cell to bind to numerous ligands on the basement membrane and on
neighbouring cells. The interactions between integrins and ligands are summarised in
Table 1.1.
Fibronectin (Fn) is a heterodimeric glycoprotein of approximately 250kDa.
Alternative splicing of the fibronectin gene in humans can generate 20 different
isoforms that dimerise to form the final product. Fibronectin is an extended and
flexible molecule composed of multiple globular domains of three repeat sequences
known as type I, II and III FN repeats. Plasma and cellular fibronectin are both
substrates for fibronectin fibril and matrix formation in an integrin-dependent
cellular process. Fibronectin has extensively been used as a prototype integrin ligand
in the study of integrin-mediated adhesion and integrin signalling (Romberger, 1997)
Laminin is a heterotrimeric glycoprotein present in the basement membrane. The
three laminin subunits form a cruciform structure that is held together with
disulphide bonds. Isoforms of the laminin subunits allow the formation of different
laminin molecules that display distinct tissue expression patterns. Within the
basement membrane, laminin can bind to other ECM proteins including collagen IV,
heparan sulphate proteoglycans, entactin and to itself. Laminin has a variety of
biological activities including cell adhesion, growth, migration, neurite outgrowth
and tumour metastasis (Malinda and Kleinman, 1996).
Fibrinogen is a soluble plasma protein of 340kDa. Synthesised primarily by
hepatocytes, this heterotrimer forms a symmetrical protein held together by 29
4
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disulphide bonds. Fibrinogen can lead to cross-linking of integrin receptors (0.1^3)
essential during the formation of a fibrin clot (Herrick et al., 1999).
Integral membrane proteins also serve as integrin ligands mediating cell-cell
adhesion. These ligands are part of the immunoglobulin superfamily and include the
ICAMs (Ig-like cell adhesion molecule) and VCAM-1 (vascular cell adhesion
molecule). The extracellular domain is composed of immunoglobulin-like repeat
units that vary in number between the different ligands (Petruzzelli et al., 1999).
Within these large ligand macromolecules, specific recognition sequences have been
identified that are crucial for ligand binding. The Arg-Gly-Asp (RGD) sequence
present in fibronectin is essential for binding to the fibronectin receptor (X5P1 and
soluble RGD peptides can inhibit fibronectin-integrin binding. The presence of RGD
sequences in multiple ligands suggests that ligand specificity may require other
recognition sequences. Recognition sites other than RGD have been identified in
both fibronectin and fibrinogen (Plow et al., 2000).
1.2 Integrin structure
Integrins are a heterodimer composed of an a (150-200kDa) and P (90-ll0kDa)
subunit. Each contains a large N-terminal extracellular domain, a single
transmembrane region and a short (<50 amino acids, except p4, >1000) cytoplasmic
region. The integrin subunits interact to form the integrin heterodimer; sequence and
structure predictions reveal several domains within the a and P subunits (Hynes,
1992).
Electron microscopy of the anbp3 integrin revealed a molecule with a globular
oblong head and two rod-like tails (Carrell et al., 1985). Most of the proposed
integrin structures have relied on primary sequence analysis and structure predictions
using homology to proteins to which tertiary structure has been solved: Figure 1.1
shows a schematic representation of the domain structure of an integrin dimer.
The N-terminal region of all a subunits contains a seven-fold repeat region, encoding
4 p-sheets that come together in a structure known as a P-propeller (Springer, 1997).
5




































With A-Domain Without A-Domain
Figure 1.1 Schematic of integrin structure.
(A) Linear diagram of the domain structure of the a and (3 subunits. The cleavage
site indicates where the post-translational cleavage may occur with some a subunits.
The aA-domain is inserted between repeat II and III of the P-propeller structure. (B)
Modular structure of a 3-D representation of an integrin with and without an aA-
domain (modified from Humphries 2000).
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Within repeats number 4-7 there are sequences (EF-hand homology) that display
divalent cation binding properties.
Alpha subunits eg, 0C2, oil, ccm and ax posses an additional A-domain between repeat
2 and 3, which contains a dinucleotide binding fold of P-strands and surrounding a-
helices (Lee et al., 1995a). Adjacent to the p-propeller domain are several modules
made up of p-sheets, known as the thigh and calf-domain. Some a subunits are post-
translationally cleaved prior to the transmembrane region to yield an N-terminal
heavy and C-terminal light chain.
The P subunits also contain an A-domain-like region that contains several metal ion-
dependent adhesion sites (MIDAS). Connecting the A-domain and the EGF-like
region is the hybrid domain and a module called the PSI region. Four cysteine-rich
EGF-like regions link the extracellular region to the transmembrane sequences
(Flumphries, 2000).
The ligand binding pocket has been mapped to the interface of the a subunit P-
propeller domain and P subunit A-domain (Figure 1.2A) (Humphries, 2000). In
integrins containing an aA-domain, the major ligand binding sites are located within
the aA-domain rather than the p-propeller region. The crystal structure of the
extracellular segment of avP3 revealed that the aP interface was very similar to that
of the Ga-Gp interface of G-proteins (Xiong et al., 2001). G-proteins undergo major
conformational changes upon GTP hydrolysis; so possibly changes at the aP
interface may explain conformational changes within the integrin during ligand-
binding/activation. The presence of a metal-ion binding site in the putative ligand
binding region may explain observations relating to the regulatory effects of metal
ions on ligand binding (Figure 1.2B).
The short cytoplasmic domains link the integrins with the cytoskeleton, either
directly or via adapter proteins (talin and a-actinin). The subunits also contain
several phosphorylation sites for protein kinases. The large cytoplasmic domain of P4
localises this integrin to hemidesmosomes in epithelial cells where it interacts with
intermediate fdaments.
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Figure 1.2 Integrin ligand binding sites.
(A) Modular representation of the ligand binding sites in a 3-D integrin model
(Humphries 2000). (B) Ligand binding sites within an avp3 representation viewed
from the top of the head (tails lying in the back). At the ap interface, ligand binding
sites (red, green and magenta) are present on both subunits. Residues important for
the MIDAS site are shown in yellow (Xiong et al., 2001).
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1.3 Cellular role of Integrins
Integrins were identified as receptors for ECM proteins. The link between ECM
proteins and the cytoskeleton by integrins allows cell adhesion to the basement
membrane. Adhesion to the ECM occurs at specialised sites within the plasma
membrane called focal adhesions or focal contacts. Focal adhesions are large
adhesion contacts located at the ends of actin stress fibres, whereas focal contacts are
much smaller and located at the tips of extending filopodia and lamellipodia (Petit
and Thiery, 2000). These sites are characterised by clusters of ligand-occupied
integrins linked to actin bundles by large multimeric protein complexes.
These cell-matrix adhesions are far from simple contact sites between the cell and the
ECM - they play essential biological roles during cell migration, cell growth and cell
survival. The Pi tail has been shown to be essential for integrin localisation to focal
adhesions (Hayashi et al., 1990; Solowska et al., 1989). In contrast, a tails may
regulate the ability of ap heterodimers to localise to these sites (Briesewitz et al.,
1993; Ylanne et al., 1993). Considerable effort has been directed at the
understanding of focal adhesion formation and their role in biological processes.
Focal adhesion formation is initiated by ligand-induced integrin clustering and is
summarised in Figure 1.3 (Miyamoto et al., 1995a; Miyamoto et al., 1995b; Petit and
Thiery, 2000). Conformational changes have been observed in the cytoplasmic
domain of anbP3 upon ligand binding, suggesting that following ligand binding new
protein interactions may occur (Leisner et al., 1999). Integrin clustering requires Rho
activity (Hotchin and Hall, 1995; Ridley and Hall, 1992), which may be mediated by
integrin-ligand binding (Ren et al., 1999). Following integrin clustering, actin-
binding proteins (talin, filamin and a-actinin) (Critchley, 2000; Miyamoto et al.,
1995a; Miyamoto et al., 1995b) and focal adhesion kinase (FAK) complex with
integrin cytoplasmic tails (Hanks et al., 1992; Schaller et al., 1992). Ligand-induced
activation of FAK at the forming focal adhesion leads to autophosphosphorylation
and the formation of a SH2 binding domain (Schaller et al., 1992; Schaller et al.,
1994). Recruitment of Src kinase to the focal adhesion and subsequent tyrosine
9










Figure 1.3 Focal adhesion formation.
Matrix binding to integrins promotes clustering and binding of cytoskeletal adaptor
proteins, FAK and actin. FAK activation allows Src binding; subsequent tyrosine
phosphorylation generates binding sites for several adaptor proteins leading to
activation ofmultiple signalling pathways.
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phosphorylation of FAK leads to the formation of SH2 and SH3 binding sites for
several signalling adapter/docking proteins (Giancotti and Ruoslahti, 1999).
Recruitment of pl30cas/crk (Vuori et al., 1996) and Grb2/SOS (Schlaepfer et al.,
1994) results in the activation of Rac/JNK and Ras signalling pathways respectively.
Grb2/SOS is also recruited to focal adhesions by the adapter protein She via Fyn
kinase (Wary et al., 1996). Active FAK may also activate the phosphoinositide 3-OH
kinase (PI3-kinase) pathway (Chen et al., 1996). Signalling pathways activated in
response to integrin-ligand binding (outside-in signalling) are essential for the effects
on cell cycle control and cell survival (see below).
The link between the actin cytoskeleton and the extracellular matrix by integrins
generates tension within the cell (Horwitz and Parsons, 1999). The adhesive strength
has been mathematically related to cell migration rates. The rate ofmigration may be
plotted as a bell-shaped curve against the strength of cell adhesion: lack of sufficient
traction, with poor cell adhesion, results in low migration rates; migration reaches an
optimum as cell adhesion increases, due to increases in cell traction; beyond this
point, strong cell adhesions fail to retract, thereby reducing migration rates again
(Holly et al., 2000; Palecek et al., 1997).
1.3.1 Control of cell cycle by integrins
The multiple biological effects attributed to integrin-ligand binding are a
consequence of the signalling molecules recruited to focal adhesions. Signals
emanating from focal adhesions can co-operate with growth factor receptor
signalling pathways for cell cycle progression. Optimal growth factor signalling in
many cells is only observed in adherent cells. The avP3 integrin can associate with
the PDGF, insulin and VEGF receptors while some Pi integrins interact with the
EGF receptor (Giancotti and Ruoslahti, 1999). Such complexes of integrins and
receptors may be required for optimal mitogenic signal pathway activation (Kumar,
1998; Miyamoto et al., 1996). Direct activation of Ras and PI3-kinase pathways at
the focal adhesions also contributes to cell cycle progression. Upregulation of cyclin-
D1 (Fang et al., 1996) and down-regulation of Cdk2 inhibitors (Zhu et al., 1996) are
11
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associated with anchorage-dependence in progression through the G1 phase of the
cell cycle.
1.3.2 Role of integrins in cell survival
Epithelial and endothelial cells that detach from the extracellular matrix undergo
apoptosis in a process termed anoikis (Frisch and Francis, 1994; Meredith, Jr. et al.,
1993). This is a mechanism to ensure that cells displaced from their natural
environment are removed before they colonise another area. Similar to cell cycle
control, anoikis displays integrin specificity. Anoikis of CHO cells was inhibited in
cells expressing (X5P1 but not avPi on a fibronectin matrix (Zhang et al., 1995). Cell
signalling from focal adhesions appears to provide the anchorage-dependent cell
survival signals. Activation of the PI3-kinase/Akt pathway by either FAK or Ras
appears to be important in the cell survival signal (Khwaja et al., 1997) and may
mediate the anchorage-independent survival. CHO cells expressing asPi display an
increase in bcl-2 expression on a fibronectin matrix, while avPi cells did not and the
cells underwent apoptosis. Thus modulation of bcl-2 expression may provide an
alternative cell survival signal (Zhang et al., 1995). The balance between cell cycle
progression and apoptosis is reflected in a balance between ERK and JNK activity,
with loss of ERK activity in detached cells pushing the balance towards apoptosis
(Xia et al., 1995). Pathways regulating cell cycle progression and cell survival by
integrin-mediated adhesion are summarised in Figure 1.4.
1.3.3 Importance of integrins and ligands in vivo
In vitro experiments have revealed that integrins play an important role in many
cellular processes. Many groups have studied the in vivo role of integrins and their
ligands, in particular with knockout animals. Most of the ECM proteins and integrin
subunits have been mutated by homologous recombination (reviewed in Hynes
1996). Ablation of the fibronectin gene produces early embryonic lethality,
suggesting that fibronectin is essential during development (George et al., 1993). In
contrast, knockouts of fibrinogen, thrombospondin and vitronectin produced viable
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Figure 1.4 Integrin and growth factor receptor signalling.
Signalling pathways activated by integrins and growth factors are shown to control
cell cycle progression and mediate cell survival. Signalling events that are well
characterised are shown by bold arrows (Giancotti and Ruoslahti, 1999; Kumar,
1998).
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animals with no obvious developmental defects (Hynes, 1996). The failure to detect
developmental defects may reflect that gene specific systems have yet to be
identified or that they may play more important roles in the adult animal.
Loss of the Pi subunit causes embryonic lethality; this is not surprising as expression
of more than 10 different integrin heterodimers is lost (Fassler and Meyer, 1995;
Stephens et al., 1995). Losses of individual Pi-associating a subunits are mostly
lethal except for the eg subunit. Mutations of the other integrin subunits reveal that
each have specific in vivo roles. This is demonstrated by the different fibronectin
integrin knockouts: each produces different phenotypes and none are severe as the
fibronectin-null phenotype. These experiments suggest that the different fibronectin
integrins each have independent non-overlapping functions during development
(Hynes, 1996).
1.4 Integrins and disease
Knockout studies have revealed that integrins play important roles during
development. Human diseases show that loss of proper control of integrin expression
or signalling can have profound effects on disease pathology. Rare genetic disorders
affecting integrin expression have been described in humans.
Leucocyte adhesion defiency-1 (LAD-1) results from a loss of P2 expression.
Germline mutations within the P2 gene disrupt a,p heterodimer formation and result
in a loss of LFA-1, Mac-1, pl50, p95 and aofc integrin expression (Anderson and
Springer, 1987). The disease is characterised by recurrent soft tissue infections,
primarily a result of the absence of neutrophil infiltration at the site of tissue injury,
since leucocyte infiltration requires P2 integrin-mediated adherence to endothelia (see
below). Glanzmann thrombasthenia results from the loss of the anbP3 integrin on
platelets. The absence of anbP3-mediated fibrinogen crosslinking, essential for clot
formation, results in excessive bleeding of gums, cuts and wounds (Hogg and Bates,
2000). Mutations have been observed both in the anb and the P3 subunits (Newman
et al., 1991). Mutations in which anbp3 fails to crosslink fibrinogen, with normal
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integrin expression, have also been described and are associated with integrin
activation (see below). These two disorders highlight two important processes
observed with human disease, cell recruitment and platelet aggregation.
An increase in monocyte and T-lymphocyte recruitment is observed in the formation
of atherosclerotic plaques in a p2-dependent process. The release of several cytokines
increases recruitment of smooth muscle cells and further monocyte infdtrates into the
plaque. Increases in matrix deposition, foam cell formation and cellular infiltration
leads to expansion of the plaque. Rupture of the plaque or endothelial damage causes
platelet aggregation to protect the exposed endothelium. Aggregation occurs in an
cqibP3-dependent process, leading to thrombus formation. Excessive aggregation can
cause further complications with embolism and blockage of small blood vessels
(Clemetson and Clemetson, 1998; Hillis and Flapan, 1998).
Asthma is characterised by excessive eosinophil recruitment and degranulation
within the lung (Bousquet et al., 1990; Wardlaw, 1999). Eosinophil recruitment is
facilitated by increases in both CC4P1 and ICAM-1 on the bronchial epithelium and p2
integrins on eosinophils (Hillis and MacLeod, 1996).
Excessive matrix deposition is observed in lung granulomas; this increased
fibronectin matrix assembly is associated with an increase in a2Pi and OC5P1
expression (Roman et al., 1995).
Anchorage independence is a hallmark of tumour cell growth. Mutations in several
genes associated with integrin signalling have been observed in tumour cells
allowing anchorage independence. Changes in the integrin expression profile have
also been observed in many tumours (Varner and Cheresh, 1996). Expression of 015P1
is reduced in transformed cells (Plantefaber and Hynes, 1989). Overexpression of
a.5pi in CHO cells increased fibronectin matrix assembly and inhibited tumour
growth when injected into nude mice (Giancotti and Ruoslahti, 1990). Loss of a2Pi
correlates with the transformed phenotype in breast epithelial cells and ectopic
expression of a2pi in these cells can suppress growth (Zutter et al., 1995). An
increase in ay expression is associated with metastatic melanoma cells and an
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inhibitory av antibody prevented melanoma tumour growth in nude mice (Felding-
Habermann et al., 1992; Mitjans et al., 1995). Changes in the integrin profile also aid
tumour cell invasion and upregulation of otvp3 is required during tumour
angiogenesis (reviewed in Varner 1996). These specific changes in the cell-integrin
profile facilitate tumour cell transformation and metastasis.
1.5 Modulation of ligand binding strength
Ligand-integrin specificity is determined by interactions within the ligand binding
site of the integrin. The ability of an integrin to bind to its ligand also depends on the
activity of the integrin itself. Integrin "activation" is a process by which integrin-
ligand binding strength is increased and cell adhesion to ligand is modulated. Upon
activation the platelet integrin anbp3 is capable of binding fibrinogen leading to
platelet aggregation. Likewise, activation of P2 integrins on non-adherent leucocytes
allows the rapid adhesion of these cells to ligand. Activation is mostly mediated by
intracellular signals acting upon the integrin in a process termed "inside-out
signalling" (Bazzoni and Hemler, 1998).
Two non-exclusive mechanisms effect integrin activation, affinity modulation and
avidity modulation (Figure 1.5). Affinity modulation is simply explained as a
conformational change within the integrin enabling ligand binding with a higher
affinity. Avidity modulation is mediated by integrins clustering within the plane of
the plasma membrane to generate concentrated areas of increased integrin activity.
The relative contribution that each mechanism plays during integrin activation is
integrin-dependent.
1.5.1 Integrin avidity modulation of p2 integrins
Activation of the P2 integrins is characteristic of avidity modulation with studies
concentrating on LFA-1 (o.lP2)- Leucocyte adhesion to endothelia, antigen
presenting cells and cytotoxic T-cell target cells requires activation of LFA-1. Cross-
linking of the T-cell receptor (TcR)/CD3 complex on T-cells stimulates LFA-1-
mediated adhesion to ICAM-1 by rapid integrin clustering (Dustin and Springer,
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1989), a process reproduced with phorbol ester treatment (Stewart and Hogg, 1996).
Clustering of LFA-1 appears to be the dominant mechanism of TcR - and phorbol
ester-stimulated adhesion. The actin cytoskeleton is critical for integrin clustering,
since cytochalasin D (inhibits actin polymerisation) can inhibit integrin clustering
and adhesion (van Kooyk and Figdor, 2000).
LFA-1 has also been observed to undergo affinity modulation upon divalent cation
stimulation (Dransfield et al., 1992; Stewart and Hogg, 1996) and Constantin et al.
(2000) has shown that chemokines can induce the high affinity state in LFA-1. The
chemokine induced high affinity state was suggested to be important during rapid
lymphocyte arrest under flow conditions (Constantin et al., 2000). Affinity
modulation has also been observed in Mac-1 ((XMP2) (Altieri and Edgington, 1988).
1.5.2 Affinity modulation of integrins
Conformational changes attributed to affinity modulation of integrins have been
observed in (X4P1, CX5P1, (XlP2, G9viP2, <^7 and anbp3 (Altieri and Edgington, 1988;
Crowe et al., 1994; Dransfield et al., 1992; Faull et al., 1993; Masumoto and Hemler,
1993; Shattil et al., 1985). Similar to LFA-1, crosslinking of TcR in a T lymphoid
cell line increased adhesion, in this case mediated by an increase in 0C5P1 affinity
(Faull et al., 1994). Integrin affinity modulation is best described for the am,P3
integrin and platelet aggregation a physiological process dependent on affinity
modulation.
Platelet aggregation in response to ADP was initially described to be dependent upon
the rapid exposure of high affinity fibrinogen receptors on the surface of platelets in
a Ca2+ dependent manner (Bennett and Vilaire, 1979). Non-activated platelets fail to
bind to fibrinogen; following stimulation activated platelets bind approximately
45,000-fibrinogen molecules/cell. These high affinity fibrinogen receptors were
subsequently described as the GPIIb-IIIa glycoprotein and later identified as the
anbP3 integrin. Integrin clustering also contributes to the increase in fibrinogen
binding and is required for the subsequent irreversible binding of ligand by anbP3
(Hato et al., 1998).
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Figure 1.5 Models of integrin activation.
(A) Affinity modulation occurs through a conformational change that generates a
high affinity ligand-binding integrin that is recognised by ligand-mimetic antibodies.
Upon ligand binding, new antibody binding epitopes are revealed. (B) Avidity
modulation occurs with clustering of integrins that generates a localised increase in
ligand binding strength.
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Shattil et al. (1985) described that following platelet activation, oqibP3 underwent a
conformational change that generated the high affinity anbP3 fibrinogen receptor.
This receptor was specifically recognised by a monoclonal antibody called PAC1
(Shattil et al., 1985). PAC1 is an IgMK murine monoclonal antibody that mimics
fibrinogen's ability to recognise the active integrin (ligand-mimetic antibody). The
presence of an RGD sequence within the heavy chain of the PAC1 antibody enables
affinity-specific recognition of otnbff? (Kunicki et al., 1996). PAC1 recognition of the
active integrin was not dependent on the pentameric structure of the antibody
(clustered integrins) as Fab fragments were still capable of recognising the active
integrin (Abrams et al., 1994).
1.6 Affinity modulation of anbp3
Platelet agonists including thrombin, ADP, epinephrine and thromboxane A2 can
trigger affinity modulation of anbP3 (Shattil et al., 1998). The identical chemical
structure of resting and activated anbp3 suggests that phosphorylation, proteolytic
cleavage and other post-translational modifications are not responsible for fibrinogen
binding (Yan et al., 2000). Upon thrombin stimulation an increase in resonance
energy transfer between fluorochromes on the separate anb and P3 subunits was
observed (Sims et al., 1991). Changes in peptide mapping of oqibP3 also revealed that
a conformational change within the integrin occurred upon activation (Yan et al.,
2000). In the absence of ternary structure information for anbP3 the precise nature of
the conformational change remains to be determined.
The conformational changes arising within anbP3 following platelet activation allow
ligand binding. Further conformational changes have also been shown to occur
following ligand binding (Du et al., 1991). Epitopes exposed on the integrin are
recognised by a group of antibodies called anti-CLIBS (cation-and-ligand-influenced
binding site) reflecting the cation and ligand sensitivity of these antibodies (Bazzoni
and Hemler, 1998). These conformational changes may therefore be important for
subsequent outside-in signalling mechanisms (Leisner et al., 1999). Several of these
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antibodies can promote ligand binding and platelet aggregation (e.g. LIBS6) by
shifting the cqibp3 affinity equilibrium towards a high affinity state (Frelinger, III et
al., 1991).
Intracellular signalling activates am>P3 and mutations within the cytoplasmic
domains of otnbP3 have revealed areas important for integrin activation. Chinese
Hamster Ovary (CHO) cells expressing otnbP3 were unable to bind to soluble
fibrinogen or PAC1 even in the presence of platelet agonists. Anti-CLIB antibodies
were able to stimulate PAC1 binding, indicating that this integrin was still capable of
undergoing a conformational change (O'Toole et al., 1990). The cytoplasmic
domains of anb and P3 have been shown to interact (Ginsberg et al., 2001) and
interaction between subunits proximal to the transmembrane region is required to
maintain the integrin in a low affinity state. This region-termed the "hinge-domain"
can form a salt-bridge between the subunits (Hughes et al., 1996) and is composed of
a GFFKR and LLv-iHRD sequence in the a and p subunits respectively (Figure 1.6).
Deletion of the GFFKR region or mutation of residues within this domain leads to
the constitutive activation of the integrin that is not inhibited by metabolic inhibitors.
This region may therefore act as a physical "on-off' switch in determining integrin
affinity (Ginsberg et al., 2001; Hughes et al., 1996; O'Toole et al., 1991).
Unlike anbP3, 005P1 expressed in CHO cells was capable of binding ligand. CHO cells
expressing anbP3 chimeras containing the cytoplasmic domain of OC5P1 were
constitutively active and capable of being bound by soluble fibrinogen and PAC1
(O'Toole et al., 1991; O'Toole et al., 1994). Activation was inhibited by metabolic
inhibitors suggesting that intracellular signalling was responsible for the activation
state of the chimera. The high affinity state of the chimera was determined by
sequences within both a and P subunits. Cytoplasmic domains of alpha subunits 0.2,
a,6A and a.6B also conferred a high affinity while those from otM, oil and av did not
(O'Toole etal., 1994).
Regions within the distal portion of the cytoplasmic domains are required for integrin
activation (Figure 1.6). Amino acid substitutions of the p subunit revealed that
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Figure 1.6 Amino acid sequences of integrin cytoplasmic tails.
Amino acid sequences of the integrin cytoplasmic tails are denoted as single letter
amino acid code with superscript numbers denoting amino acid number. The
positions of integrin chimeras are denoted by the straight line. The hinge sequences
are shown in red and sequences important for integrin activation are shown in blue.
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phosphorylation was not required for integrin activation. However, mutation of a
conserved NPXY motif resulted in the complete loss in PAC1 binding from the
chimeric-active integrin (O'Toole et al., 1995). A similar mutation in Pi was also
shown to be important for Pi activation (Mastrangelo et al., 1999). Mutation of a
second NXXY motif displayed a more modest reduction in PAC1 binding. These
motifs, identified in several cell surface receptors, function as internalisation
sequences; the P-turn structure within integrins may reflect a novel role for these
sequences as recognition sites for intracellular proteins (Ginsberg et al., 2001). The
talin head domain has been shown to bind to this region and in CHO cells can
activate anbp3 affinity (Calderwood et al., 1999). The p-turn structure of this region
may be constrained by a RPPLEED sequence in the am, subunit, thereby producing
the inactive conformation (Ginsberg et al., 2001).
Intracellular signalling is proposed to modulate integrin affinity through the binding
of factors to the cytoplasmic tails. Overexpression of Pi and P3 in CHO cells
expressing the active anbaspsPi chimera inhibited PAC1 binding. Titration of
cytoplasmic factors away from the chimeric integrin to the isolated P tails is thought
to mediate this inhibition (Chen et al., 1994). Several proteins have been identified
that can bind to integrins (reviewed in Liu 2000 and Hemler 1998) (Hemler, 1998;
Liu et al., 2000). Proteins such as talin (Calderwood et al., 1999), P3-endonexin
(Kashiwagi et al., 1997), cytohesin-1 (Kolanus et al., 1996) and CD98 (Fenczik et
al., 1997) have been shown to modulate integrin affinity in overexpression studies;
the importance of the endogenous forms of these proteins remain to be clarified.
The intracellular signals modulating integrin affinity have yet to be fully
characterised. Initial studies in platelets revealed that G-protein-coupled receptor
signalling, phospholipase C stimulation and tyrosine phosphorylation were important
in agonist-stimulated integrin activation (Shattil and Brass, 1987). Recent studies in
cells other than platelets have shown that the Ras family of small GTP-binding
proteins can also modulate integrin affinity (Hughes et al., 1997). Inside-out
signalling will be described in more detail below.
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1.7 Consequences of Integrin Affinity on Cellular Processes
Modulation of integrin affinity alters integrin-ligand binding. Integrin-dependent
processes such as adhesion, migration and matrix assembly can be sensitive to such
changes, though they do not rely solely on ligand binding but also require post-
occupancy events such as integrin clustering and cytoskeletal attachments.
CHO cells do not express anbp3 and fail to spread on fibrinogen, whereas CHO cells
that express 01^3 spread on fibrinogen and also display random migration
(Huttenlocher et al., 1996). The migration rate is dependent on fibrinogen
concentration and displays a bell-shaped correlation as described previously (Palecek
et al., 1997). Activation of anbP3 with the LIBS6 mAb reduces the migration rate as
a result of the increased adhesion to fibrinogen (Huttenlocher et al., 1996). Deletion
mutants within the integrin cytoplasmic tails can generate constitutively active
integrins, the inability of cytoskeletal attachments however fail to alter the migration
rate. (Ivins et al., 2000) has shown that neuronal outgrowth of late embryonic
neuronal cells on laminin is dependent on the affinity of c^Pi. Suppression of a,6pi
during central nervous system development stops neuronal outgrowth from extending
further; re-activating these integrins with Mn2+ or R-Ras G38V restores neuronal
outgrowth (Ivins et al., 2000). The presence of an active avP3 on a subpopulation of
metastatic breast cancer cells (but absent on non-metastatic cells) facilitates cell
interactions with platelets, enabling flow arrest within the vasculature. Deletion of P3
in these cells prevents interaction with platelets but may be restored by introducing
the constitutively active P3D723R mutant (Felding-Habermann et al., 2001). These
breast cancer cells therefore express an active avP3 integrin to facilitate the
metastatic process.
Fibronectin matrix assembly by cells also requires integrin-ligand binding. The anbp3
integrin can bind fibronectin, but it cannot support matrix assembly in the inactive
(low affinity) state; activating this integrin with LIBS6 mAb allows fibronectin
matrix assembly (Wu et al., 1995). The constitutively active integrin, anb(X6Ap3Pi
permits matrix assembly; suppressing this integrin with Ras G12V expression
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abrogates matrix assembly by these cells (Hughes et al., 1997). The fibrosarcoma
tumour cell line HT1080 does not assemble a fibronectin matrix, but activating the
endogenous asPi integrin with Mn2+ or a Pi stimulating antibody restores matrix
assembly by these cells. Inhibition of the elevated ERK1/2 activity in these cells due
to an activated allele ofN-Ras restored matrix assembly (Brenner et al., 2000). It was
therefore proposed that ERK signalling may suppress the asPi integrin.
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Ras and Ras Signalling
The Ras proteins and associated signalling pathways have been the focus of intense
research for the last twenty years. The Harvey and Kirsten strains of murine sarcoma
retrovirus (Ha-MSV and Ki-MSV) were isolated from mouse tumours induced by the
murine leukaemia virus that were passaged through rats (Harvey, 1964; Kirsten and
Mayer, 1967). The transforming potential of these viruses was encoded by a 21kDa
protein (Scolnick et al., 1979; Shih et al., 1979), which we now know as the viral
oncogenes ras. The acronym Ras was derived from the words rat sarcoma, from
which these genes were initially identified. The viral oncogenes from Ha-MSV and
Ki-MSV were shown to be derived form normal rat cellular proteins called Harvey-
Ras (Ha-Ras/H-Ras) and Kirsten-Ras (Ki-Ras/K-Ras) (Ellis et al., 1981; Langbeheim
et al., 1980; Shih et al., 1979). The importance of these ras genes was brought to the
forefront upon the discovery that the dominant oncogenes of several human tumours
were mutant alleles of the ras gene. These human oncogenes were shown to be
homologous to the viral H-ras and K-ras (Der et al., 1982; Parada et al., 1982;
Santos et al., 1982). From a neuroblastoma cell line a third member of this family
was identified, N-Ras (Shimizu et al., 1983).
The ras genes were the first oncogenes implicated in human tumours and conversion
of the normal cellular proto-oncogenes were mapped to single amino acid changes
(Reddy et al., 1982; Tabin et al., 1982). Mutations in codons 12, 13 or 61 convert
one of the three ras genes into active oncogenes present in a variety of human
tumours (reviewed in Bos 1989) (Bos, 1989). In addition to the genesis of many
tumours, oncogenic ras plays an essential role in tumour maintenance (Chin et al.,
1999).
1.8 Ras genes and proteins
The ras genes have been identified in most species ranging from yeast to humans. In
fact the human ras gene can rescue a ras-deficient yeast cell and a mutant yeast Ras
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protein can transform mouse fibroblasts (Defeo-Jones et al., 1985; Kataoka et al.,
1985). The high degree of sequence conservation between species suggests that the
ras genes play a fundamental role within the cell.
The ras genes contain four exons and a 5' non-coding exon (exon <jj). The introns
differ widely in their sequence and size, with the genomic sequences spanning 3, 7
and 35kb for H, N and K-ras respectively. K-ras has two alternative fourth exons
producing K-ras4A and K-ras4B that differ only in their terminal 25 amino acids
(Barbacid, 1987). These genes encode for 189 amino acids (188 for K-ras4B) and the
proteins are all approximately 21kDa in size, hence the name p21 Ras. The ras
promoter sequence is characteristic of cell housekeeping genes with the genes being
expressed in all cell lineages and organs.
Sequence comparison of the Ras proteins reveal that the first 86 amino acids are
identical and the next 78 reveal a very high degree of homology. It is within the
terminal 25 amino acids the "hypervariable domain" that the sequence is divergent.
The ras genes code for proteins that bind guanine nucleotides and have an intrinsic
GTPase activity (Gibbs et al., 1984; McGrath et al., 1984; Shih et al., 1980; Sweet et
al., 1984). Studies have shown that Ras complexed with guanosine triphosphate
(GTP) is active and that hydrolysis of GTP to GDP produces an inactive Ras-GDP
protein (Field et al., 1987; Sweet et al., 1984). Scheele et al. (1995) have shown that
of the 20,000 Ras molecules, in a resting NIH 3T3, cell approximately 0.3% is in the
active GTP-bound state (Scheele et al., 1995). The mechanism by which endogenous
Ras activity is increased will be described shortly.
Ras proteins are synthesised on free ribosomes within the cytoplasm (Ulsh and Shih,
1984). Following synthesis a series of post-translational modifications at the C-
1
terminal CAAX motif target Ras to the plasma membrane (Figure 1.7). Cysteine ,
conserved in all Ras proteins, is farnesylated, the AAX sequence removed by
proteolysis and the Cys186 carboxylmethylated. Palmitoylation of cysteines in H, N-
Ras and K-Ras4A or a poly-lysine stretch in K-Ras4B further contributes to the
membrane localisation signal of the Ras proteins (Hancock et al., 1990). Membrane
localisation is essential for Ras function and that deletion of Cys186 prevents Ras
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Figure 1.7 Ras C-Terminal Modifications.
(A) An expanded view of the Ras hypervariable region (grey) shows the sequential
modifications that occur to newly translated Ras proteins. (B) Sequence alignment of
the four Ras isoforms. The CAAX motif (light grey) contains the conserved cysteine
residue (red). Cysteines that are palmitoylated are shown in blue with the polybasic
lysine residues ofK-Ras4B shown in green. Modified from Prior et al. (2001).
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transforming activity (Willumsen et al., 1984). Membrane targeting of such mutants
by other lipid modifications can rescue the transforming capacity of the Ras protein
(Buss et al., 1989; Lacal etal., 1988).
Mutation and deletion studies have revealed several regions important for Ras
function (Figure 1.8). Guanine nucleotide binding is mediated by interactions with
both the phosphate groups and the purine ring. Sequence motifs important for
guanine nucleotide binding show similarity with other GTP/GDP binding proteins,
including heterotrimeric G-proteins and elongation factor-Tu (EF-Tu) (Lowy and
Willumsen, 1993). The intrinsic GTPase activity is contained within the conserved
N-terminal 166 amino acids and mutation of residues 12 or 61 disrupt the catalytic
rate of hydrolysis (Sweet et al., 1984). Structural predictions suggest that amino acid
substitution of Gly12 may disrupt the interaction with the y-phosphate thereby
reducing GTP hydrolysis (Barbacid, 1987). The hypervariable domain is one of five
regions that are dispensable for cell transformation. However, recent studies show
that this region may be important for correct membrane micro-domain localisation
and effector pathway utilisation (Booden et al., 2000; Jaumot et al., 2001; Prior and
Hancock, 2001).
Mutations within the "effector" domain drastically reduce Ras transforming ability
without affecting guanine nucleotide binding or hydrolysis (Sigal et al., 1986;
Willumsen et al., 1986). This region, also known as "switch 1", undergoes
conformational changes upon GTP binding and hydrolysis (Pai et al., 1989;
Schlichting et al., 1990), the dynamics of which have recently been described (Ma
and Karplus, 1997). The effector domain has been shown to be essential in binding
the known Ras effectors (Rodriguez-Viciana et al., 1997; White et al., 1995).
1.8.1 Differences between the Ras isoforms
The Ras proteins are virtually identical except for the hypervariable region. The
strong conservation of these divergent sequences between species suggests the
importance of these unique sequences (Barbacid, 1987). Although the ras genes are
expressed ubiquitously, each gene has a slightly different expression pattern between
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Figure 1.8 Schematic of the structure of Ras.
The Ras protein is divided into three regions according to the percentage sequence
homology between the Ras isoforms. The individual regions important for Ras
functions are highlighted with the coloured blocks. Red circles denote positions of
activating mutants.
Integrin Affinity Modulation by Ras Signalling Molecules
organs: H-ras is highly expressed in the brain, N-ras in the thymus and testis and Jv-
ms in the gut and testis (Leon et al., 1987). These expression patterns, however, do
not correlate with the selective activation of the ras genes in different tumours
(Fiorucci and Hall, 1988). For instance K-ras is preferentially activated in colon and
pancreas carcinomas, H-ms in bladder and kidney carcinomas and N-ras in myeloid
and lymphoid disorders (Bos, 1989).
Of the three ras genes only K-ras appears to be essential and sufficient for
development, as double knockout of W-ras and N-ras are viable (Esteban et al.,
2001; Koera et al., 1997; Umanoff et al., 1995). Effector pathway utilisation also
varies between isoforms: K-Ras is a more potent activator of Raf than H-Ras, but the
converse is true for PI3-kinase activation (Yan et al., 1998). The Ras isoforms also
differ in their ability to induce cell transformation and migration (Voice et al., 1999).
The localisation of these Ras isoforms into different plasma membrane micro-
domains may contribute to their differing biological effects (Prior and Hancock,
2001).
1.9 Regulation of Ras activity
The Ras proteins cycle between an active GTP-bound and an inactive GDP-bound
state (Figure 1.9) (Bourne et al., 1990). The majority of Ras within a cell is in the
GDP-bound state (Scheele et al., 1995) and therefore activation requires replacement
of GDP by GTP. This exchange of GTP for GDP requires proteins known as
Guanine Exchange Factors (GEF) such as SOS (Quilliam et al., 1995). These GEF
proteins form a complex with Ras-GDP and GDP is displaced, being immediately
replaced by GTP due to the high GTP/GDP ratio within a cell. The GEF
subsequently dissociates, leaving an active Ras-GTP complex (Boguski and
McCormick, 1993). GTP is hydrolysed back to GDP by the intrinsic GTPase activity,
recycling Ras back to the inactive state. The intrinsic rate ofGTP dissociation is very
slow (John et al., 1990), therefore GTPase Activating Proteins (GAP) stimulate GTP
hydrolysis, thereby limiting Ras activity (Polakis and McCormick, 1993).
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Figure 1.9 Cycling of Ras between GDP and GTP bound states.
Ras GEFs can stimulate the exchange of bound GDP for GTP producing the active
Ras protein. Ras GAPs stimulate the intrinsic Ras GTPase activity that hydrolyses
GTP to GDP, returning Ras to the inactive state.
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1.9.1 Ras activation
Ras is the convergence point for extracellular signals to be transmitted into the cell.
Receptors mediating Ras activation include receptor tyrosine kinases (e.g. epidermal
growth factor (EGF) receptor), cytokine receptors (e.g. IL-2 receptor), T-cell
receptors, G-protein coupled receptors (e.g. muscarinic receptor) and integrins.
The best described of these signals is that of growth factor stimulation of Ras
activity. Platelet derived growth factor (PDGF) can increase the proportion of Ras-
GTP within minutes of treatment (Gibbs et al., 1990). Receptor tyrosine kinases
(RTK) autophosphorylate several key tyrosine residues within their cytoplasmic
region upon ligand binding (Pazin and Williams, 1992). These phosphotyrosyl sites
allow binding, through SH2 domains, of adaptor proteins including She and Grb2
(Baltensperger et al., 1993; Gale et al., 1993; Lowenstein et al., 1992).
Autophosphorylation of She upon RTK activation can also generate a Grb2 binding
site (Rozakis-Adcock et al., 1992). The transient activation of Ras is mediated by
recruitment of the Ras-GEF SOS to the plasma membrane via a SOS/Grb2 complex.
This may be mediated either by direct binding of Grb2 to RTK or via She (Li et al.,
1993; Olivier et al., 1993). Integrin activation of Ras at focal adhesion has also been
described previously to use the Shc/Grb2 complex (Figure 1.3).
G-protein coupled receptors activate Ras via their associating heterotrimeric G-
protein subunits. G-protein subunits can mediate phosphorylation and transactivation
of RTK in a growth factor-independent manner, thereby recruiting the adaptor
molecules as described above (Delia Rocca et al., 1999; Luttrell et al., 1999). G-
proteins can also use the integrin-signalling complex to activate Ras (reviewed in
Luttrell 1999). GPy subunits can also activate PI3-kinase y (Lopez-Ilasaca et al.,
1997; Malarkey et al., 1995; van Biesen et al., 1995) and in xenopus, expression of
the pi 10 subunit of PI3-kinase produced an increase in GTP-loading of Ras (Hu et
al., 1995a). G-proteins are also capable of activating Ras-GEFs such as RasGRFl
and RasGRP (Reuther and Der, 2000). Ga subunits have also been shown to increase
ERK1/2 activation in a Ras-independent manner mediated by PKC activation
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(Gudermann et al., 2000) or through the activation ofRaplGEFs that can activate B-
Raf (Mochizuki et al., 1999).
T-cell activation of Ras also uses the Grb2/SOS complex to activate Ras; membrane
recruitment of Grb2 may be mediated by protein-interactions with T-cell proteins
such as SLP-76 or LAT (Marie-Cardine and Schraven, 1999)
Mammalian SOS is related to the drosophila son-of-sevenless product required for
Ras activation in drosophila (Bowtell et al., 1992). SOS contains a cdc25 homology
domain that is responsible for GEF activity (Lai et al., 1993); it also contains several
interaction domains including SH3, Dbl homology and pleckstrin homology domains
(Malumbres, 1998). Other Ras-GEFs include RasGRF, RasGRF2 and RasGRP
(Ebinu et al., 1998; Fam et al., 1997; Martegani et al., 1992).
1.9.2 Ras inactivation
Ras-GAPs stimulate the intrinsic GTPase activity of Ras, thereby reducing Ras
activity. Several of the oncogenic mutants of Ras such as G12V are unresponsive to
GAP activity and are therefore constitutively in the active GTP-bound state
(Scheffzek et al., 1997; Trahey and McCormick, 1987). Several mammalian GAPs
have been identified (Malumbres, 1998) including pl20-GAP (Trahey and
McCormick, 1987) and neurofibromatosis type 1 protein (NF1) (Ballester et al.,
1990). Whether these proteins also have Ras effector function is described in
Chapter4.
1.10 Ras Superfamily
The Ras proteins were the first described members of the Ras superfamily of small
GTP-binding proteins, which now contains more than 100 members (reviewed in
Takai 2001). According to their primary sequence and biological function these
members can be classified into sub-families: Ras, Rho, Rab, Arf and Ran (Matozaki
et al., 2000; Takai et al., 2001). The Rho family members are associated with the cell
cytoskeleton and gene expression (Mackay and Hall, 1998; Ridley and Hall, 1992)
and the Rab family with secretory and endocytic pathways (Schimmoller et al.,
33
Integrin Affinity Modulation by Ras Signalling Molecules
1998). The Arf family are also associated with vesicular trafficking pathways and
can also activate phospholipase D (Brown et al., 1993), (Mitchell et al., 1998; Moss
and Vaughan, 1998) while the Ran family are key for coordinating and driving
nuclear traffic (Moore, 1998).
The Ras subfamily currently contains 16 members: H-Ras, N-Ras, K-Ras4A and K-
Ras4B, R-Ras proteins (R-Ras, R-Ras2/TC21 and R-Ras3/M-Ras), Ral proteins (A
and B), the Raps (1A, IB, 2A and 2B), Rheb, Rin (this should not be confused with
Rinl, a Ras effector) and Rit (Matozaki et al., 2000). With the exception of the Ras
proteins, Rap2A, Rin and Rit which all have a farnesyl group, all are localised to the
membrane by a geranylgeranyl lipid group, which may allow specific membrane
targeting for their biological properties (Reuther and Der, 2000).
R-Ras is more than 50% identical to Ras with an identical effector domain (Lowe et
al., 1987). R-Ras can bind to the same effectors as Ras, but it has only been reported
to activate PI3-kinase (Marte et al., 1997) and although it has been shown to
transform cells, it does so to a lesser extent than Ras (Cox et al., 1994). R-
Ras2/TC21 also shows homology to Ras (Drivas et al., 1990) and transforming
ability (Graham et al., 1994) and has been the only other Ras member found to be
mutated in a human tumour cell line (Chan et al., 1994). R-Ras may have a role in
apoptosis (Wang et al., 1995) and integrin affinity regulation (Sethi et al., 1999;
Zhang et al., 1996a) but the precise function of the R-Ras family remains to be
clarified.
The Rap proteins, initially proposed to antagonise Ras biological activity (Kitayama
et al., 1989), may play a more complex role in cell signalling (Reuther and Der,
2000). The Ral proteins are activated by RalGEFs, including RalGDS, that are
known Ras effectors (see below). Biological activity of recent additions to the Ras
family, Rheb (Yamagata et al., 1994) and Rit (Lee et al., 1996), remains to be
determined (Reuther and Der, 2000).
The identification of several exchange factors and GTPase-activating proteins for
many of the Ras subfamily members suggests that each may have specific biological
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roles within the cell. Elucidation of effectors downstream of these proteins may
allow a better understanding of the signalling pathways initiated by these proteins.
1.11 Ras signalling and effectors
Ras is the convergence point for a multitude of extracellular activating signals. The
intricacy and complexity of Ras signalling continues with its downstream pathways.
Ras has long been known to mediate cell cycle progression, most evident in
transformed cells; several other biological effects are also attributed to Ras signalling
including cell survival, morphogenesis, differentiation and migration. The divergent
biological effects attributed to Ras activation are in part dependent upon the
downstream pathways activated by the Ras "effectors". Ras effectors preferentially
bind to the Ras-GTP complex, display an increase in activity following Ras
interaction and are sensitive to mutations within the Ras effector domain (Marshall,
1996). One of the first and most intensely studied Ras effector is Raf.
As with the discovery of the ras genes, raf was identified as the transforming
component of the mouse sarcoma virus 3611 (Rapp et al., 1983). The pro-oncogene
c-raf-1 was identified in non-transformed cells (Kozak et al., 1984) and was shown
to be capable of activating the p42/p44 mitogen activated protein kinases (MAPKs)
or extracellular-signal-regulated kinases (ERK1/2) (Howe et al., 1992). Activation of
ERK1/2 observed following Ras activation was dependent on MEK activation
(Kosako et al., 1992; Kyriakis et al., 1992). Raf was capable of phosphorylating and
activating MEK, placing Raf upstream of MEK and ERK1/2 in the Ras mitogenic
signalling pathway (Avruch et al., 1994). The discovery that Raf is an effector of Ras
(Han et al., 1993; Warne et al., 1993; Zhang et al., 1993) suggested that a signalling
cascade of Ras-Raf-MEK-ERK was required for mitogenic signalling (Avruch et al.,
1994; Dickson et al., 1992; Gomez and Cohen, 1991). This signalling cascade will be
described in more detail shortly.
Historically there has been a considerable body of evidence supporting the
hypothesis that the Raf-ERK cascade was solely responsible for Ras function.
Constitutively active mutants of Raf and MEK were both able to transform rodent
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fibroblasts similar to that of Ras (Alessi et al., 1994; Bonner et al., 1985; Mansour et
al., 1994; Stanton, Jr. et al., 1989) and that Raf can overcome the loss of Ras
function to transform cells (Feig and Cooper, 1988; Smith et al., 1986a). Expression
of dominant negative mutants of Raf-1, MEK and ERK can attenuate Ras
transforming activity (Bruder et al., 1992; Cowley et al., 1994; Khosravi-Far et al.,
1995; Kolch et al., 1991; Schaap et al., 1993; Westwick et al., 1994). Genetic studies
performed in drosophila and C.elegans also revealed the importance of the Ras-Raf
pathway (Campbell et al., 1998; Elan et al., 1993).
The increasing number of Ras effectors identified indicates that Raf signalling may
be part of a far more intricate Ras signalling pathway. Ral-GEFs and PI3-kinase are
just two of the best described alternative Ras effectors (Malumbres, 1998). Figure
1.10 describes the known Ras effectors and a simplified schematic of their
downstream pathways. This growing number of Ras effectors suggests that Raf may
not be the sole effector responsible for Ras function.
Ras and Raf are both capable of fully transforming NIH 3T3 rodent fibroblasts.
Similar experiments performed in rat intestinal epithelial (RIE-1) cells show that
only activated Ras can cause transformation and that Raf-independent signalling was
required for transformation (Oldham et al., 1996). In human thyroid epithelial cells
activated MEK upregulated ERK 1/2 activation; but only activated Ras led to
proliferation (Gire et al., 1999). Alternative signalling pathways have also been
observed in yeast homologues of Ras signalling (Campbell et al., 1998). The most
direct evidence for Raf-independent pathways comes from the generation of Ras
effector mutants. White et al. (1995) generated Ras G12V effector mutants that
displayed differential binding and activation of Raf, RalGDS and PI3-kinase
(Rodriguez-Viciana et al., 1997; White et al., 1995). The interaction of these effector
mutants with Ras effectors is summarised in Table 1.2. Ras (G12V, T35S), capable
of binding Raf, display limited transforming ability; co-expression with Ras mutants
defective for Raf binding produced synergistic transforming ability (Khosravi-Far et
al., 1996; Rodriguez-Viciana et al., 1997; White et al., 1995). Ras-dependent
membrane ruffling observed in quiesced fibroblasts was only observed with the Ras
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Figure 1.10 Ras Effector Pathways.
Identified Ras effectors (boxed) can activate several downstream pathways that
mediate the multitude ofRas functions.
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Table 1.2 Ras Effector Mutant Interactions.
Raf RalGDS pllOa Rin-l PLCe AF6 PKC^ MEKK1
Ras G12V y y y y y y y /
Ras (G12V, E37G) X y X y y y nd nd
Ras (G12V, T35S) y X X X X y nd nd
Ras (G12V, Y40C) X X y X X y nd nd
Interactions between Ras effector mutants and effectors denoted by /; X- no
interaction observed; nd - not determined.
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(G12V, Y40C) mutants and not with activated Raf (Joneson et al., 1996). Khosravi-
Far et al. (1996) showed that all three Ras mutants were capable of inducing growth
in low serum, soft agar and the formation of tumours in nude mice (Khosravi-Far et
al., 1996); however; only the Ras (G12V, T35S) mutant has been shown to display
experimental metastasis in vivo (Webb et al., 1998). Biological effects attributed to
Ras may therefore require a combination of signals through the Ras effector
pathways.
1.11.1 Ral guanine exchange factors
Ral-GEFs are Ras effectors that activate the Ras related proteins of the Ral family.
Four Ral-GEFs have been identified, Ral guanine nucleotide dissociation stimulator
(RalGDS) (Albright et al., 1993; Hofer et al., 1994; Spaargaren and Bischoff, 1994),
RalGDS-likel/2 (Rgll/2) (Hill et al., 1995; Peterson et al., 1996) and RalGDS-like
factor (Rlf) (Wolthuis et al., 1996).
The Ras (G12V, E37G) mutant capable of binding the RalGEFs produced synergistic
transforming ability in combination with Raf signalling (Khosravi-Far et al., 1996;
Rodriguez-Viciana et al., 1997; White et al., 1996). The Ras (G12V, E37G) mutant
has also been shown to have effects on proliferation of thyrocytes (Miller et al.,
1997) and synergised with Ras (G12V, Y40C) in growth factor-independent myeloid
cell growth (Matsuguchi and Kraft, 1998). Synergism in cell transformation with Raf
signalling has also been observed with RalGDS and Rlf (Urano et al., 1996; White et
al., 1996; Wolthuis et al., 1997) and these GEFs can also reproduce the Ras G12V
effects on transcription (Ramocki et al., 1998; Wolthuis et al., 1997). The
significance of RalGEF-Ral activity has been highlighted by the ability of a
dominant negative RalA (28N) to inhibit Ras function (Miller et al., 1997; Urano et
al., 1996; White et al., 1996; Wolthuis et al., 1997). The GTPase defective RalA
mutant (23V) has in general failed to reproduce any Ras function and it has been
proposed that hydrolysis of GTP may be important for Ral effector activation
(Wolthuis et al., 1997). RalGEFs and Ral signalling may therefore contribute to Raf-
independent Ras function.
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A putative Ral effector, RLIP76 (Ral-binding domain) has been identified that
displays GAP activity towards Racl and Cdc42 (Cantor et al., 1995; Jullien-Flores et
al., 1995). RLIP76 may therefore allow crosstalk between the Ral and Rac/Cdc42
pathways downstream of Ras. Ral is also required for phospholipase D (PLD)
activation in forming a complex between Ral-PLD and Arf (Jiang et al., 1995; Luo et
al., 1998). How these effectors relate to Ral function remains to be clarified.
1.11.2 PI3-kinase
Phosphatidylinositol-3-OH kinase (PI3-kinase) phosphorylates the D3 position of the
inositol ring on phosphoinositides (Carpenter and Cantley, 1996). Both Ras G12V
and Ras (G12V, Y40C) can stimulate PI3-kinase activity (Rodriguez-Viciana et al.,
1994; Rodriguez-Viciana et al., 1997) and the subsequent increase in phosphorylated
lipid products. With the use of Ras (G12V, Y40C) and activated mutants of PI3-
kinase, PI3-kinase activity has been shown to contribute to Ras mediated
transformation, DNA synthesis, cell morphology and cell survival (Kauffmann-Zeh
et al., 1997; Khosravi-Far et al., 1996; Matsuguchi and Kraft, 1998; Rodriguez-
Viciana et al., 1997; Xue et al., 2000). Phosphorylated lipid products of PI3-kinase
can regulate the activities of a wide range of proteins (Downward, 1998); Akt, p70S6
kinase and RacGEFs have received the most attention. Akt activity modulates
glycogen metabolism, protein synthesis and cell survival (Datta et al., 1999). The
anti-apoptotic effects of Akt are mediated by actions on the pro-apoptotic factor
BAD, caspase 9 and NF-kB signalling (Datta et al., 1999). Activation of RacGEFs
by PI3-kinase products (Hawkins et al., 1995) may link Ras signalling to the Rho
family of proteins and mediate the cytoskeletal changes observed in Ras transformed
cells (Malumbres, 1998).
The Rho family of proteins has profound effects upon the actin cytoskeleton (Ridley
and Hall, 1992) and can promote cell cycle progression (Olson et al., 1995). Rac and
Cdc42 can stimulate JNK and p38 MAPK activity (Coso et al., 1995; Westwick et
al., 1994) and all three members can activate transcription factors (Hill et al., 1995).
Khosravi-Far et al. (1995) and other groups have reported that activated mutants of
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these proteins synergise with Raf in mediating cell transformation and that dominant
negative mutants reduce Ras transforming activity (Khosravi-Far et al., 1995; Qiu et
al., 1995). These and other results show that the Rho proteins may contribute to Ras
biological function (Bar-Sagi and Hall, 2000).
1.11.3 Other Ras Effectors
Ras signalling research has concentrated on the three effectors Raf, RalGEFs and
PI3-kinase. Several other Ras effectors have been identified: MEKK1 (Russell et al.,
1995), Phospholipase C-s (Kelley et al., 2001; Lopez et al., 2001; Song et al., 2001),
pl20-GAP (Leblanc et al., 1998), AF6 (Kuriyama et al., 1996), Rinl (Han and
Colicelli, 1995) and PKC£, (Diaz-Meco et al., 1994). Ras-mediated signalling and
biological effects attributed to these effectors are described further in Chapter 4.
1.12 Raf Signalling
Raf, a serine/threonine kinase, couples Ras activation to mitogenic signalling by
ERK1/2 (Figure 1.11). Considerable effort has been directed toward the
understanding of the mechanisms leading to Raf activation and subsequent activation
of ERK1/2. Three Raf isoforms have been identified in mammals, Raf-1 (c-Raf-1),
A-Raf and B-Raf). Pritchard et al. (1995) have shown that conditionally oncogenic
forms of the Raf isoforms display differential catalytic activity towards MEK (B-Raf
> Raf-1 > A-Raf) and that this activity is represented by changes in ERK activation
(Pritchard et al., 1995). The Raf isoforms display differential expression patterns
within mice and knockout studies reveal that each isoform may have unique
functions (Hagemann and Rapp, 1999; Wojnowski et al., 1997; Wojnowski et al.,
1998; Wojnowski et al., 2000).
1.12.1 Raf Activation
Upon Ras activation, Raf is recruited to the plasma membrane where it becomes
activated. Targeting Raf to the plasma membrane generates an active Raf protein
(Stokoe et al., 1994). Raf contains two functional domains, an amino-terminal
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Figure 1.11 Ras-ERK Cascade.
The Ras-ERK signalling cascade is shown with active Ras (red box) activating
inactive Raf (black box). This cascade continues with phosphorylation ofMEK and
subsequently ERK1/2. Map Kinase Phosphatase (MKP) can dephosphorylate
ERK1/2 returning it to the inactive state. PD - PD098059 binds inactive MEK1 to
cause inhibition.
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regulatory domain and the carboxy-terminal catalytic domain. Two Ras binding
motifs, the Ras binding domain (RBD) and a cysteine-rich domain (CRD), are
present in the amino-regulatory domain (Morrison and Cutler, 1997). The amino-
terminal suppresses catalytic activity and its removal, forming Raf-BxB,
constitutively activates Raf (Stanton, Jr. et al., 1989). Inactive Raf exists within the
cytosol complexed with several proteins, including the phosphoserine binding
protein 14-3-3 (Wartmann and Davis, 1994). This complex is recruited to the plasma
membrane by an initial interaction between active Ras and the Raf RBD. A possible
conformational change within Raf, facilitated by phosphatidylserine (PS) and
displacement of the 14-3-3 proteins, permits Ras binding independent of Raf RBD
(Hu et al., 1995b) to Raf CRD. Phosphorylation of Ser338 and Tyr340/341 by Pak
(Chaudhary et al., 2000) and oncogenic Src (Marais et al., 1995) respectively leads
to full activation of Raf kinase activity. Raf catalytic activity is also modulated by
phosphorylation by protein kinase A (PKA) (Wu et al., 1993), Akt (Zimmermann
and Moelling, 1999) and protein kinase C (PKC) (van Dijk et al., 1997).
Most of the studies relating to Raf activation have concentrated on Raf-1; whose full
activation requires Ras-mediated membrane localisation and phosphorylation
(Blumer and Johnson, 1994; Marais et al., 1995). A-Raf displays a similar
requirement for membrane localisation and phosphorylation for activation. In
contrast, B-Raf is strongly activated by Ras alone (Marais et al., 1997). Activation of
B-Raf can also occur through an interaction with active Rap. The activation of Rap
GEFs leads to the GTP loading of Rap and subsequent activation of B-Raf (Bos,
1998). B-Raf activation produces an increase in ERK1/2 activation that is
independent of Ras activity (Ohtsuka et al., 1996).
1.12.2 Raf to ERK Signalling
Raf to ERK 1/2 signalling described in Figure 1.11, requires the activation of the dual
specificity kinases MAPK/ERK Kinasel/2 (MEK1/2) (Dent et al., 1992), also known
as Map Kinase Kinasel/2 (MAPKK1/2) (Dhanasekaran and Premkumar, 1998).
MEK1/2 are cytoplasmic proteins of 43kDa and 46kDa respectively and are encoded
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by two distinct genes on separate chromosomes (Brott et al., 1993; Zheng and Guan,
1993).
Raf, phosphorylates both Ser218/Ser222 on MEK1 and Ser219/Ser223 on MEK2 (Alessi
et al., 1994) leading to full activation ofMEK activity. Substitution of both of these
serine residues to either glutamic or aspartic acid residues generated constitutively
active mutants (Alessi et al., 1994; Cowley et al., 1994; Mansour et al., 1994),
capable of transforming NIEI 3T3 cells in vitro (Cowley et al., 1994; Mansour et al.,
1994). The interaction between Raf and MEK can be disrupted by Raf Kinase
inhibitor protein (RKIP), an adaptor protein that binds both Raf and MEK and
prevents MEK activation. This inhibition reduces Raf induced gene expression and
transformation of NIH 3T3 cells (Yeung et al., 1999). The regulation of RKIP
binding may therefore place a threshold level of Raf activity required prior to MEK
interaction and activation (Kolch, 2000).
MEK, identified by its ability to activate ERK (Crews et al., 1992; Crews and
Erikson, 1992; Nakielny et al., 1992), phosphorylates ERK on threonine and tyrosine
residues. These residues, Thr183 and Tyr185 (ERK2) are present within the MAPK
consensus sequence of Thr-X-Tyr, where X is glutamic acid (TEY motif) (Payne et
al., 1991; Ray and Sturgill, 1988). Phosphorylation of both of these residues is
required for activation (Anderson et al., 1990) and stimulates ERK activity by 500-
1000 fold compared to dephosphorylated ERK (Robbins et al., 1993).
Dephosphorylation of these residues returns ERK1/2 back to its inactive state. Map
kinase phosphatases (MKP) that can specifically dephosphorylate both threonine and
tyrosine residues can regulate in vivo ERK activity (Alessi et al., 1993; Keyse, 1998).
Mimicking the negative charges on these residues with glutamic or aspartic acid
residues have failed to generate constitutively active mutants (Her et al., 1993;
Robbins et al., 1993). An in-frame fusion between ERK2 and MEK1 produced a
constitutively active ERK2 fusion protein that had no effect on endogenous ERK
activity (Robinson et al., 1998).
ERK2 was initially identified as a protein phosphorylated during growth factor
stimulation (Ahn et al., 1991; Boulton et al., 1991; Rossomando et al., 1989).
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Activation of ERK is essential for Ras-mediated mitogenic signalling. Upon
activation, ERK can translocate into the nucleus (Chen et al., 1992; Lenormand et
al., 1993; Sanghera et al., 1992) where several ERK 1/2 substrates have been
identified (Su and Karin, 1996). Phosphorylation of the transcription factor Elk-1 by
ERK enhances ternary complex formation (TCF) between Elk-1, serum response
factor (SRF) and the serum response element (SRE) present in several promoter
sequences (Gille et al., 1992; Marais et al., 1993). Activation of TCF stimulates
transcription of SRE containing genes including the transcription factor c-fos (Gille
et al., 1992; Janknecht et al., 1993). Other nuclear targets include c-Myc, Ets-1 and
ATF-2 (Abdel-Hafiz et al., 1992; Seth et al., 1992). p90RSK, a cytoplasmic target of
ERK phosphorylation (Sturgill et al., 1988), also translocates into the nucleus where
it can phosphorylate c-Fos and modulate transcription (Chen et al., 1992; Chen et al.,
1993). The growth factor-induced stimulation of transcription is essential for cell
proliferation and passage of cells through the G1 phase of the cell cycle. Induction of
cyclin D1 expression and degradation of the cell cycle inhibitor p27Kipl induced by
Ras-ERK signalling facilitates passage through G1 and entry into the S-phase of the
cell cycle (Aktas et al., 1997; Kerkhoff and Rapp, 1998; Lavoie et al., 1996;
Malumbres, 1998). Excessive Ras-ERK signalling can induce the expression of the
inhibitor p21Cipl leading to growth arrest (Pumiglia and Decker, 1997; Tombes et al.,
1998) and may be a mechanism to regulate growth factor-induced cell proliferation
(Malumbres, 1998).
Not all of the activated ERK translocates into the nucleus, with ERK phosphorylating
several cytoplasmic proteins. ERK can stimulate arachidonic acid production by
phosphorylation of cytoplasmic phospholipase A2 (cPLA2) (Kramer and Sharp,
1997; Lin et al., 1993; Nemenoff et al., 1993). Arachidonic acid is an important
bioactive molecule required in the generation of prostaglandin, thromboxanes and
leukotrienes (Needleman et al., 1986). Myosin light chain kinase (MLCK) is also
activated by ERK phosphorylation (Morrison et al., 1996). Myosin activity,
stimulated by myosin light chain phosphorylation, causes actin-myosin contraction
and the generation of force within the cell (Kamm and Stull, 2001). This force
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generation has been proposed to be required during integrin clustering at forming
focal adhesions (Burridge et al., 1997). In this regard, the stimulation of MLCK
activity can target active ERK to newly forming focal adhesions where it may be
involved in focal adhesion assembly or signalling (Fincham et al., 2000). Klemke et
al. (1997) have reported that inhibition of MLCK activity can suppress ERK1/2-
induced cell migration on ECM (Klemke et al., 1997). The activation ofMLCK may
therefore be an important effector in modulating cell adhesion and migration in
response to ERK signalling. ERK can also phosphorylate SOS (Dong et al., 1996);
which may therefore allow feedback regulation of the Ras-ERK signalling cascade.
In recent years there have been an increasing number of reports suggesting
MEK/ERK-independent effects by activated Raf. Mice in which the raf-1 gene is
knocked-out die during embryogenesis, yet cells derived from the embryo display
normal ERK1/2 activation. This suggests that while raf-1 is essential during
development, Raf-1 may not be the in vivo MEK activator, which is likely to be B-
Raf (Huser et al., 2001). Phosphorylation of Raf -Tyr340/341 is essential for activation
ofMEK kinase activity and substitution to phenylalanine residues prevents activation
(Marais et al., 1995). Mice in which raf-lFF was substituted for endogenous raf-1,
apparently have a normal phenotype, even though Raf-1FF has no activity towards
MEK. These viable mice show that Raf-1 function other than MEK activation is
essential for development and survival (Huser et al., 2001). Other biological
processes independent of MEK/ERK activity are further described in Chapter 5
together with possible Raf effectors, in addition to MEK.
1.13 MAPK Signalling Cascade
This signalling cascade mediated by sequential phosphorylation and activation of
proteins has parallels both in mammalian signalling systems and in model organisms.
The Ras-ERK pathway in humans mediates mitogenic signalling. Other pathways
regulate responses to cytokines and cell stress. In yeast, these signalling cascades
regulate the mating response, cell-wall biosynthesis and glycerol accumulation
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(Blumer and Johnson, 1994). Nature appears to have conserved this mechanism of
sequential phosphorylation reactions to regulate a diverse array of cellular functions.
ERK1/2, activated by Ras, have several homologues in humans that are collectively
known as the "MAP kinase superfamily" of proteins. This superfamily of proteins
can be classified into subgroups comprised of ERKs, c-jun N-terminal kinases
(JNKs) and p38 MAP kinases. These MAP kinases are components of several protein
signalling cascades that are activated in response to a diverse array of stimuli. Figure
1.12 highlights the main components of these signalling pathways.
1.13.1 ERKs
ERK1/2 signalling stimulated by growth factors mediates mitogenic signalling. A
total of seven ERKs have been identified in humans. After ERK1/2, ERK5 is the
next best described member of this family. ERK5 is stimulated by growth factors
(Kato et al., 1997) and several components of the signalling pathway have been
identified. ERK5 can synergise with ERK2 signalling (Pearson et al., 2001) and this
is described further in Chapter 5. Very little is currently known about the
physiological role played by the remaining ERK proteins.
1.13.2 JNKs and p38 MAP Kinases
The c-Jun N terminal kinases (also known as the stress-activated kinases) are
activated in response to cellular stress such as osmotic shock and UV irradiation;
they are also activated by cytokines such as tumour necrosis factor a (TNFa) and
interleukin-1 (IL-1) (Paul et al., 1997; Weitzman, 2000). Stimulation of these
pathways leads to cell apoptosis and growth arrest, but there is evidence to suggest
that JNK signalling may modulate other cell - and - stimuli specific biological roles.
JNKs are activated by phosphorylation of their consensus Thr-Pro-Tyr (TPY) motif,
analogous to the TEY motif in the ERKs (Dhanasekaran and Premkumar, 1998).
JNK phosphorylates several substrates including transcription factors, c-Jun,
activated transcription factor 2 (ATF2), Elk-1 and the death domain protein MADD
(Harper and LoGrasso, 2001)
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Figure 1.12 MAPK Superfamily.
Members of the MAPK superfamily (bold) are shown with their known upstream
kinases and activating stimuli. Downstream targets of MAPK phosphorylation are
also shown.
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p38 MAP kinase, another stress activated protein kinase, is analogous to the high
osmolarity glycerol responsive 1 (HOG1) pathway in yeast and is stimulated in
response to growth factors, cellular stress and inflammatory cytokines.
Phosphorylation of the Thr-Glu-Tyr (TGY) phosphorylation motif by MAPKK
stimulates p38 MAP kinase activity (Dhanasekaran and Premkumar, 1998). p38
MAP kinase activity stimulates several transcription factors, activated transcription
factor-2, c-AMP-responsive element, CHOP, myocyte enhance factor 2C and the
kinase MAPKAPK-2. Activation of MAPKAPK-2 stimulates several transcription
factors itself (Harper and LoGrasso, 2001). The response of p38 MAP kinase activity
can lead to apoptosis, changes in the cell cycle and the upregulation of inflammatory
cytokines during tissue inflammation (Ono and Han, 2000). Recent work has also
shown that p38 MAP kinase is also required during development and differentiation
(Nebreda and Porras, 2000).
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Integrins and Ras
Modulation of surface expression of integrins allows a cell to regulate the adhesive
strength of a cell to ECM or counter receptors. Leucocytes can increase P2
expression to facilitate recruitment to sites of tissue injury (Hillis and MacLeod,
1996). Cells can also change the integrin profile of a cell, thereby allowing cell
migration to more suitable environments. Integrin profile changes have commonly
been observed in tumour cells and have been described previously (reviewed in
Varner 1996).
Ras is the most commonly mutated gene in human tumours (Bos, 1989). As
previously described, Ras signalling can activate several pathways that can lead to
transcriptional changes, which include changes in integrin expression levels.
Expression of constitutively active Ras increased LEA-1 (CXLP2) expression in a
thymocyte cell line (O'Rourke et al., 1998) and p3 expression in human melanoma
and pancreatic carcinoma cell lines (Woods et al., 2001). Conversely, Ras61L
expression in an endothelial cell line displayed a reduction in CX3P1 integrin
expression (Shin et al., 1999). Reduction of oncogenic K-Ras expression in human
colon carcinoma cells by antisense DNA increased otiPi and ot5Pi expression, while
decreasing 0C3P1 and covPs expression (Schramm et al., 2000). Expression of Ras
G12V in a pro-B cell line, however, had no significant effect on ot4pi, (X5P1, LFA-1
and a6pi levels (Fujimoto et al., 2001; Shibayama et al., 1999; Tanaka et al., 1999).
Integrin expression levels in CHO cells expressing either anbp3 or aiibOt6AP3Pi (aP-
py cells) were also unaffected by expression of H-Ras G12V or R-Ras G38V (active)
(Hughes et al., 1997; Sethi et al., 1999; Zhang et al., 1996a). These results indicate
that modulation of integrin surface expression levels by ras genes are both integrin -
and - cell specific.
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1.14 Signalling Pathways that Regulate Integrin Affinity
Integrin "activation", as previously discussed, results in the increase of ligand
binding strength by the integrin. Activation is often measured by an increase in cell
adhesion to immobilised substrates such as fibronectin, laminin and ICAM1.
Adhesion is a complex process that requires a combination of integrin affinity and
avidity changes. Signalling pathways that modulate cell adhesion therefore should
not be solely ascribed to integrin affinity changes (Hughes P. and Pfaff, 1998). In this
regard, cell binding to soluble ligands and ligand-mimetic antibodies are a better
measure of affinity changes.
Soluble fibrinogen or PAC1 (the ligand-mimetic antibody of anbPa) binding to
platelets increases upon platelet activation by ADP, thrombin and epinephrine
(Bennett and Vilaire, 1979). Agonist-induced activation of phospholipase Cp by G-
protein coupled receptors stimulates production of IP3 and diacylglycerol (DAG)
9+
(Smith et al., 1986b). HVmediated release of intracellular Ca and DAG activation
of protein kinase C induce activation of anbP3 (Shattil et al., 1998; Shattil and Brass,
1987). Platelets from mice deficient in Gaq fail to activate PLCp in response to
agonists and are unable to aggregate (Offermanns et al., 1997). Inhibition of agonist-
induced tyrosine phosphorylation has also been shown to inhibit anbP3 activation
(Shattil et al., 1992). Activation of anbp3 by thrombin was inhibited by wortmannin
treatment of platelets (Zhang et al., 1996b). This suggests that activation of PI3-
kinase and production of phosphoinositides may also be important for integrin
activation.
ADP stimulation of Gai and the inhibition of adenylyl cyclase is also important for
platelet aggregation. ADP-dependent platelet aggregation in mice lacking Gotj2 is
strongly inhibited due to a failure in the activation of otnbp3 (Jantzen et al., 2001).
otnbP3 expressed in human B-lymphocytes is activated in response to formyl Met-
Leu-Phe (fMLP) treatment. Activation was sensitive to pertussis toxin treatment and
a PKC inhibitor, suggesting that Gai and PKC were required for integrin activation
(Qi et al., 1998).
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anbP3 expressed in CHO cells, however, failed to respond to any anbP3-stimulating
agonists including ADP, thrombin and phorbol esters (O'Toole et al., 1990). anbP3 on
CHO cells can be activated by stimulation of the co-expressed platelet glycoprotein
Ib-IX (GPIb-IX) (Gu et al., 1999) in a pathway dependent on protein kinase G
(PKG) activation of Raf-MEK-ERKl/2 (Li et al., 2001). However, independent
activation of the PKG-ERK pathway in the absence of GPIb-IX activation failed to
reproduce anbP3 activation.
1.14.1 Small GTP-binding proteins, H-Ras and R-Ras
Substitution of the anbp3 cytoplasmic domain with that of the fibronectin (005P1) or
laminin (oc6aPi) integrin produces a constitutively active chimeric integrin in CHO
cells (O'Toole et al., 1991; O'Toole et al., 1994). Expression of Ras G12V in these
cells suppressed this active integrin conformation in a pathway sensitive to MAP
kinase phosphatase 1 expression (Hughes et al., 1997). In contrast Ras Q61L
expression in a haematopoietic cell line can activate the native CX4P1 and OC5P1 integrin
in an ERK1/2 independent manner (Liu et al., 1999; Shibayama et al., 1999). In a
mast cell line, asPi activation by Ras G12V was sensitive to the PI3-kinase inhibitor,
wortmannin (Kinashi et al., 2000). Integrin affinity modulation by active Ras may
therefore be integrin, cell and integrin affinity-state specific.
Expression of active R-Ras G38V in CHO cells can activate am>P3 and reverse Ras
G12V suppression of the chimeric integrin (Sethi et al., 1999; Zhang et al., 1996a).
Effectors of R-Ras integrin affinity modulation remain to be identified, although C-
Terminal prenylation (Oertli et al., 2000) and a putative SH3 binding domain within
R-Ras have been shown to be important (Wang et al., 2000). A small death-domain
containing protein, PEA-15, can reverse Ras G12V integrin suppression in a pathway
impaired by dominant negative R-Ras (Ramos et al., 1998). Activation of Ephrin
receptors, a receptor tyrosine kinase, led to R-Ras phosphorylation and decreased
adhesion to ECM proteins. It is proposed that disruption of R-Ras effector binding
through phosphorylation of Tyr66 within the effector domain may also impair R-Ras
signalling and therefore facilitate the loss in ECM adhesive strength (Zou et al.,
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1999). The recruitment of the protein tyrosine phosphatase, SHP2 to the receptor and
dephosphorylation of FAK and paxillin may contribute to the loss in adhesion (Miao
et al., 2000). By contrast, activation of Ephrin-ligand expressing cells by their
receptors display an increase in adhesion to ECM in a Pi dependent manner (Davy
and Robbins, 2000; Huai and Drescher, 2001). Affinity of the Pi integrins remains to
be determined, though it is interesting to note that activation of receptor and ligand
can have opposite effects on integrin-mediated cell adhesion.
1.14.2 Other Signalling Molecules
Inhibition of PI3-kinase activity can inhibit activation of anbP3 in platelets (Zhang et
al., 1996b). The production of 3-phosphorylated phosphoinositides may allow the
recruitment of proteins containing PH domains to the plasma membrane. Cytohesin,
a pleckstrin homology (PH) domain containing protein is recruited to the plasma
membrane upon PI3-kinase activation (Nagel et al., 1998). Its interaction with the
cytoplasmic tail of LFA-1 can induce adhesion to ICAM-1 (Kolanus et al., 1996) and
can also generate an activation epitope on LFA-1 recognised by the antibody mAb24
(Dransfield et al., 1992; Geiger et al., 2000).
Rapl, another small GTP binding protein has also been shown to induce activation
dependent epitopes in LFA-1. In a pro-B-cell line, crosslinking of the T cell receptor
induced activation of LFA-1 that was impaired by expression of a dominant negative
Rapl construct (Katagiri et al., 2000). In Jurkat cells, crosslinking of CD31
(PECAM-1) induced mAb24 binding to LFA-1 through the activation of Rap-1
(Reedquist et al., 2000). Rap-1 can activate B-Raf (Ohtsuka et al., 1996) although no
activation ofERR 1/2 was observed with CD31 crosslinking.
In lymphocytes, the chemokine stromal derived factor-1 (SDF-1) can induce soluble
ICAM-1 binding to LFA-1 in a process that is inhibited by pertussis toxin
(Constantin et al., 2000) whereas upregulation of ct4pi activity required the Src
kinase p56Lck that was potentiated by the phosphatase inhibitor pervanadate
(Feigelson et al., 2001).
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Isolated pi cytoplasmic tails can suppress the chimeric integrin in CHO cells (Chen
et al., 1994). CD98, an early T-cell activation antigen, can associate with Pi integrins
and reverse this integrin suppression (Fenczik et al., 1997; Fenczik et al., 2001).
Crosslinking of CD98 can stimulate adhesion to ECM (Fenczik et al., 1997) and PI3-
kinase activity (R. Rintoul, personal communication). Whether PI3-kinase activity is
required for reversal of integrin suppression remains to be determined.
1.15 Aims of this Thesis
The mechanisms modulating integrin affinity are currently poorly understood. Active
H-Ras (Ras G12V) has been shown to suppress the active chimeric integrin
(ociibCX.6AP3P i) expressed in CFIO cells (aP-py cells) in a pathway sensitive to MKP-1
expression (Hughes et al., 1997).
The aims of this thesis were:
1. Establish the aP-py integrin affinity reporter and transfection system.
2. Reproduce the initial findings of integrin suppression by Ras G12V.
3. Examine the requirement of ERK1/2 activation for integrin suppression.
4. Determine which Ras effector pathways mediate integrin suppression.
5. Identify new components of the integrin suppression pathway.
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MATERIALS AND METHODS: CHAPTER 2
2.1 Materials
All chemicals were purchased from Sigma (Dorset, U.K.) unless otherwise stated.
The following reagents were obtained from Life Technologies (Paisley, UK):
Dulbecco's Modified Eagles Medium (DMEM); Penicillin; Streptomycin; dialysed
foetal bovine serum (FBS); L-glutamine; 30% (w/v).
Antibodies were obtained from the following sources: anti-Ha (Y-ll), anti-myc
(9E10 and A14), anti-ERK2 (C-14), anti-Raf (E-10) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Phospho-ERKl/2 (ERK-PT115) was from
Sigma (Dorset, UK) and Phospho-Akt (Ser 473) was from New England BioLabs
(Beverly, USA). Anti-PKBa antibody was a kind gift from Dr. D. Alessi
(Department of Biochemistry, University of Dundee). Anti-RalA antibody was from
Transduction Laboratories (Lexington, USA). All anti-species specific horseradish
peroxidase-conjugated antibodies were from DAKO (Bucks, UK).
DNA constructs Tac-a5 (permission from Dr. S. E. LaFlamme, Centre for Cell
Biology and Cancer research, NY, USA), pDCR-H-Ras (G12V and effector mutants)
(permission from Dr. M. H. Wigler, Cold Spring Harbour Laboratory, NY, USA),
pSG5-pl 10-CAAX and pSG5-R-Ras G38V (permission from Prof. J. Downward,
ICRF, London, UK) were all provided by Dr. M. H. Ginsberg (Scripps Research
Institute, La Jolla, USA) and have been described previously (LaFlamme et al.,
1992; Oertli et al., 2000; Wennstrom and Downward, 1999; White et al., 1995). Dr.
S. M. Keyse (ICRF, Dundee, UK) provided pSG5-MKP-l (Keyse and Emslie, 1992).
pCDNA3-Raf-BxB CAAX was provided by Dr. C. K. Weber (University of Ulm,
Germany) (Daub et al., 1998). pEFm-A-Raf, B-Raf and Raf-1 were provided by Dr.
R. Marais (Institute of Cancer Research, London, UK) (Marais et al., 1997). Dr. J. L.
Bos (University of Utrecht, Utrecht, Netherlands) provided pMT2-RalA (WT, 23V
and 28N) (Wolthuis et al., 1997) and pGEX-RalBD (Wolthuis et al, 1998). Dr. M.
White (University of Texas Southwestern Medical Centre, Texas, USA) provided
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pCDNA3-Raf-BxB T481A (Pearson et ah, 2000). Dr. M. H. Cobb (University of
Texas Southwestern Medical Centre, Texas, USA) provided pCMV5-ERK2-MEKl
(WT and KD) (Robinson et ah, 1998). pCMV-Ha-MEKIDD (permission from Dr.
M. J. Weber, University of Virginia, Charlottsville, USA) was provided by Prof. W.
Kolch (Beatson Institute for Cancer Research, Glasgow, UK) (Catling et ah, 1995).
Drosophilia DNA pWRhpA-Auk and pBluescript-Cass were provided by Dr. N.
Brown (Cambridge University, Cambridge, UK). The small cell carcinoma cDNA
library (H33) was obtained from the UK Human Genome Mapping Project Resource
Centre, Cambridge, UK.
2.2 Cell Culture
The aP-py CHO cell line was a kind gift from Dr Mark Ginsberg (Scripps Institute,
La Jolla, USA). This cell line stably expresses a chimeric integrin comprised of
ociiba.6AP3Pi (Hughes et ah, 1997). Expression of this integrin is maintained through
G418 selection and expression driven by the polyoma T antigen.
The aP-py cell line was cultured in Dulbeccos Modified Eagles Media (DMEM)
(Sigma), supplemented with 10% (v/v) foetal bovine serum (FBS) (heat inactivated
at 57°C for 1 hour), 1% (v/v) non-essential amino acids (Life Technologies) and
G418 antibiotic (400pg/ml) (Promega) to maintain expression of the integrin.
Quiescent media for a.p-py cells was supplemented with 0.1% (v/v) heat inactivated
FBS rather than 10% (v/v).
All media contained 50 IU/ml penicillin, 50 IU/ml streptomycin and 5mg/ml L-
glutamine and all cell lines were maintained in a humified atmosphere of 5%
C02/95% air at 37°C. All cell lines were used at the lowest possible passage number
and regularly screened for mycoplasma infection.
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2.3 Chemical competence and transformation of E.Coli
2.3.1 Generation of chemical competent E.Coli
Transformation competent E. Coli strains DH5oc and BL21 were purchased from Life
Technologies (Paisley, UK), strains MC0161/P3, TOPIO and TOP10/P3 were
purchased from Invitrogen (Groningen, Netherlands). Additional competent stocks of
DH5a, BL21 and TOPIO were made according to the method by (Hanahan, 1983).
An overnight culture of E.Coli (0.8-1% v/v) was used to inoculate 250 ml of SOC
media (Life Technologies, Paisley, UK) and grown (18°C at 225rpm) to an
absorbance at 600nm of 0.4-0.8 units. All subsequent steps to generate competent
cells were performed on ice. Cells were pelleted (3000 rpm at 4°C) in a Sorvall
RT6000B centrifuge (Stevanage, UK) and gently resuspended in 84 ml chilled
transformation buffer containing lOmM PIPES, 15mM CaCh^FfO, 25mM KC1,
55mM MnCl2.4H20, pH6.7. Following a 10-minute incubation on ice, cells were
pelleted and resuspended in 20 ml transformation buffer. Dimethyl sulphoxide (7.5%
v/v) was added and cells incubated for a further 10-minutes on ice. Competent cells
were aliquoted into chilled eppendorfs and snap frozen in liquid nitrogen. All
competent cells were stored at -70°C.
2.3.2 Transformation of E.Coli
Frozen aliquots of cells were thawed on ice and transferred to chilled eppendorfs. In
the case of MC0161/P3 and TOP10/P3 cells, P-mercaptoethanol (25mM final
concentration) was added to cells prior to addition of DNA. DNA (l-10ng) was
gently mixed with the cells and allowed to rest for 30 minutes on ice. Cells were
heat-shocked at 42°C in a thermomixer (Eppendorf, Cambridge, UK) for 45-60
seconds and returned onto ice for a further 2 minutes. Transformed cells were
allowed to grow by incubating the cells in antibiotic free SOC media for 60 minutes
at 37°C (225 rpm in thermomixer), prior to spreading on appropriate antibiotic
selection plates. Plates were incubated at 37°C overnight in an incubator (Stuart
57
Integrin Affinity Modulation by Ras Signalling Molecules
Scientific, UK). Individual colonies were picked into LB broth containing antibiotics
and grown overnight for DNA purification and restriction enzyme digest verification.
2.4 DNA Purification
Small scale (l-10ml) DNA purifications were performed using Wizard SV Miniprep
kits (Promega) as per manufacturers instructions. Diagnostic restriction digests were
performed with appropriate restriction enzymes (Promega) and resolved on 1%
agarose (Seakem, Rockland, Maine, USA) gels containing 0.3pg/ml ethidium,
bromide to enable UV visualisation.
Large scale (100-500ml) DNA purifications were performed using the Qiagen
Endotoxin Free Maxiprep kit (Qiagen, Crawley, UK) as per manufactures
instructions. For low copy plasmids, the Qiagen Midiprep kits were used together
with their low copy number plasmid protocol. Purified DNA was checked with
diagnostic digests and quantified using on the Pharmacia Biotech Ultrospec 2000 UV
spectrophotometer (Amersham Pharmacia Biotech, Amersham, U.K)
2.5 Cell Transfection
Transient transfections of a,p-py and CHO-K1 cells were performed with
Lipofectamine™ Plus reagent (Life Technologies) as described by Chen et al. (1994)
(Chen et al., 1994). Cells were seeded at an appropriate density to reach 50-70%
confluency overnight in 100/60mm dishes (Corning, High Wycombe, UK). Purified
DNA was placed in 5ml BD Falcon tubes (Part No: 352034, Oxford, UK) in a
volume ranging from l-20jul, the DNA was pre-complexed with llOpl of the Plus
reagent mixture and gently mixed. The Plus reagent mixture contained Plus reagent
0.25% (v/v) diluted in DMEM containing 1% (v/v) non-essential amino acids
DMEM (+AA). Following a 15 min incubation at room temperature, the DNA was
complexed with llOpl of the Lipofectamine mixture and gently mixed. The
Lipofectamine reagent contained Lipofectamine 0.25% (v/v) diluted in DMEM
(+AA). After a further 15 min incubation at room temperature, the transfection
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mixture was made up to a final volume of 4 ml with pre-warmed DMEM (+AA) and
placed onto washed cells. Cells were cultured for 5 hrs at 37°C and then fed with
complete media (4 ml). Twenty four hours after transfection, media containing DNA
and Lipofectamine was removed and replaced with fresh complete media. For
experiments when protein kinase activities were to be assessed, the transfection
media was replaced with quiescent media. For PD098059 (Calbiochem, Nottingham,
UK) studies, the inhibitor was added to quiescent media at the appropriate
concentration and time as stated. Forty eight hours post transfection; cells were either
lysed for SDS-PAGE anlaysis or used for integrin affinity determination.
All plasmids used for transient transfections were titrated for maximal expression in
the aP-py cells. Subsequent studies experiments for integrin affinity determination or
western blot analysis were performed on transfected cells using optimal DNA
quantities unless otherwise stated.
2.6 Assessment of protein concentration
Protein concentrations were quantified using a BCA protein assay (Pierce, IL, USA).
A protein standard curve was generated using bovine serum albumin (Sigma) at a
range of 0.1-0.5mg/ml diluted in 1:10 lysis buffer. Samples were diluted 1 in 10 in
dFUO and lOpl incubated with 200pl BCA reagent (30 minutes, 37°C) in 96 well
plates. Protein concentration was determined using an automated plate reader (MRX
microplate reader, Dynatech, Chantilly VA).
2.7 SDS Page and Western Blotting
2.7.1 Cell Lysis
Transfected cells were washed once with ice cold PBS and lysed in buffer containing
50mM Hepes (Na Salt), 0.3M NaCl, 1.5mM MgCl2, 1.2mM EDTA, 0.5% Triton X-
100, 20mM p-glycerophosphate, lOOrnM sodium fluoride, lOmM sodium
pyrophosphate, ImM sodium vanadate, 0.5mM dithiothreitol (DTT). One
Complete™ protease inhibitor tablet (Boehringer Manheim, Lewes, UK) was added
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per 50ml of lysis buffer. Lysates were cleared by centrifugation at 13000 rpm for 10
minutes at 4°C, assessed for protein concentration (described in 2.6) and solubilised
in 4 x sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
sample buffer at 99°C for 5 minutes.
2.7.2 SDS PAGE and Western Immunoblotting
Samples were cooled and equal amounts of protein (10-100 pg) were resolved on
SDS polyacrylamide gels using a vertical electrophoresis tank Biorad Protean 3
system (Biorad, Hemel Hempstead, UK) and (ATTO Corp., Japan). Samples were
electrophoresed at 100-150 Volts using SDS-Tris-Glycine electrophoresis buffer for
1-2 hours beside pre-stained molecular weight markers (Life Technologies, Paisley,
U.K.). For optimal separation, 8% gels were used for 60-120 kDa proteins, 10% gels
for 40-70 kDa proteins and 12% gels for 10-40 kDa proteins.
Proteins were transferred onto Hybond C nitrocellulose membranes (Amersham
Pharmacia Biotech, Amersham, U.K.) in a methanol based transfer buffer at 400
milliamps for 1 hour using a Mini Protean II blotting tank (Biorad, UK). Equal
protein loading was confirmed by incubating blots for 5 minutes in Ponceau S
(Sigma), which allows visualisation of protein bands. Non specific protein binding
sites on the membranes were blocked by incubation in PBS-Tween 20 containing 5%
non-fat dried milk powder for 1 hour at room temperature. Membranes were probed
with appropriate primary antibodies (Table 2.1) diluted in PBS-Tween 20 containing
5% non-fat dried milk powder overnight at 4°C. Membranes were washed in PBS-
Tween 20 (3 x 30 second vigorous washes and 3x10 minute washes) before species
appropriate horseradish peroxidase (HRP) conjugated secondary antibody (DAKO,
Ely, UK) (diluted in washing buffer) was added for 1 hour (Table 2.1). Finally,
membranes were rewashed as above and immunoreactive bands were identified
using enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech,
Amersham, U.K) as per manufacturer's instructions.
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Table 2.1 Immunoblotting antibody dilutions
Primary Antibody Dilution Secondary Antibody Dilution
Ha Antibody (Y-l 1) 1:500 Anti-Rabbit HRP 1:1000
Myc Antibody (9E10) 1:1000 Anti-Mouse HRP 1:1000
Myc Antibody (A 14) 1:1000 Anti-Rabbit HRP 1:1000
Phospho-ERKl/2 1:2000 Anti-Mouse HRP 1:1000
ERK2 (C-14) 1:2000 Anti-Rabbit HRP 1:1000
Phospho-Akt 1:500 Anti-Rabbit HRP 1:1000
Akt-alpha 1:500 Anti-Sheep HRP 1:1000
RalA 1:1000 Anti-Mouse HRP 1:1000
Raf(E-lO) 1:1000 Anti-Mouse HRP 1:1000
4 x SDS-PAGE sample buffer. 50mM Tris-HCl, 10% (v/v) glycerol, 2% (v/v) SDS,
0.1% (v/v) bromophenol blue and 10% (v/v) P-mercapoethanol.
SDS polyaeryIamide gels: Separating Gel - 0.375M Tris base (pH8.8), 0.1% (v/v)
SDS, 8-12% (v/v) acrylamide (Life Technologies, Paisley, UK), 0.1% (v/v)
ammonium persulphate and 0.08% (v/v) TEMED
Stacking Gel - 0.13M Tris base (pH8.8), 0.15% (v/v) SDS, 4.6% (v/v) acrylamide,
0.13% (v/v) ammonium persulphate and 0.1% (v/v) TEMED
Gel electrophoresis buffer: 5 mM Tris base (pH 8.3), 25 mM glycine and 0.01%
(v/v) SDS.
Transfer buffer: 210 mM glycine, 24.7 mM Tris base and 20% (v/v) methanol.
PBS-Tween 20 Wash Buffer: PBS containing 0.2% (v/v) Tween 20 (Sigma)
2.8 Integrin Affinity Determination by Flow Cytometry
2.8.1 Cell Staining
Integrin affinity in transfected cells was analysed by three colour flow cytometry
forty eight hours post transfection. Cells were transfected with test DNA (0-1 Opg)
together with 0.75pg Tac-a.5 transfection reporter construct (extracellular domain of
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the IL-2 receptor and the intracellular domain of the as integrin). Single cell
suspensions of trypsinised cells were resuspended in a total volume of 50pl
containing 0.4% (v/v) PAC1 ascites (gift from S. Shattil, Scripps Institute, La Jolla,
USA) (Shattil et al., 1985) for 30 minutes at room temperature in Hepes/NaCl buffer
(20mM Hepes, 140mM NaCl, 1.8 mM CaCb, 1 mM MgCh and 2mg/ml Glucose, pH
7.4). Internal controls for each sample were performed containing either 5mM EDTA
or lOOpM MnCb or 2pM Ab33 (activating antibody). Cells were washed with cold
PBS and incubated on ice with 50pl DMEM containing 4% (v/v) anti-mouse IgM-
FITC (Biosource, Nivelles, Belgium) for 30 minutes in the dark. Cells were washed
again and incubated on ice for a further 30 minutes with 50pl DMEM containing 2%
(v/v) anti-Tac-R-phycoerythrin (R-PE) (DAKO, Ely, UK). Cells were finally washed
and resuspended in cold PBS. Immediately prior to analysis on a FACS-Caliber (BD,
Erembodegem, Belgium), ToPro3 (Molecular Probes, Leiden, Netherland) at a final
concentration of lpM (in PBS) was added to each sample.
2.8.2 FACS and data analysis
PAC1 binding was determined by gating for live and highly transfected cells
(ToPro3 negative and high Tac binding respectively). To obtain numerical estimates
of integrin activation, an integrin activation index (AI) was calculated.
AI = 'Fn-Fp
\FA~Fl J




Fn : Geometric mean fluorescence intensity (MFI) of PAC1 binding of the native
integrin
Fi : MFI of PAC1 binding in the presence of 5mM EDTA
Fa : MFI of PAC1 binding in the presence of lOOpM Mn2+ or 2pM Ab33
AIo : Activation index with the control vector
AI : Activation index with DNA under test
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2.9 Gene Subcloning
Drosophila genes cassowary and auk were obtained from Dr. N. Brown (Cambridge,
UK). Cassowary was cloned into the DNA cloning vector pBluescriptSK and auk
into the pWRhpA drosophila transformation vector, neither were mammalian
expression vectors.
The Ral genes were obtained from J.Bos (Utrecht, Netherlands) and were cloned into
the pMT2 vector that expresses poorly in a(3-py CHO-K1 cells.
2.9.1 High fidelity PCR of genes
Primers were designed flanking the gene of interest with each forward primer and
reverse primers containing appropriate restriction sites (Table 2.2). All primers were
screened against Genbank databases to check for mismatches or cross-reactivity's,
none were found. High fidelity PCR was performed using Pfu Turbo DNA
polymerase (Stratagene, Amsterdam, Netherlands). Twenty nanograms of template
DNA were amplified in a reaction volume of 50pl containing (IX Pfu reaction buffer
(contains 2mM MgSC^), 0.2mM dNTPs each, 0.2p.M of each primer and 2.5 U of
Pfu polymerase). Reactions were performed on a MWG Primus 96 Plus machine
(Ebersberg, Germany), with cycle conditions as described in (Table 2.3). PCR
products were resolved on a 1% agarose gel containing 0.3pg/ml ethidium bromide
to enable UV visualisation.
Table 2.2 Gene cloning primers










Underlined sequence highlights the incorporated restriction enzyme sequences.
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Table 2.3 PCR Cycle conditions for gene cloning
Cycle Stage Cass PCR Auk PCR Ral PCR
Stage 1 94°C for 1 min 94°C for lmin 95°C for 1 min
Stage 2
94°C for 30 sec
70°C for 30 sec
72°C for 2 min
25 cycles
96°C 30 sec
67°C for 4 min
30 cycles
95°C for 1 min
62°C for 1 min
72°C for 1 min
25 cycles
Stage3 72°C for 10 min 72°C for 10 min 72°C for 10 min
2.9.2 Cloning of genes into pGEMT Vector
PCR products were ethanol precipitated and 500ng of the product were used in a
poly-A tail reaction containing 2mM dATP and 2.5U standard Taq polymerase
(Promega, Southampton, UK), reactions were performed for 30 minutes at 70°C.
Poly-A tailed PCR products were ligated into the pGEMT vector (Promega) using
the Rapid ligation kit. Ligations were performed as per manufacturers instructions
using 50ng of precut pGEMT vector and a 3:1 insert ratio. Following a 2 hour
ligation at room temperature, 50% of the ligation mixture was transformed into
DH5a E.Coli and spread onto LB agar plates containing 50pg/ml ampicillin, 0.5mM
isopropy-beta-D-thiopyranoside (IPTG) and 80pg/ml 5-Bromo-4-chloro-3-indolyl
beta-D-galactopyranoside (X-Gal). White colonies were subsequently amplified and
screened for correct insert size by appropriate restriction digests, cass/ral (BamHl-
Hindlll) and auk (EcoRl-Hindlll). Successful ligations were sent for sequencing at
the CIR sequencing facility using the ABI automated fluorescence sequencing kit.
Sequences from clones that matched template DNA were subsequently used for sub-
cloning into the mammalian expression vector, pCMV-Tag3B (Stratagene;
Amsterdam, Netherlands).
2.9.3 Sub-cloning genes into pCMV-Tag3B vector
Both insert containing plasmid and pCMV-Tag3B (Stratagene, Amsterdam,
Netherlands) (5pg) (target plasmid) were digested with 20U of BamHl and Hindlll
in a final volume of 30pl, for 2 hours at 37°C. Following digestion, pCMV-Tag3B
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DNA was treated with 20U shrimp alkaline phosphatase (Boehringer Manheim,
Lewes, UK) for 30 minutes at 37°C. Dephosphorylation of free terminal phosphate
groups on the target plasmid was terminated by incubating the mixture at 65°C for 15
minutes. Ligation control samples included single cut pCMV-Tag3B (BamHl alone)
and unphosphatased vector. All digestions were gel purified using the Qiagen Gel
extraction kit (Crawley, UK) as per manufacturers instructions. Purified DNA was
quantified as described previously (2.4). Ligation into the target plasmid was
performed using lOOng cut vector and a 3:1 molar ratio of insert with 3U T4 DNA
ligase (Promega, Southampton, UK) in a final volume of lOpl. Ligations were
performed using a cycling PCR reaction of 14°C for 30 seconds and 24°C for 30
seconds, for a total of 2 hours. Control ligations were performed in the absence of
insert or with single cut vector. Following ligation, the ligation mixture was
transformed into DH5a E.Coli as described previously (2.3.2). Positive colonies
were amplified and screened with restriction digests.
2.10 Library Amplification
Mammalian cDNA expression library H33 (Small cell lung carcinoma) was obtained
from the Human Genome Mapping Project (Cambridge, UK). The library was cloned
into the pCDM8 vector (Invitrogen, Groningen, Netherlands) that contains a CMV
promoter and the polyoma origin of replication (facilitates replication in a(3-py cells)
with insert sizes greater than 500bp. Library DNA (15ng) was transformed into either
MC0161/P3 or TOP10/P3 E.Coli strains (3xl00pL) as described in 2.3.2.
Transformations were subsequently spread onto 25x25cm (Corning, High Wycombe,
UK) LB-Agar plates containing 50pg/ml ampicillin and lOpg/ml tetracycline and
plates were incubated overnight at 37°C. Transformations were repeated six times to
obtain sufficient number of colonies as to cover the quoted complexity of the library
ten times.
Colonies were scraped from each plate into antibiotic free LB-Broth and DNA
purified from the culture using the Qiagen Midiprep-Kit following the low copy
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number plasmid protocol. Purified DNA was quantified by UV spectrophotometry
and verified by restriction digestion with the Xhol restriction enzyme. DNA from
individual preparations were pooled and used in the genetic screen.
2.11 Library Screening
2.11.1 Cell Sorting
The genetic screen of the SCLC cDNA expression library was performed as
described in Fenczik et al. (1997). Transfection of a(3-py cells was performed as
described previously (2.5), in 100mm tissue culture plates. A total of 19 plates were
transfected: pCDM8 (4pg), Ras G12V (3pg) and 17 plates with H33 library DNA
(4pg) all with 2pg of Tac-as reporter construct. Integrin affinity determination was
performed 48 hours after transfection as described in 2.8. Sixteen library transfected
plates were trypsinised and resuspended in a total of 1.35ml of Hepes/NaCl buffer,
single cell suspension of cells (6 x 225jul) were incubated with 25pi PAC1 ascites
fluid to give a final concentration of 0.4% (v/v). Cells were washed with cold PBS
and incubated on ice with 250pl DMEM containing 4% (v/v) anti-mouse IgM-FITC
(Biosource, Nivelles, Belgium) for 30 minutes in the dark. Cells were washed again
and incubated on ice for a further 30 minutes with 250pl DMEM containing 2% (v/v)
anti-Tac-PE (DAKO, Ely, UK). Cells were finally washed and resuspended in cold
PBS at a concentration of 2 x 106 cells/ml.
Cell sorting was performed on a FacsVantage cell sorter (BD, Erembodegem,
Belgium) with a 70-micron flow nozzle. Immediately prior to cell sorting, 7-AAD
(Molecular Probes, Leiden, Netherland) a cell viability dye at a final concentration of
20ng/ml was added to each of the six sort tubes. Cells transfected with pCDM8 and
Ras G12V enabled the sort gate, 7-AAD negative (live), Tac positive (transfected)
and low PAC1 binding (suppressed integrin) to be set (Figure 6.11). Cells collected
in 3ml DMEM were subjected to HIRT extraction of plasmid DNA (Hirt, 1967).
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Briefly, cells were transferred to 1.5ml eppendorfs and centrifuged at 1000 rpm for
10 minutes and resuspended in 400pl lysis solution (0.6% SDS (w/v) and lOmM
EDTA). Following a 20 minute incubation at room temperature, lOOpl of 5M NaCl
solution was added and the mixture incubated at 4°C overnight. Lysates were
clarified by centrifugation at 13000 rpm for 10 minutes and subjected to two cycles
of phenol/chloroform purification (lysate: phenol/choloroform 1:1 ratio). DNA
within the aqueous phase was subjected to ethanol precipitation with 20pg of
glycogen (Boehringer Manheim, Lewes, UK). DNA resuspended in lOOpl dH20 was
precipitated with 3M sodium acetate 10% (v/v) and 300% (v/v) ethanol by
centrifugation at 13000 rpm for 20 minutes. The DNA pellet, washed with 70%
ethanol, was resuspended in a final volume of 8pl dH20.
DNA was digested overnight with 10 units Dpnl restriction enzyme at 37°C and
used to transform TOP10/P3 E.Coli (Invitrogen, Groningen, Netherlands) as
described in 2.3.2. Individual bacterial colonies were grown, stored and pooled into
groups of 10 for plasmid purification (midi-prep) as described in 2.4. Library pools
(4pg) were transformed into aP-py cells and re-screened for integrin affinity
modulation by Facs analysis.
2.12 Ral Activity Assay
2.12.1 Production of GST-RalBD agarose beads
LB broth (500ml) containing 50pg/ml ampicillin was inoculated with BL21 E.coli
transformed with the pGEX-GST-RalBD construct and grown (37°C at 225rpm) to
an absorbance at 600nm of 0.4-0.6 units. IPTG was added to a final concentration of
0.2mM and the culture was allowed to grow for a further 3 hours. Bacteria were
centrifuged at 4000 rpm for 25 minutes and resuspended in 10 ml lysis solution
(PBS, 5mM DTT, 2mg/ml lysozyme (Sigma) and Complete™ protease inhibitor
tablet). All subsequent steps were performed on ice. Following a 30 minute
incubation on ice, bacteria were sonicated (Ultrawave U50, Belmont Instruments,
Glasgow, UK) 4 times for 30 seconds on ice and then Triton X-100 added 2% (v/v).
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Bacterial lysates were placed on a roller for 20 minutes at 4°C; lysates were then
clarified by centrifugation at 12000 rpm for 30 minutes at 4°C. Bacterial lysates
mixed with 1 ml expanded glutathione-agarose beads (Sigma, Poole, UK) were
incubated on a roller overnight at 4°C. Beads were centrifuged at 1500 rpm for 15
minutes at 4°C and resuspended in 1 ml 100% glycerol and stored at -20°C until
required.
2.12.2 Ral Assay
Cells transfected (100mm dishes) as described in 2.5 were quiesced 24 hours prior to
lysis. Cells washed in ice-cold PBS were lysed in 450pl Ral lysis buffer (50mM Tris-
HC1, pH7.4, 200mM NaCl, 2.5mM MgCb, 1% NP-40 (v/v), 15% glycerol (v/v) and
Complete™ protease inhibitor tablet). Lysates were clarified by centrifugation at
13000 rpm for 10 minutes at 4°C and protein concentration estimated as described
previously. Protein concentrations were normalised and 400pl of each cell lysate
were incubated with 50pl of GST-RalBD-agarose beads for 60 minutes on a roller at
4°C, the remaining 50pl of cell lysate was solubilised with 4 x SDS-PAGE sample
buffer at 99°C for 5 minutes. Agarose beads were washed 4 times with Ral lysis
buffer and finally resuspended in 30jil 1 x SDS-PAGE sample buffer. Whole cell
lysates and Ral activity assay samples (20pl) were analysed by SDS-PAGE on a 15%
gel and western blots were probed with an anti-RalA monoclonal antibody
(Transduction Laboratories, Oxford, UK).
2.13 NF-kB Binding Assay
2.13.1 Nuclear Protein Extraction
Cells were transfected as described in 2.5 and quiesced twenty four hours prior to
lysis. The extraction procedure was performed on ice with ice-cold reagents. Cells
were washed with PBS and lysed in 500pl buffer A (20mM Hepes, lOmM KCl,
ImM EDTA, ImM DTT, lOOpM sodium vanadate, 10% glycerol, 0.2% NP-40 (v/v)
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and Complete™ protease inhibitor tablet). Cell nuclei were sedimented by
centrifugation at 10000 rpm for 10 minutes at 4°C and resuspended in 50pl buffer B
(20mM Hepes, 350mM NaCl, lOmM KC1, ImM EDTA, ImM DTT, lOOpM sodium
vanadate, 20% glycerol (v/v) and Complete™ protease inhibitor tablet). Nuclei were
incubated for 30 minutes on ice and then clarified by centrifugation at 13000 rpm for
10 minutes at 4°C. Nuclear protein concentration was estimated as described in 2.6.
2.13.2 Electrophoretic Mobility Shift Assay (EMSA)
The NF-kB consensus oligonucleotide (5'-AGT TGA GGG GAC TTT CCCAGG C-
3') and the SP-1 oligonucleotide (5'-ATT CGA TCG GGG CGG GGC GAG-3')
were purchased from Promega (Southampton, UK). The NF-kB oligonucleotide
(3.5pmol) was labelled with y- P ATP (lOpCi) with T4 polynucleotide kinase
according to the manufacturers instructions (Promega). Binding reactions performed
in a total of lOpl contained 5jug nuclear extract, 2jul EMSA binding buffer (50mM
Tris-HCl, pH7.5, 20% glycerol (v/v), 5mM MgCl2, 2.5mM EDTA, 2.5mM DTT,
250mM NaCl and 0.25mg/ml poly(dI-dC)*poly(dI-dC) and 1 pi y-32P-labelled probe.
Control binding reactions also contained either unlabelled NF-kB, SP-1
oligonucleotides (1.75pmol) or an anti-NF-kb P65 antibody (Santa Cruz, La Jolla,
USA). Binding reactions were performed for 20 minutes at room temperature and
then resolved on a 4% non-denaturing polyacrylamide gel run in 0.5 x TBE buffer at
200 volts. Gels were transferred to Whatman 3M paper (Whatman Inc, New Jersey,
USA), dried on a Biorad Gel-Dryer (Biorad, Hemel Hempstead, UK) at 80°C for 1
hour and exposed to Kodak X-Ornat film (Sigma) at -70°C with an intensifying
screen. Gels were also exposed to a Molecular Dynamics phospho-screen and
analysed on a Molecular Dynamics Storm™ 860 phospho-imager (Amersham
Pharmacia Biotech, Amersham, U.K). Band densitometry was performed with the
ImageQuant 5.0 software (Amersham Pharmacia Biotech).
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2.14 ERK Activity Assay
Cells were transfected as described in 2.5 and quiesced twenty four hours prior to
lysis. Samples were lysed on ice as for SDS-PAGE in 0.5ml lysis buffer (25mM
Hepes (Na salt), 0.3M NaCl, 1.5mM MgC12, 0.2mM EDTA, 0.5% Triton X-100
(v/v), 20mM (3-glycerophoshate, 0.5mM DTT, ImM sodium vanadate (pH 7.4) and
Complete™ protease inhibitor tablet (Boehringer Manheim)). Lysates were cleared
by centrifugation at 13000 rpm for 10 min and protein concentration determined as
described previously. Protein concentrations were normalised and 400j.il of each cell
lysate were incubated with 2pg of anti-myc (9E10) antibody (Santa Cruz) for 1 hour
at 4°C. Anti-mouse agarose beads (20pl/sample, Sigma) were added and the samples
vortexed for 1 hour at 4°C. Agarose beads were washed three times at 4°C in a buffer
containing 20mM Hepes, 50mM NaCl, 2.5mM MgCE and O.lmM EDTA and once
in kinase buffer containing 20mM Hepes, 0.5mM sodium fluoride, 7.5mM MgCb,
0.2mM EGTA, 2mM DTT, lOmM P-glycerophosphate, 0.5mM sodium vanadate and
Complete™ protease inhibitor tablet. Each sample was incubated at 30°C for 20
minutes in 20pl of kinase buffer containing lOpg myelin basic protein, lOOpM ATP
and lpCi y-33P ATP (500Ci/mmol) (Amersham Pharmacia Biotech). Samples were
spotted onto Whatman p81 paper (Whatman Inc, New Jersey, USA) and washed
extensively in 0.5% phosphoric acid and allowed to dry, radioactivity was quantified
by liquid scintillation counting using 'Flo-Scint' IV (Packard, Biosciences,
Groningen, Netherlands) and a Packard 1900 TR liquid scintillation analyser.
2.15 Immunoflourescence
Transfected cells were grown on sterile glass coverslips (22 x 22mm, Fisher,
Loughborough, UK) placed within 6 well tissue culture plates (Corning, High
Wycombe, UK). Cells were washed twice with PBS and fixed with ice cold 70%
methanol for 10 minutes followed with a second wash with PBS. Non-specific
binding sites were blocked with 0.2% fish skin gelatin/PBS (Sigma) for 20 minutes.
Coverslips were probed with anti-myc (9E10) antibody at a dilution of 1 in 50 in
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0.2% fish skin gelatin/PBS for 20 minutes. Washed cells were then probed with anti-
mouse Alexa-Green 488 (Molecular Probes) conjugated secondary antibody diluted 1
in 400 in 0.2% fish skin gelatin/PBS for 20 minutes. Coverslips were removed from
the tissue culture plates, washed in distilled H2O, allowed to dry and mounted on
slides using DAKO fluorescent mounting media (DAKO, Ely, UK). Slides were
visualised on a Carl-Zeiss Axiovert 5100 microscope (Jena, Germany) and images
captured using a Coolsnap cooled CCD camera and OpenLab 3.01 software
(Improvision, Lexington, USA).
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RESULTS: CHAPTER 3
Integrin Affinity Modulation by Ras and Raf
3.1 Introduction
Integrin "activation" can be broadly defined as an increase in ligand binding to the
integrin receptor. Integrins can use both affinity and avidity modulation to regulate
ligand binding. This thesis will concentrate on the mechanisms of integrin affinity
modulation and "integrin activation" will refer to integrin affinity unless otherwise
stated. Affinity modulation is associated with a conformational change within the
integrin that is both a dynamic and regulated cellular process (reviewed in Hynes
1992).
Fibrinogen binding to platelets requires prior activation of the fibrinogen receptor
cqibp3, this active integrin is specifically recognised by the PAC1 monoclonal
antibody (Shattil et al., 1985). PAC1, a ligand-mimetic antibody recognises ligand
binding sites within the active anbp3 integrin. Integrin-ligand binding is a divalent
cation dependent process. Chelation of Ca2+/Mg2+ with EDTA at 22°C can inhibit
PAC1 binding, while Mn2+ has often been used as a general activator of ligand
binding to integrins (Abrams et al., 1994; Gailit and Ruoslahti, 1988). Antibodies
that recognise Ligand-Induced Binding Sites (e.g. LIBS6 and Ab33) of otnbp3 also
activate the integrin by stabilising the active conformation (Frelinger, III et al.,
1990).
At present, the mechanisms regulating integrin affinity are poorly understood. A
model system in Chinese Hamster Ovary (CHO) cells was developed to allow
genetic and pharmacological study of integrin affinity modulation. Cells expressing
anbP3 fail to bind PAC1 even in the presence of activatory stimuli (O'Toole et al.,
1990). This suggests that integrin effectors absent in CHO cells may regulate ctnbP3
affinity. Substitution of the ctnbp3 cytoplasmic domain with asPi restored PAC1
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binding, other a chain chimeras including 0C2, ot6A and oi6B also allowed PAC1
binding (O'Toole et al., 1994). A CHO cell line stably expressing the chimeric
integrin anbOt6AP3Pi (ap-py cells) was used to screen cDNAs for their ability to
suppress the PAC1 binding integrin. An active variant of H-Ras (Ras G12V) was
capable of inhibiting PAC1 binding (integrin suppression) to the active chimeric
integrin in a MAP kinase dependent manner. Integrin suppression was not restricted
to the anbO-6AP3Pi integrin as other anbp3 chimeras were also suppressed (Hughes et
al, 1997).
Ras expression in several cells types have been reported to alter integrin expression
levels. Modulation of integrin levels by Ras appears to be both integrin and cell type
specific.
To understand the mechanisms of Ras-mediated integrin suppression, the aP-py
model system will be setup in this laboratory. Subsequent to reproducing initial
findings of Ras G12V-mediated integrin suppression, the Ras-ERK pathway will be
further examined for its role in integrin suppression.
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3.2 Detecting affinity modulation in the ap-py system
To further understand the process of integrin affinity modulation, a model system
(aP-py cells) was developed in CHO-K1 cells. These highly transfectable cells,
stably express a chimeric integrin on the cell surface that is used as a reporter for
integrin affinity modulation (Hughes et al., 1997).
3.2.1 PAC1 antibody binds to aP*py cells
Integrin affinity status of untransfected aP-py cells was determined as described in
Materials and Methods. Both the primary PAC1 mouse monoclonal antibody and its
secondary anti-mouse IgM-FITC (fluorescein isothiocyanate) antibody were titrated
for maximal binding to the aP-py cells. Figure 3.1A shows a representative
histogram of FL1-FITC fluorescence against cell counts. Compared to an IgM
isotype matched control antibody, the PAC1 antibody binds to untransfected aP-py
cells. Mean fluorescence intensity increased from 6.67 arbitrary units (AU) to 49.29
AU in the presence of the PAC1 antibody for this histogram.
3.2.2 Modulation of the integrin by external factors
To show that the chimeric integrin could undergo affinity modulation, cells were
treated with 5mM EDTA, lOOpM Mn2+ or 2pM Ab33. Figure 3.IB shows a
representative histogram of five experiments of FL1-FITC fluorescence of PAC1
binding to aP-py cells in the presence of EDTA or Mn2+. In the absence of
exogenous mediators, the mean fluorescence intensity of the native integrin was 74.8
± 8.5 AU. Addition of EDTA led to a loss of PAC1 antibody binding to 16.3 ± 1.4
2"b
AU, an increase in antibody binding was observed with lOOpM Mn (89.8 ±11.9
AU). The mean fluorescence of PAC1 binding in the three states allows a numerical
estimate of integrin activation to be calculated as an activation index as described in
Materials and Methods (2.8.2), where 0 units represents an inactive integrin (EDTA)
2+
and 100 units an active (high affinity) integrin (Mn ). The activation index (AI) for
these aP-py cells was 80.7 ± 2.3 units. This demonstrates that aP-py cells
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Figure 3.1 PAC1 antibody binding to aP-py cells.
PAC1 antibody binding to ap-py cells was determined by flow cytometry.
(A) PAC1 antibody binding to aP-py cells (solid black) and IgM isotype matched
control antibody (black line). (B) PAC1 binding in the presence of external factors,
untreated (solid black), 5mM EDTA (light grey line) or lOOpM Mn2+ (dark grey
line). Histograms are representative of five experiments.
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constitutively express the chimeric integrin anba.6AP3Pi in the active state that can be
modulated with external mediators.
3.2.3 Transfection of ap-py cells
CHO-K1 cells were chosen as the model system for their high transfection
capabilities. Hughes et al. (1997) have previously used Life Technologies reagent
Lipofectamine, to successfully transfect ap-py cells. A cell surface marker encoding
the extracellular domain of the IL-2 receptor, termed Tac, and the intracellular
domain of the 0.5 integrin (Tac-a.5) was used as a marker for transfection.
Transfection efficiency of ap-py cells was detected by flow cytometry using an
antibody against the IL-2 receptor, Tac-R-PE (R-phycoerythrin). Figure 3.2A shows
that transfection of the Tac-a.5 construct into ap-py cells leads to an increase in Tac-
PE fluorescence in the FL2 channel. Compared to an IgGi isotype matched control
antibody, 93% of the cells were positive for Tac-PE antibody binding. The Tac
positive cells displayed a range in FL2 fluorescence, representing the degree of
transfection with the Tac-005 construct.
To optimise transfection efficiency, Life Technologies new transfection reagent,
Lipofectamine Plus was tested. Figure 3.2B shows that the Plus reagent in
combination with Lipofectamine increased transfection from 47.5% to 78.6 %. The
Plus reagent was unable to transfect aP-py cells alone (0.1% transfection). All
subsequent transfections were performed with Lipofectamine in combination with
the Plus reagent.
The reporter construct Tac-a.5 was titrated for maximal expression in aP-py cells.
Transfection of 0.75pg of the Tac-ocs construct was sufficient to obtain a high degree
of Tac-PE positive cells (79%) (Figure 3.2C). Higher amounts of the construct were
not used so as not to interfere with constructs under test.
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Figure 3.2 Optimisation of transfection efficiency of the Tac-a5 reporter
construct.
(A) Tac antibody binding to a(3-py cells transfected with 0.75pg Tac-as was
determined by flow cytometry (solid black) and binding of the IgGi isotype matched
control antibody (grey line). Markers 1 and 2 separate untransfected and transfected
cells according to their FL2 fluorescence. Histogram is representative of three
experiments. (B) Percentage of Tac positive cells in cells transfected with 0.75 pg
Tac-a.5 with different transfection reagents and (C) with increasing quantity of the
Tac-as DNA.
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3.3 Integrin Affinity Modulation by Ras
3.3.1 Ras G12V expression mediates a loss of PAC1 antibody
binding
Integrin affinity status in transfected cells was determined as described in Materials
and Methods (2.8). The dot blots display PAC1-FITC binding (integrin status) on the
x-axis and Tac-PE antibody binding (transfection efficiency) on the y-axis. The
quadrant marker on each dot blot differentiates on the x-axis, cells with high and low
integrin affinity status and on the y-axis, highly transfected cells (red) against cells
transfected to a lesser extent (blue). The quadrant marker separating highly
transfected cells was set for individual experiments to contain the top 20-25% of Tac
positive cells. Figure 3.3 shows representative dot blots from cells transfected with
control vector or the Ras G12V construct. In control vector transfected cells the
majority of highly transfected cells (69%) are in the upper right hand quadrant.
Addition of 5mM EDTA to the cells leads to a leftward shift in the cell population
representing a loss of PAC1 binding with (96%) in the upper left quadrant. Addition
of 2pM Ab33 or 50pM Mn2+ (not shown) to the cells leads to a shift in the cell
population to the right. In the presence of these activating stimuli, the percentage of
cells in the high PAC1 binding quadrant increased to (87%). Addition of EDTA or
the activating stimuli to the cells act as internal controls for each transfection
representing a minimum and maximum of PAC1 binding in these cells. Transfection
of the Ras G12V construct into a|3-py cells (Figure 3.3) leads to a decrease in PAC1
binding. This is particularly evident in the highly transfected cells with (68%) in the
upper left quadrant compared to only (31%) in control vector transfected cells. Cells
with an intermediate degree of transfection show a decreased loss in PAC1 antibody
binding. Cells with low transfection efficiency fail to show any decrease in PAC1
binding. PAC1 binding in the presence of either EDTA or Ab33/Mn2+ were similar
to that observed with the control vector.
78









10" 10' 10' 10"












t • ■ ~









• " •* V* v. :
10"
Ras G12V
< '10° 10' 10' 10"

























ISrafir' '1 :W 9BS63S^f-"IwwjVXMv
J "o?S
1 '
i i lllin. i i ininir'"i*ninf<iii ■ i i mm
Ab33
10"
Figure 3.3 Integrin Affinity Modulation by Ras G12V.
Flow cytometry was performed on Ras G12V and control vector (lpg) transfected
cells to determine integrin affinity. Representative dot blots show PAC1 binding
versus Tac binding of Ras transfected cells, high Tac binding cells are shown in red.
In addition to the native integrin, PAC1 binding was also performed in the presence
of 5mM EDTA or 2pM Ab33. The quadrant markers separate both high and low Tac
and PAC1 binding cells. The percentage of high Tac binding cells in the upper left-
hand quadrant are shown for each dot blot.
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The Ras G12V construct is tagged with the 8 amino acid haemaglutinin epitope (Ha).
Expression of the Ha-tagged Ras protein was determined by western blotting of cell
lysates prepared from Ras transfected cells with increasing quantity of the Ras G12V
construct, total DNA quantity was normalised to 5pg with control vector in each
case. Figure 3.4A shows that the Ha-tagged Ras protein runs as a single band at
approximately 23 kDa and that 1 pg of Ras DNA is sufficient for optimal expression
in a[3-py cells. Occasionally a second band is observed in Ras G12V transfected cells
with the anti-Ha antibody. This 24-25kDa band has been observed in H-Ras
transfected COS cells as a post-translated modified form of the H-Ras protein (Voice
et al., 1999).
Examining the activation index in these Ras G12V transfected cells, the reduction in
specific PAC1 binding was used to calculate the percentage inhibition relative to the
control vector. Figure 3.4B shows that increasing the quantity of Ras G12V DNA led
to a rise in the percentage inhibition relative to control cells. This inhibition was
maximal (81 ± 3.8%) with transfection of approximately 2pg of Ras G12V DNA.
3.3.2 Ras G12V expression leads to ERK1/2 activation
In cells transfected with Ras G12V DNA, activation of the classical Ras-ERK
pathway was determined with a phospho-specific antibody that recognises dual
phosphorylated ERK 1 and 2. Figure 3.5A shows that in cells quiesced overnight
there was an increase in phosphorylation of both ERK1/2 in Ras G12V transfected
cells compared to cells transfected with control vector. The degree of
phosphorylation was similar in all Ras G12V transfected cells. Total ERK2 levels in
all samples were similar and unaffected by Ras expression in these cells (Figure
3.5B).
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Figure 3.4 The effect of Ras G12V expression on integrin affinity.
(A) Lysates from cells transfected with increasing quantity of Ras G12V were
probed with the anti-Ha antibody to detect Ras expression. This western blot is
representative of three experiments. (B) Suppression of the active integrin was
determined in Ras G12V transfected cells. Percentage inhibition was calculated by
comparing the activation index in the presence of Ras G12V DNA to that of the
control vector. The results shown are the mean ± SEM of 3 independent.
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Figure 3.5 Activation of ERK in Ras G12V transfected cells.
(A) Ras G12V transfected cell lysates were probed with the phospho-specific ERK
antibody and (B) the ERK2 antibody. The western blots are representative of three
independent experiments.
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3.4 Integrin Affinity Modulation by Raf
3.4.1 Raf expression mediates a loss of PAC1 antibody binding
The Raf kinase is a downstream effector of Ras. A membrane targeted Raf mutant
(Raf-BxB CAAX) that lacks the Ras binding regulatory domain was used as a
constitutively active kinase (Daub et al., 1998). Transfection of Raf-BxB CAAX into
a(3-py cells displayed a similar loss in PAC1 binding as that oberved with Ras G12V
DNA. Figure 3.6 shows that highly transfected Raf-BxB CAAX cells have lost
PAC1 binding and that 68% of the cells are now in the upper left hand quadrant
compared to 31% for control vector transfected cells. As observed with Ras G12V
transfected cells, cells with poor Raf transfection efficiency fail to show any decrease
inPACl binding.
Expression of the Raf-BxB CAAX construct in aP-py cells was determined by
western analysis of cell lysates. Membranes probed with the anti-FIa antibody
identified a protein that runs as a single band at approximately 42-44 kDa (Figure
3.7A). Optimal expression of this construct was seen when lpg of DNA was used
per transfection. Similar expression levels were observed with increasing quantity of
DNA.
Figure 3.7B shows the percentage inhibition of the active integrin with respect to
increasing Raf-BxB CAAX DNA. Maximum inhibition of the integrin was observed
when cells were transfected with lpg of DNA resulting in an inhibition of 60.6 ±
9.8%. Increasing the quantity of DNA did not significantly increase the level of
inhibition (Figure 3.7B).
3.4.2 Raf-BxB CAAX expression leads to ERK1/2 activation
The Raf kinase is an an upstream activator of the ERK1/2 pathway. Using the
phospho-specific ERK antibody, the phosphorylation state of ERK1/2 was examined
in Raf transfected cells. Figure 3.8A shows that in cells quiesced overnight there was
an increase in phosphorylation of both ERK 1 and 2 in Raf transfected cells
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Control RasG12V Raf-BxB-CAAX
PAC1 Binding
Figure 3.6 Integrin affinity modulation by Raf.
Flow cytometry was performed on Raf transfected cells to determine integrin
affinity. Representative dot blots show PAC1 binding versus Tac binding of both Ras
and Raf transfected cells, high Tac binding cells are shown in red. Cells were
transfected with 1 pg ofDNA in each case. The quadrant marker separate both high
and low Tac and PAC1 binding. The percentage of high Tac binding cells in the
upper left hand quadrant are shown for each dot blot. The dot blots are representative
of three experiments.
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Figure 3.7 The effect of Raf-BxB CAAX expression on integrin affinity.
(A) Lysates from cells transfected with increasing quantity of Raf-BxB CAAX DNA
were probed with the anti-Ha antibody to detect Raf expression The western blot is
representative of three experiments. (B) Integrin affinity of Raf transfected cells was
determined by flow cytometry. The results shown are the mean ± SEM of 3
independent experiments.










Figure 3.8 Activation of ERK in Raf-BxB CAAX transfected cells.
(A) Raf transfected cell lysates were probed with the phospho-specific ERK antibody
and (B) the ERK2 antibody. The western blots are representative of three
experiments.
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compared to cells transfected with the control vector. A comparable increase in
phosphorylation compared to control cells was observed in all Raf transfected cell
with increasing quantity of Raf DNA. Total ERK2 levels in all samples were similar
and unaffected by Raf expression in these cells (Figure 3.8B).
3.4.3 Differential effects of Raf isoforms on integrin affinity and
ERK1/2 activation
To date three Raf isoforms have been identified, Raf-1, A-Raf and B-Raf. These
isoforms have been shown to have differential effects on ERK1/2 activation (Marais
et al., 1997), transforming ability and their regulation. Previous results have shown
that transfection of Raf-1 into a|3-py cells could mediate a loss of PAC1 binding
(Figure 3.7B). It was hypothesised that expression of the Raf isoforms may reveal
differential effects on integrin affinity. Using constructs encoding wildtype Raf
isofoms, aP-py cells were transfected and integrin affinity was determined. Figure
3.9A shows that all three Raf isoforms were expressed in ctf3-py cells, with molecular
weights of 68, 93 and 70kDa for the myc-tagged A, B Raf and Raf-1 isoforms
respectively. B-Rafwas expressed at a higher level than both A-Raf and Raf-1.
The Raf isoforms have been shown to have different capabilities to stimulate
ERK1/2 phosphorylation. Figure 3.9B shows that compared to the empty vector, B-
Raf and Raf-1 both displayed an increase in ERK1/2 phosphorylation, with wildtype
B-Raf displaying the largest increase in phosphorylation. In contrast, expression of
A-Raf did not display any significant increase in ERK1/2 phosphorylation.
Expression ofERK2 was unaffected by Raf isoform expression (Figure 3.9C).
Figure 3.9D shows that wildtype Raf-1 can mediate a loss in PAC1 binding thereby
suppressing the active integrin. The percentage inhibition by wildtype Raf-1 was
31.2 ± 3.2% compared to 60.6 ± 9.8% for the constitutively active Raf kinase.
Increasing expression of Raf-1 protein to levels of B-Raf failed to increase integrin
suppression further. Transfection of wildtype B-Raf also inhibits the active integrin
to a greater degree than Raf-1 (57.2 ± 2.9%). In comparison to both Raf-1 and B-Raf,
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Figure 3.9 Effect of Raf isoforms on integrin affinity and ERK1/2
phosphorylation.
Cell lysates from Raf transfected cells were probed with (A) the anti-myc (9E10)
antibody. Lysates were also probed with (B) the phospho-specific ERK and (C)
ERK2 antibody. These western blots are representative of three experiments. (D)
Integrin affinity was determined in Raf transfected cells. The results shown are the
mean ± SEM of 3 independent experiments. Cells were transfected with 3pg of Raf
isoform DNA/Raf empty vector, lpg ofRas G12V was used as a positive control.
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the Raf isoform A-Raf failed to display any inhibition (-6.1 ± 6.2%). of PAC1
antibody binding
3.5 Reversal of Ras-mediated inhibition by MKP-1
To test whether ERK1/2 activation may be required for integrin suppression, integrin
suppression was examined in the absence of ERK1/2 phosphorylation. Map kinase
phosphatase 1 (MKP-1) is a broad spectrum phosphatase that dephosphorylates both
ERK1 and 2 in addition to several other members of the MAPK superfamily (Chu et
al., 1996). Transfection of a(3-py cells with a construct expressing MKP-1, which is
constitutively active in its wildtype form, reveals a protein of approximately 39kDa
by western blotting. A faint band detected with a reduced mobility in MKP-1
transfected cells may reflect a post-translationally modified MKP-1. Co-expression
of MKP-1 and Ras G12V in aP-py cells does not change the level of expression of
either MKP-1 or Ras G12V (Figure 3.10). Lysates from these co-expression
experiments were also probed with the phospho-specific ERK antibody. Figure 3.10
shows that as previously shown (Figure 3.5), expression of Ras G12V leads to an
increase in ERK1/2 phosphorylation. Transfection of MKP-1 into control vector
transfected cells leads to a complete loss of ERK1/2 phosphorylation; this was also
observed in Ras G12V transfected cells. Following long film exposure times, faint
ERK1/2 phosphorylation bands were observed in Ras G12V-MKP-1 transfected
cells, however, no bands were observed in control vector transfected cells. ERK2
protein levels in transfected cells remained constant and were unaffected by co-
expression ofMKP-1 (Figure 3.10E).
To determine whether activation of ERK 1/2 was required by Ras G12V for integrin
affinity modulation, ap-py cells were co-transfected with Ras G12V and MKP-1.
Figure 3.11 shows that co-transfection of MKP-1 into Ras G12V transfected cells
reversed the loss in PAC1 antibody binding observed in Ras G12V transfected cells.
Inhibition of the active integrin fell from 51.9 ± 3.7% to 5.5 ± 5.6% in MKP-1 co-
transfected cells. Expression of MKP-1 in control vector transfected cells led to a
slight increase (activation -11.1 ± 9.7%) in PAC1 antibody binding. This data
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Figure 3.10 Effect of expression of Ras G12V and MKP1 in co-transfected cells.
Lysates from cells co-transfected with Ras G12V (lpg) and MKP1 (2pg) were
probed with either (A) the anti-Ha antibody or (B) the anti-Myc (A 14) antibody.
Lysates were also probed for ERK phosphorylation with (C and D) phospho-specific
ERK antibody and (D) ERK2 antibody. Westerns blots are representative of three
experiments.












Figure 3.11 Effect of MKP1 expression on integrin affinity.
Integrin affinity was determined in Ras G12V (lpg) transfected cells, co-transfected
with either MKP1 (2pg) or control vector. The results shown are the mean ± SEM of
3 independent experiments.
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indicates that a MAP kinase sensitive to MKP-1 dephosphorylation may be involved
in Ras G12V integrin affinity modulation.
3.6 Inhibition of MEK1 fails to reverse Ras-mediated
integrin inhibition
Downstream of the Raf kinase are the MAPK kinases known as MEK1 and 2.
MEK1, the major contributor to ERK1/2 phosphorylation within cells is inhibited by
the Parke-Davis compound PD098059. PD098059 is a selective inhibitor of MEK1
with a reported IC50 value of lOpM in Swiss 3T3 cells (Dudley et al., 1995).
3.6.1 Inhibition of ERK phosphorylation with PD098059
Figure 3.12A shows that PD098059 (lOpM) was sufficient to inhibit Ras G12V-
mediated ERK1/2 phosphorylation back to control vector levels. At concentrations
greater than 10pM, ERK1/2 phosphorylation was reduced further to levels below
basal. Pre-treating control cells with PD098059 (lOOpM) was sufficient to inhibit
ERK 1/2 phosphorylation, however in Ras G12V transfected cells, a low level of
ERK 1/2 phosphorylation remained. PD098059 concentrations greater than 100p.M
were not used as a result of precipitates forming in the culture media.
Treatment of cells with the PD098059 compound did not alter total ERK levels or
effect Ras G12V expression levels (Figure 3.12B and C).
Performing band densitometry of the phospho-ERK blot an estimate of the IC50 for
the PD098059 compound was calculated for inhibition of ERK1/2 phosphorylation
in Ras G12V transfected cells. Figure 3.12D shows that the PD098059 compound
has an IC50 of 12pM, calculated by non-linear regression curve fitting. The IC50
value for PD098059 was similar to that quoted in the published literature (Dudley et
al., 1995).
Treatment of Ras G12V transfected cells with PD098059 (30pM) for 30 minutes was
sufficient to inhibit ERK1/2 phosphorylation. To determine the extent to which
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Figure 3.12 Effect of PD098059 on ERK phosphorylation in Ras G12V
transfected cells.
(A) ERK phosphorylation was determined in Ras G12V (lpg) transfected cells in the
presence of increasing concentration of the MEK1 inhibitor PD098059. ERK2
expression levels were also examined in treated cells (B). Expression of Ras G12V
was determined with the anti-Ha antibody (C). Western blots are representative of
two experiments. (D) Band densitometry was performed on a phospho-ERK blot
(Figure 3.12A) using the ERK2 band for analysis. IC50 determination was carried
out using non-linear regression curve fitting.
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Figure 3.13 Timecourse of PD098059 inhibition of ERK1/2 phosphorylation in
Ras G12V cells.
Ras G12V (lpg) transfected cells were treated with PD098059 (30pM) (PD) for
times ranging from lmin to 16 hours. Lysates were probed with (A) the phospho-
specific ERK antibody, (B) ERK2 antibody and (C) anti-Ha antibody.
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PD098059 can inhibit ERK1/2 phosphorylation, cells were pre-treated with
PD098059 for up to 16 hours prior to cell lysis. Figure 3.13A shows that in Ras
G12V transfected cells, inhibition of ERK1/2 phosphorylation occurred within 5
minutes and that phosphorylation levels remained below control levels for up to 16
hours of PD098059 treatment. ERK1/2 phosphorylation was also inhibited in control
vector transfected cells for up to 16 hours. ERK2 and Ras G12V expression levels
were unaffected by prolonged PD098059 treatment (Figure 3.13B and C). The
second band detected by the anti-FIa antibody that runs at approximately 24-25kDa is
a post-translationally modified form of H-Ras G12V that has previously been
described (Voice et al., 1999).
3.6.2 PD098059 fails to reverse Ras-mediated inhibition
Incubating a(3-py cells with 5mM EDTA together with the PAC1 antibody during
staining for flow cytometry for 30 minutes is sufficient to inhibit PAC1 binding to
the cells. This suggests that affinity modulation of the integrin can occur in a short
period of time. Previous results have shown that 30 minute pre-treatment of cells
with the PD098059 inhibitor can prevent ERK1/2 phosphorylation in Ras G12V
transfected cells (Figure 3.13A). Quiesced cells were treated with PD098059 (30pM)
for 30 minutes prior to staining for integrin affinity state determination. Soybean
trypsin inhibitor (2mg/ml) was used in this set of experiments, to neutralise the
trypsin, rather than serum containing media to avoid complications arising from
rapid ERK1/2 activation by serum components. Figure 3.14A shows that Ras G12V
transfected cells treated with PD098059 (30pM) displays no change in the
percentage inhibition of the active integrin, 65 ± 11.3 and 63 ± 15.5% respectively
for diluent and PD098059 treated cells. Statistical analysis (one-way ANOVA)
showed no significant difference (P>0.05) between either control or Ras G12V
transfected cells treated with DMSO and PD098059. Control vector PD098059
treated cells displayed a slight increase in PAC1 antibody binding compared to
diluent treated cells (-15 ± 13.4%).
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Figure 3.14 The effect of 30 minute PD098059 treatment on integrin affinity in
Ras transfected cells.
(A) Suppression of integrin activation was determined in Ras G12V (lpg)
transfected cells treated with PD098059 (30pM) for 30 minutes. The results shown
are the mean ± SEM of 4 independent experiments. Ras G12V transfected cell
lysates treated with PD098059 were probed with (B) the phospho-specific ERK
antibody, (C) the ERK2 antibody and (D) the anti-Ha antibody. Western blots are
representative of three experiments. Statistical analysis was performed by one-way
ANOVA test.
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Figure 3.15 The effect of 16-18 hour PD098059 treatment on integrin affinity in
Ras transfected ceils.
(A) Suppression of integrin activation was determined in Ras G12V (lpg)
transfected cells treated with PD098059 (30pM) for 16-18 hours. The results shown
are the mean ± SEM of 4 independent experiments. Ras G12V transfected cell
lysates treated with PD098059 were probed with (B) the phospho-specific ERK
antibody, (C) the ERK2 antibody and (D) the anti-Ha antibody. Western blots are
representative of three experiments. Statistical analysis was performed by one-way
ANOVA test.
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Treatment of either Ras G12V or control vector transfected cells with PD098059
(30pM) inhibited ERK1/2 phosphorylation (Figure 3.14B). No change in total ERK2
levels or expression of the Ha-tagged Ras G12V were observed in PD098059 treated
cells (Figure 3.14 C and D). The PD098059 inhibitor can prevent ERK1/2
phosphorylation in Ras G12V transfected cells for a sustained period of time (Figure
3.13A). Inhibition of ERK1/2 phosphorylation was observed in cells treated
overnight (16-18 hrs). To determine whether reversal of Ras G12V-mediated integrin
suppression required a prolonged period of time in the absence of ERK1/2
phosphorylation, cells were treated with PD098059 for between 16-18 hours. Figure
3.15A shows that treatment of Ras G12V transfected cells with PD098059 only
produced a slight decrease in integrin suppression, 58.3 ±2.1 to 46.3 ± 2.0 percent.
This drop in percentage inhibition was not statistically significant (P>0.05) by the
one-way ANOVA test. Treatment of control vector transfected cells with PD098059
showed no change in integrin affinity (1.5 ± 5.9%).
Treatment of either Ras G12V or control vector transfected cells with PD098059 for
16-18 hours inhibited ERK1/2 phosphorylation (Figure 3.15B). No change in total
ERK2 levels or expression of the Fla-tagged Ras G12V was observed in PD098059
treated cells (Figure 3.15C and D).
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3.7 Discussion
The a(3-py transfection and flow cytometry system, developed by Dr. M. Ginsberg
and colleagues (Scripps Research Institute, La Jolla, USA), was set up in this
laboratory to enable the examination of the role of Ras and its effectors, together
with ERK1/2 activation for their role in modulating integrin affinity.
PAC1, a ligand mimetic antibody, specifically recognises the a.nbP3 integrin when in
the high affinity state (Shattil et al., 1985). The ability of the PAC1 antibody to bind
to the chimeric otnba6AP3Pi integrin present on the aP-py cells is in agreement with a
previous report that this integrin is constitutively active in aP-py CHO-K1 cells
(Hughes et al., 1997). Full length anbP3 expressed in CHO-K1 cells is not recognised
by the PAC1 antibody. It would seem likely that interactions of cell specific factors
in CHO-K1 cells to the o.6aPi cytoplasmic domain within the chimera must induce a
conformation change in the integrin to the high affinity state. Chimeras containing
the (X5P1 cytoplasmic domain have also been shown to produce a high affinity
integrin state (Hughes et al., 1997).
The affinity status of this integrin was modulated through exogenous factors;
chelation of Ca2+ and Mg2+ ions with EDTA at 20-22°C induced a low integrin
affinity state, termed "suppressed integrin". Conversely, Mn2+ or an anbP3
stimulating antibody, Ab33, increased the activation index of the chimeric integrin.
CHO-K1 cells are a highly amenable cell line for transfection. Several transfection
reagents and electroporation techniques have been used to transfect these cells. Using
the Tac-a.5 reporter construct, which has previously been shown to have no effect on
integrin affinity in ap-py cells (Chen et al., 1994), we were able to optimise the
transfection procedure for these cells in this laboratory. Lipofectamine Plus was used
to enhance transfection efficiency to that compared with Lipofectamine, which has
previously been used successfully to transfect the aP-py cells (Hughes et al., 1997).
The Plus reagent, a proprietary formulation is a pre-complexing reagent that aids
complex formation between DNA and lipid. The Plus reagent in combination with
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Lipofectamine increased transfection efficiency by 65% above Lipofectamine alone.
In addition to the increased transfection efficiency, the protocol required a reduced
quantity of DNA and lipid to achieve the increased level of transfection. Following
this protocol, most constructs used throughout this thesis displayed transfection
efficiencies between 50 and 80%.
Hughes et al. (1997) have previously shown that H-Ras can suppress the chimeric
integrin in ocP-py CHO-K1 cells (Hughes et al., 1997). Suppression of the active
integrin was not a consequence of a decrease in integrin expression levels as normal
PAC1 antibody binding was restored in the presence of an activating anbP3
monoclonal antibody, anti-LIBS6 (O'Toole et al., 1994). It was also shown that
normal PAC1 binding in Ras G12V transfected cells was restored by activating the
integrin, indicating that expression of the chimeric integrin was unaffected by Ras
expression in ap-py cells. Fujimoto et al. (2001) have recently shown that stable
expression of Ras G12V in a pro-B cell line had no effect on the expression of a^Pi
(Fujimoto et al., 2001). This correlates with the observations of ctP-py cells
transfected with Ras G12V. The chimeric integrin contains the cytoplasmic domain
of the otePi integrin and therefore signalling events towards this integrin should
reflect that observed with the full length a,6Pi integrin.
Integrin suppression by Ras was reproduced in this laboratory using a mutant of Ras
(G12V) that is constitutively active. Substitution of the glycine at position 12 to a
valine disrupts the endogenous Ras GTPase activity; the increase in GTP loading of
Ras generates a Ras protein that predominates in the active conformation (Trahey
and McCormick, 1987). Ras G12V suppressed the chimeric integrin, represented as a
decrease in PAC1 binding. This effect was cell-autonomous as untransfected cells
(Tac negative) do not show a decrease in PAC1 binding (Figure 3.3), this suggests
that Ras G12V transfected cells cannot affect integrins on neighbouring
untransfected cells.
Affinity modulation of integrins by active Ras expression has also been reported by
several groups recently. Active Ras has been shown to activate LFA-1 ((XLP2) in T-
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cells, while in a pro-B cell line, activation of both (X4P1 and OC5P1 was observed (Liu
et al., 1999; Shibayama et al., 1999; Tanaka et al., 1999). These results apparently
contradict this data that active Ras mediates integrin suppression. Activation of
integrin affinity by Ras has only been observed with integrins in their resting state.
Transfection of Ras G12V into CHO-K1 cells expressing full length anbP3 was
shown not to activate the low affinity anbP3 (Zhang et al., 1996a). The action of Ras
on the constitutively active chimeric integrin may reflect differential effects of Ras
dependent on the affinity state of the native integrin and the cell type.
Several proteins have been described that bind to Ras, many of these proteins are
also activated by the GTP bound form of Ras (Marshall, 1996). One of the best
described effectors downstream of Ras is the serine-threonine kinase Raf-1 (Kolch,
2000). Overexpression of the wildtype Raf-1 protein or a constitutively active mutant
(Raf-BxB CAAX) both suppressed the chimeric integrin. Activation of Raf-1 has
been shown to require binding to membrane localised Ras and activation by the
tyrosine kinase, Src (Blumer and Johnson, 1994). Basal Ras and Src activity in cells
transfected with wildtype Raf-1 alone, may not sufficiently activate Raf-1 kinase
activity in ap-py cells. Partial activation of Raf-1 in cells transfected with wildtype
Raf-1 alone, may reflect the reduction in integrin suppression observed with wildtype
Raf-1 compared to Raf-BxB CAAX. The active Raf-1 mutant (Raf-BxB CAAX)
suppressed the chimeric integrin to a similar degree to that of Ras G12V. Expression
of active Src in aP-py cells has also been shown to suppress integrins through
activation of endogenous Ras and Raf (Hughes et al., 1997). Thus, activation of
endogenous Ras and Raf activity can induce suppression of integrin activation.
Expression of either Ras G12V or Raf-BxB CAAX both increased ERK1/2
phosphorylation in aP-py cells. Dual phosphorylation of ERK2 on amino acids
Thrl83 and Tyrl85 by MEK leads to an increase in ERK kinase activity (Crews et
al., 1992). ERK1/2 activation correlated with integrin suppression in both Ras and
Raf transfected cells. A similar correlation was observed with the differential
activation of ERK1/2 by the Raf isoforms. Suppression was greatest with B-Raf; this
kinase displayed increased ERK1/2 activation compared to both Raf-1 and A-Raf.
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High basal B-Raf activity has been attributed to the requirement of only Ras
interaction for activation (Marais et al., 1997). A-Raf in contrast failed to suppress
the integrin and activate ERK1/2. Pritchard et al. (1995) have shown that A-Raf is a
poor activator of MEK causing reduced ERK1/2 phosphorylation (Pritchard et al.,
1995). We cannot exclude the possibility that transfection of wildtype A-Raf into
a,p-py cells may not generate an active kinase and explain the lack of integrin
suppression. Marais et al. (1997) have shown that similar to Raf-1, A-Raf requires
both Ras and Src for activation. As wildtype Raf-l was partially activated in ot(3-py
cells, demonstrated by the increase in ERK1/2 phosphorylation, the failure of A-Raf
to suppress integrins may reflect the lack of ERK1/2 activation, rather than a lack of
Raf kinase activity.
The requirement for ERK1/2 activation by Ras and Raf for integrin suppression was
addressed by the use ofMKP-1 and PD098059. Both MKP-1 and PD098059 prevent
accumulation of active ERK1/2 within cells by active Ras either through
dephosphorylation of ERK1/2 (Alessi et al., 1993) or inhibition ofMEK1 (Dudley et
al., 1995). The reduction in ERK1/2 activation by these two methods produced
conflicting effects on integrin suppression. MKP-1 reversed Ras G12V-mediated
integrin suppression by 89% while prolonged PD098059 treatment only reduced
suppression by 20%.
PD098059 is a highly specific inhibitor of ERK1/2 activation (Dudley et al., 1995),
at a concentration of 30pM used during these experiments; PD098059 has been
shown to have no inhibitory effects on activation of other members of the MAPK
superfamily including JNK and p38 MAP kinase (Davies et al., 2000). PD098059
reduces ERK1/2 activation through the stabilisation of inactive MEK1 within the
cells (Alessi et al., 1995). The absence of active MEK1 and ERK1/2 in Ras G12V
transfected cells treated with PD098059 suggests that neither components
downstream of Rafmay be required for suppression. PD098059 has also been shown
to have no significant effect on adhesion to fibronectin induced by activation of CO4P1
and a5Pi by active Ras (Liu et al., 1999; Shibayama et al., 1999). These results also
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suggest that a pathway insenisitive to PD098059 may exist for Ras-mediated integrin
affinity modulation.
The inability of PD098059 to reverse Ras G12V-mediated integrin suppression may
reflect a PD098059 insensitive pathway downstream of Ras. This pathway either
diverges at the point of Ras through another Ras effector besides Raf, or that Raf
may activate a MKP-1 sensitive kinase pathway that is not dependent on ERK1/2
activation. Both of these proposals will be addressed in subsequent chapters.
The reversal of integrin suppression by MKP-1 may reflect the broad specificity of
this enzyme. MKP-1 has shown overlapping substrate specificity with other members
of the MAPK superfamily including JNK and p38 MAPK (Chu et al., 1996). Hughes
et al. (1997) have shown that activation of JNK, by active cdc42, in a(3-py cells does
not lead to integrin suppression (Hughes et al., 1997). Inhibition of p38 MAP kinase
with SB203580 has also been shown to have no effect on Ras G12V-mediated
integrin suppression (P. Hughes personnel communication). This would implicate a
MAP kinase other than ERK1/2, JNK or p38 MAP kinase sensitive to MKP-1
dephosphorylation is responsible for Ras G12V-mediated integrin suppression.
In summary the a(3-py integrin affinity detection model and transfection system were
set up in this laboratory and that initial findings that active Ras and Raf mediate
integrin suppression were reproduced. This suppression while sensitive to MKP-1
co-expression was not affected by treatment with PD098059. This raises the
possibility of multiple Ras effectors being involved or that a pathway insentive to
PD098059 is required for integrin suppression.
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RESULTS: CHAPTER 4
Integrin Suppression by Ras Effectors
4.1 Introduction
Ras is a small guanine nucleotide binding protein that cycles between an active GTP
bound and an inactive GDP bound state. Upon GTP binding, the Ras protein
undergoes a conformational change localised to two main areas of primary structure;
switch region 1 (amino acid 32-40) and switch region 2 (60-76) (reviewed in Polakis
1993). Mutations of residues within the switch region 1, termed the "effector-
domain" have shown a reduction in Ras transforming ability (Sigal et al., 1986;
Willumsen et al., 1986). The first Ras effector to be identified was the GTPase
activating protein (pi20 GAP) (Trahey and McCormick, 1987) subsequently, Raf
kinase, PI3-kinase and Ral-GDS were also shown to be effectors (Han et al., 1993;
Hofer et al., 1994; Rodriguez-Viciana et al., 1994; Spaargaren and Bischoff, 1994;
Warne et al., 1993; Zhang et al., 1993). Other Ras effectors have been identified; see
Discussion, (reviewed in Campbell 1998).
Single amino acid mutations within the effector domain have revealed that multiple
effector pathways contribute to cell transformation. The best described of which are
Thr35-Ser35 (T35S), Glu37-Gly37 (E37G) and Tyr40-Cys40 (Y40C), all within the Ras
G12V background. Initial yeast two hybrid and binding studies performed with Ras
mutants and effectors Raf, PI3-kinase and Ral-GDS, displayed preferential binding
to only one of the effectors while failing to bind to the other two. Ras (G12V, T35S)
is able to bind to Raf, Ras (G12V, E37G) to Ral-GDS and Ras (G12V, Y40C) to PI3-
kinase (Rodriguez-Viciana et al., 1997; White et al., 1995).
These mutants have routinely been used to ascribe Ras effectors to cell function. Cell
transformation has principally been attributed to Raf signalling, however, Ras
(G12V, E37G/Y40C) signalling synergised with Ras (G12V, T35S) to enhance
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transformation (Khosravi-Far et al., 1996; Rodriguez-Viciana et al., 1997; White et
al., 1995). Tumour metastasis, however, appears to rely on Ras-Raf signalling (Webb
et al., 1998). These mutants have also been used to analyse Ras function in cell
proliferation, DNA synthesis, transcription factor activation and skeletal myogenesis.
In this chapter Ras mutants and their effectors have been used to examine their role
in Ras G12V-mediated integrin suppression. Integrin affinity during co-expression
studies with Ras mutants and R-Ras G38V will also be performed.
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4.2 Effect of Ras effector mutants on integrin affinity
In the previous chapter, expression of an active mutant of Ras or Raf has shown to
mediate integrin suppression. A MAP kinase pathway was implicated to mediate
integrin suppression, however, the MEK1 inhibitor PD098059 failed to reverse Ras
G12V-mediated integrin suppression. These results (Chapter3) raise the possibility
that Ras effectors in addition to Raf may play a role in integrin suppression. The H-
Ras G12V effector mutants in the same expression vector as Ras G12V allow us to
examine whether other Ras effector pathways are required for integrin suppression.
4.2.1 Activation of ERK by Ras effector mutants
The Ras effector mutations generated in the Ras G12V background were transfected
into aP-py cells. Figure 4.1A shows that all three mutants were expressed in aP-py
cells at approximately 23kDa. Both Ras (G12V, E37G) and Ras (G12V, T35S)
mutants displayed similar expression levels to Ras G12V, however a reduced level of
expression was consistently observed with Ras (G12V, Y40C).
Probing cell lysates with the phospho-specific ERK antibody showed an increase in
ERK1/2 phosphorylation with Ras G12V (Figure 4.IB). Neither Ras (G12V, E37G)
nor Ras (G12V, Y40C) transfected cells displayed any increase in ERK1/2
phosphorylation above control vector transfected cells. Compared to control cells,
ERK 1/2 phosphorylation was slightly increased in Ras (G12V, T35S) transfected
cells but not to the same extent as Ras G12V. Total ERK2 levels remained
unchanged in Ras transfected cells (Figure 4.1C).
4.2.2 Ras effector mutants can mediate integrin suppression
Integrin affinity was determined in cells transfected with the Ras effector mutants.
Integrin affinity in Figure 4.2 was represented as an activation index (AI, see
Materials and Methods) to highlight the large variability that was observed with Ras
(G12V, Y40C). Integrin activation index in control cells (70.7 ± 8.5) fell to 17.4 ±
4.1 in Ras G12V transfected cells (77.0 ± 4.3% inhibition). Both Ras (G12V, E37G)
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Ras G12V
Figure 4.1 Effect of expression Ras G12V effector mutants on ERK
phosphorylation.
Lysates from cells transfected with the Ras G12V effector mutants (lpg) were
probed with (A) the anti-Ha antibody (B) phospho-specific ERK antibody and (C)
ERK2. The western blots are representative of three experiments.
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Figure 4.2 Effect of Ras G12V effector mutants on integrin affinity.
Activation index was determined in aP-py cells transfected with Ras G12V (lpg) or
Ras G12V effector mutants (lpg). The results shown are the mean ± SEM of 3
independent experiments. Statistical analysis was performed by one-way ANOVA
test; asterisk indicates a significant difference (P<0.05).
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(25.3 ± 14.6) and Ras (G12V, T35S) (27.9 ± 6.6) also displayed a drop in activation
index. The Ras (G12V, Y40C) (49.3 ± 17.0) mutant also displayed some integrin
suppressive capabilities, however suppression was highly variable between
transfections. Except for Ras (G12V, Y40C) transfected cells, all other transfected
cells displayed a significant differences in activation index (P<0.05) compared to
control cells. Increasing Ras (G12V, Y40C) expression to levels similar to Ras
(G12V, E37G/T35S) did not increase integrin suppression further (data not shown).
These results suggest that Ras effectors other than Rafmay also contribute to integrin
suppression, which may explain the inability of PD098059 to reverse Ras G12V-
mediated integrin suppression. Individual effector pathways downstream of Ras were
subjected to further analysis for their role in integrin suppression.
4.3 Integrin suppression by Ras (G12V, T35S)
The Ras (G12V, T35S) mutant has been shown to bind to Raf (White et al., 1995)
and increase Raf activity. The increase in Raf activity was approximately 3-4 fold
less than Ras G12V (Rodriguez-Viciana et al., 1997). PD098059 failed to reverse
Ras G12V-mediated integrin suppression, treating Ras (G12V, T35S) transfected
cells with PD098059, the effect of specifically inhibiting the Ras/Raf pathway was
determined.
4.3.1 PD098059 prevents ERK1/2 phosphorylation
Cells transfected with Ras G12V or Ras (G12V, T35S) were treated with PD098059
(30pM) for 16-18 hours and cell lysates analysed for ERK1/2 phosphorylation.
Figure 4.3A shows that both Ras G12V and Ras (G12V, T35S) caused an increase in
ERK1/2 phosphorylation compared to control transfected cells. While Ras (G12V,
T35S) stimulates ERK1/2 phosphorylation above control vector transfected cells, the
increase in Ras G12V transfected cells is far greater. These results were similar to
that observed previously (Figure 4. IB). PD098059 inhibited ERK1/2
phosphorylation in all transfected cells. Total ERK2 and Ha-Ras expression were not
affected by PD098059 treatment (Figure 4.3B and C).
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Figure 4.3 Effect of PD098059 on Ras (G12V, T35S) transfected cells.
Cells transfected with Ras G12V or Ras (G12V, T35S) (lpg) were treated with
PD098059 (30pM) for 16-18 hours. Lysates were probed with (A) phospho-ERK
antibody, (B) ERK2 antibody and (C) anti-Ha antibody. Western blots are
representative of between 2 and 3 experiments.
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4.3.2 PD098059 fails to reverse integrin suppression
The increase in ERK1/2 phosphorylation by Ras (G12V, T35S) transfection was
inhibited by PD098059 (30pM) treatment. Integrin suppression by Ras (G12V,
T35S) however, was only slightly inhibited by PD098059 treatment (56.0 ± 5.5% to
47.3 ± 2.6%). Figure 4.4 shows that the effect of PD098059 on Ras (G12V, T35S)
transfected cells was similar to that observed with Ras G12V transfected cells (58.1
± 1.6% to 42.3 ± 4.3%). Addition of PD098059 to either Ras G12V or Ras (G12V,
T35S) was not significantly different (P>0.05) to DMSO diluent treated cells. These
results suggest that the Ras (G12V, T35S)/Raf pathway may mediate integrin
suppression by a PD098059 insensitive pathway.
4.3.3 MKP-1 expression prevents ERK1/2 phosphorylation
MKP-1 expression prevented ERK1/2 phosphorylation and reversed integrin
suppression by Ras G12V (Chapter 3.5). Whether MKP-1 expression would have a
similar effect on Ras (G12V, T35S) transfected cells was determined.
Figure 4.5A and B shows that in cells co-transfected with Ras G12V and MKP-1,
both constructs were expressed and that expression levels were similar between co-
transfectants. ERK1/2 phosphorylation in Ras G12V and Ras (G12V, T35S)
transfected cells was completely inhibited in cells co-transfected with MKP-1
(Figure 4.5C). Total ERK2 levels were unaffected by MKP-1 co-transfection (Figure
4.5D).
4.3.4 MKP-1 reverses Ras (G12V, T35S)-mediated integrin
suppression
Integrin suppression mediated by Ras (G12V, T35S) was reversed in cells co-
transfected with MKP-1 (Figure 4.6). Inhibition fell from 54.6 ± 5.1% to 3.4 ± 9.6%
in MKP-1 co-transfectants. The reversal of Ras (G12V, T35S)-mediated integrin
suppression was similar to that observed in cells transfected with Ras G12V. MKP-1
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Figure 4.4 Effect of PD098059 on integrin affinity in Ras (G12V, T35S)
transfected cells.
Integrin affinity was determined in cells transfected with Ras G12V or Ras (G12V,
T35S) (1 p.g) treated with PD098059 (30pM) for 16-18 hours. The results shown are
the mean ± SEM of 5 independent experiments. Statistical analysis was performed by
one-way ANOVA test.



















Figure 4.5 Effect of MKP-1 co-expression with Ras (G12V, T35S) on ERK
phosphorylation.
Lysates from cells co-transfected with Ras (G12V, T35S) (l|4g) and MKP-1 (2pg)
were probed with (A) anti-myc (A 14) antibody and (B) anti-Ha antibody. Lysates
were also probed with (C) phospho-specific ERK antibody and (D) ERK2 antibody.
The western blots shown are representative of 3 experiments.








Figure 4.6 Effect of MKP-1 co-expression on Ras (G12V, T35S) mediated
integrin affinity.
Integrin affinity was determined in cells co-transfected with either Ras G12V or Ras
(G12V, T35S) (lpg) and MKP-l/empty vector (2pg). The results shown are the
mean ± SEM of 3 independent experiments.
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co-expression with the control vector was able to slightly activate the integrin (-11.1
± 9.7%).
The results observed with cells transfected with Ras (G12V, T35S) mirror those
previously observed with Ras G12V. The results suggest that integrin suppression by
the Ras (G12V, T35S)/Raf effector arm is mediated by a PD098059 insensitive
pathway that remains sensitive to MKP-1 co-expression.
4.4 Integrin suppression by Ras (G12V, E37G)
The Ras (G12V, E37G) effector mutant displayed integrin suppressive abilities
similar to that of Ras (G12V, T35S). The Ras (G12V, E37G) mutant has been shown
to bind specifically to RalGDS and shows no increase in Raf or PI3K activity
(Rodriguez-Viciana et al., 1997). This suggests that the pathway downstream of Ras
(G12V, E37G) may modulate integrin affinity through RalGDS. RalGDS is a
member of three known RalGEFs that increase the activity ofRal downstream of Ras
(Albright et al., 1993; Hofer et al., 1994). Using constructs that express
constitutively active and dominant negative forms of RalA (bind active RalGEFs and
prevent signalling), we assessed the role Ral may play in Ras (G12V, E37G)-
mediated integrin suppression.
4.4.1 Expression of RalA in a(3-py cells
Initial expression studies with the RalA constructs provided by J. Bos (Netherlands)
displayed very poor expression in the a[3-py CHO-K1 cells (data not shown). To
increase expression of the Ral constructs, the three Ral constructs (wildtype, 23V
(active) and 28N (dominant negative)) were cloned by high fidelity PCR into an
alternative mammalian expression vector, pCMV-Tag3B. Cells transfected with the
RalA constructs expressed a protein of 26kDa, detected on a western blot with the
anti-myc (9E10) antibody (Figure 4.7). All three constructs displayed similar
expression levels in the a(3-py cells.
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Figure 4.7 Ral activity of RalA mutants.
Lysates from cells transfected with either control Tag3B vector or RalA mutants
(2pg) were probed with (A) the anti-myc (9E10) antibody. Lysates were subjected to
(B) pull down assay with a GST-Ral BD fusion protein. Ral bound to the beads was
probed with the anti-Ral antibody. (C) Whole cell lysates were probed with the anti-
Ral antibody. Western blots are representative of 3 experiments.
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4.4.2 Activity of RalA in transfected cells
RalA activity was measured in a pull-down assay with the Ral binding domain of
RLIP76 (RalBD), a Ral effector. The amount of Ral precipitated with RalBD has
been shown to correlate with the level ofGTP bound Ral (Wolthuis et al., 1998). Ral
activity was measured in cells transfected with the RalA constructs. Figure 4.7B
shows that a small amount of Ral was precipitated in cells transfected with wildtype
RalA compared to control 3B transfected cells. Cells transfected with the
constitutively active RalA (23V) displayed a large quantity of precipitated Ral,
whereas very little was precipitated with the dominant negative RalA (28N). Upon
long film exposure times, a small amount of Ral was detected in RalA 28N
transfected cells. Whole cell lysates probed with the anti-RalA antibody show that
the three RalA constructs were expressed to similar levels. Endogenous RalA was
also detected with the anti-RalA antibody in control 3B transfected cells (Figure
4.7C).
4.4.3 Effect of RalA expression in Ras (G12V, E37G) transfected
cells
The Ras (G12V, E37G) mutant has been shown to increase Ral dependent signalling
(Wolthuis et al., 1997). Ral activity was measured in cells co-transfected with Ras
(G12V, E37G) and RalA. Whole cell lysates from transfected cells were probed with
the anti-RalA antibody (Figure 4.8A). Endogenous RalA expression was not affected
with expression of either Ras (G12V, E37G) or RalA constructs. Myc-tagged RalA
expression was similar in all transfected cells. Expression of either Ras G12V or Ras
(G12V, E37G) led to an increase in endogenous RalA activity compared to control
vector transfected cells (Figure 4.8B). An increase in Ral activity was also observed
in cells transfected with RalA 23V. The dominant negative RalA construct (28N)
inhibited Ral activation in both control and Ras (G12V, E37G) transfected cells.
Figure 4.8C shows that expression of Ha-Ras (G12V, E37G) was similar in all
transfected cells.
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Figure 4.8 Ral activity in Ras (G12V, E37G) and RalA transfected cells.
Ral activity was measured in lysates from cells transfected with Ras (G12V, E37G)
(lpg) and RalA mutants (2pg). (A) Active Ral bound to GST-Ral BD agarose beads
was probed with the anti-RalA antibody. (B) Whole cell lysates were also probed
with the anti-RalA antibody and (C) the anti-Ha antibody. The western blots shown
are the representative of 3 experiments.
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4.4.4 Effect of Ras (G12V, E37G) and RalA co-expression on
integrin affinity
It was shown that RalA 23V is active in transfected cells and that RalA 28N can
prevent Ras (G12V, E37G) activation of endogenous Ral. The effect of constitutively
active and dominant negative RalA on integrin affinity is shown in Figure 4.9.
Compared to control 3B vector transfected cells, RalA 23V did not lead to any
significant suppression of integrins (3.8 ± 7.4%) (P>0.05). The dominant negative
RalA (28N) only produced a small activation of the integrin (-5.8 ± 10.8%, P>0.05).
In cells co-transfected with Ras (G12V, E37G), inhibition of Ral activation with
RalA 28N only slightly reduced integrin suppression (57.1 ± 0.55% to 47.3 ± 3.3%).
Co-expression of Ras (G12V, E37G) and RalA 23V did not increase integrin
suppression further than Ras (G12V, E37G) alone (41.6 ± 3.9%). No significant
difference in percentage inhibition was observed (P>0.05) in cells co-expressing Ras
(G12V, E37G) and RalA mutants compared to co-expression with the RalA empty
vector.
These results suggest that while Ras (G12V, E37G) can mediate integrin
suppression, activation of the Ral pathway may not necessarily be required for
integrin suppression.
4.5 PI3K activation is not required for integrin suppression
The Ras (G12V, Y40C) displayed inconsistent levels of integrin suppression. This
mutant has only been shown to interact with the PI3-kinase pi 10a and leads to an
increase in PIP3 levels (35% of Ras G12V) (Rodriguez-Viciana et al., 1997). Ras
(G12V, Y40C) showed no interactions with Raf or RalGDS (Rodriguez-Viciana et
al., 1997). To test whether PI3-kinase activation by Ras (G12V, Y40C) was
responsible for affects on integrin affinity, a membrane targeted pi 10a (pi 10a-
CAAX) construct was used.
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Figure 4.9 Effect of RalA expression on integrin affinity.
RalA mutants (2pg) were co-transfected with Ras (G12V, E37G) (lpg) or empty
vector. Percentage inhibition was calculated in reference to the Tag3B empty vector.
The results shown are the mean ± SEM of three independent experiments. Statistical
analysis was performed by one-way ANOVA test.
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In cells transfected with either Ras G12V or pi lOa-CAAX, cell lysates probed with
an anti-Akta antibody showed similar expression in all transfected cells (Figure
4.1OA). This sheep polyclonal antibody also cross reacts with a protein
approximately 36kDa in size, that protein has yet to be identified. An increase in Akt
phosphorylation (PI3-kinase effector pathway) was observed in Ras G12V and
pi lOa-CAAX transfected cells in comparison to appropriate control vector
transfected cells (Figure 4.1 OB).
Cells transfected with pllO-CAAX were also assessed for integrin affinity. Figure
4.IOC shows that cells transfected with pllO-CAAX did not lead to integrin
suppression (-1.0 ± 10.9%). The cells were responsive to suppressive signals as the
positive control Ras G12V was capable of suppressing integrins (57.8 ± 1.0%).
These results suggest that while Ras (G12V, Y40C) may be capable of suppressing
integrins, the only known specific Ras effector of this mutant, PI3-kinase is unable to
mediate integrin suppression.
4.6 Effect of R-Ras G38V expression on integrin affinity
R-Ras, a small GTP binding protein with sequence similarities to the Ras genes has
been shown to reverse Ras G12V-mediated integrin suppression (Sethi et ai, 1999).
Ras G12V-mediated integrin suppression appears to involve several of its
downstream effectors. The effect ofR-Ras expression on Ras G12V effector mutants
(E37G and T35S) was therefore determined. Ras (G12Y, Y40C) was not used due to
the insignificant integrin suppression observed in Figure 4.1 and with pi 10-CAAX.
Substitution of a glycine to a valine residue at the corresponding position to the
G12V mutation in H-Ras produces a constitutively active R-Ras protein (R-Ras
G38V). Lysates from cells co-transfected with Ras G12V effector mutants and R-Ras
G38V were analysed for expression of the constructs (Figure 4.11). Expression of the
Ha-tagged Ras G12V and the effector mutants was similar to that in Figure 4.1A.
The Ras effectors were expressed as a 23kDa protein with similar expression to that
of Ras G12V.
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Figure 4.10 Effect of pllO-CAAX expression on Akt phosphorylation and
integrin affinity.
Lysates from cells transfected with Ras G12V (lpg), pllO-CAAX (lpg) or
appropriate control vectors were probed with (A) phospho-Akt antibody and (B) anti-
Akta antibody. The western blots shown are representative of 3 experiments. (C)
Integrin affinity was also determined. Percentage inhibition was calculated in
reference to the Ras empty vector. The results shown are the mean ± SEM of three
independent experiments.
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Figure 4.1 IB shows that myc-tagged R-Ras G38V was expressed as a 26kDa protein
and that expression of this protein was not affected by co-transfection with the Ras
G12V effector mutants.
4.6.1 R-Ras G38V can reverse integrin suppression by the Ras
effector mutants
Transfection of R-Ras G38V into a(3-py cells has previously been shown not to
significantly affect integrin affinity of the chimeric integrin (Hughes et al., 1997;
Sethi et al., 1999). Transfection of R-Ras G38V displayed a small increase in PAC1
binding (-6.3 ± 2.8%) compared to empty vector transfected cells (Figure 4.11C). As
described by Sethi et al. (1999), co-expression of R-Ras G38V with Ras G12V
reversed Ras G12V-mediated integrin suppression (52.7 ± 6.7% to 5.8 ± 9.9%). The
ability of R-Ras G38V to reverse Ras G12V-mediated suppression was mirrored in
cells transfected with the Ras G12V effector mutants. Integrin suppression fell from
46.2 ± 4.1% to 3.3 ± 5.2% for Ras (G12V, E37G) and 52.0 ± 1.5% to -3.7 ± 9.1% for
Ras (G12V, T35S) in cells transfected in the absence and presence of R-Ras G38V
respectively.
These results indicate that the action ofR-Ras G38V on integrin affinity may act at a
point where the suppressive signals from Ras G12V effector pathways may
converge.
4.7 Effect of Ras G12V effector mutants on cell morphology
The morphology of a cell is governed by several factors including the arrangement of
cytoskeletal components and adhesion strength to substrates. Hughes et al. (1997)
suggested that suppression of integrins in aP-py cells transfected with an active Raf
might contribute to the round morphology of the cells. We have used the Ras G12V
effector mutants to assess whether integrin suppression is responsible for the
morphological changes that occur in these cells.
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Figure 4.11 Effect of co-expression of Ras effector mutants and R-Ras G38V on
integrin affinity.
Ras G12V effector mutants (lpg) were co-transfected with R-Ras G38V (lpg) or
control vector. Lysates from transfected cells were probed with (A) anti-Ha antibody
and (B) anti-myc (9E10) antibody. The western blots shown are the representative of
3 experiments. (C) Integrin affinity was also determined, percentage inhibition was
calculated in reference to cells transfected with Ras G12V control vector and R-Ras
G38V control vector. The results shown are the mean ± SEM of three independent
experiments.
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Figure 4.12 Cell Morphology of Ras effector mutant transfected cells.
Cells plated on glass coverslips were transfected with Ras G12V or effector mutants
(lpg). Forty eight hours post transfection, cell morphology was observed by phase
microscopy. Cell morphology pictures are representative of 4 experiments. Scale bar
represents 100pm and the arrows represent the described morphology within the text.
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Cells grown on glass coverslips were transfected with Ras G12V or the Ras G12V
effector mutants. Forty-eight hours after transfection, cell morphology was assessed
by phase microscopy (Figure 4.12). Control vector transfected cells displayed a flat,
spread phenotype similar to that of untransfected ctP-py cells. In contrast, Ras G12V
transfected cells were rounder, more refractile and occasionally possessed long
"neurite-like" extensions. Ras (G12V, T35S) transfected cells displayed a similar
morphology to Ras G12V transfected cells. Cells were refractile, did not display the
spread morphology and had more pronounced "neurite-like" extensions. Cells
transfected with Ras (G12V, Y40C) were more akin to that of control vector
transfected cells. The cells were flat, non-refractile and did not possess any "neurite-
like" extensions. Cells transfected with Ras (G12V, E37G) displayed intermediate
cell morphology with slightly rounder cells than control vector cells. These cells
however lacked any neurite-like extensions observed with Ras G12V and Ras
(G12V, T35S) transfected cells.
Cells transfected with the Ras effector mutants did not significantly differ in cell
viability and cell growth during the timecourse of these experiments. The
morphological changes observed with transfected cells did not qualitatively increase
the number of adherent cells though a detailed assessment of adhesive strength
remains to be determined (see Chapter7). Once trypsinised, all cells displayed similar
forward and side scatter (size) properties by flow cytometry.
These results suggest that while the Ras G12V effector mutants can suppress
integrins, suppression of integrins does not appear to be solely responsible for the
round refractile cell morphology.
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4.8 Discussion
The results presented in this chapter show that individual Ras G12V effector mutants
mediate integrin suppression indicating the possibility of multiple pathways being
involved. While these pathways utilise different effectors, the suppressive signals
may converge at a point where R-Ras can reverse integrin suppression.
Amino acid substitutions within the Ras effector domain have generated Ras mutants
that display specificity towards individual Ras effectors (Rodriguez-Viciana et al.,
1997; White et al, 1995). The Ras G12V (E37G, T35S and Y40C) mutants have
successfully been used to link Ras effector pathways to cell function (Khosravi-Far
et al., 1996; Matsuguchi and Kraft, 1998; Rodriguez-Viciana et al., 1997; Webb et
al., 1998; White et al., 1995).
Integrin suppression by all three Ras effector mutants suggests that the Ras/Raf
pathway is not alone in mediating integrin suppression. Individual Ras effector
mutants have shown limited transforming capabilities in certain NIH3T3 lines
compared to Ras G12V. Synergism was observed by combining two Ras effector
mutants suggesting that complete cell transformation required signals from at least
two pathways (Khosravi-Far et al., 1996; White et al., 1995; White et al., 1996). In
the case of integrin suppression, Ras (G12V, E37G/T35S)-mediated integrin
suppression to almost the same degree as that with Ras G12V. No additional
suppression was observed by combining these two mutants. Maximal integrin
suppression may therefore only require any one of the three effector pathways.
This hypothesis may explain the inability of PD098059 to reverse Ras G12V-
mediated suppression. Inhibition of the Raf/ERK pathway may allow an alternative
Ras effector pathway to mediate integrin suppression. However, the failure of
PD098059 to inhibit integrin suppression by Ras (G12V, T35S) that only activates
Raf argues against a role for MEK and ERK1/2. PD098059 complexes with
dephosphorylated, inactive MEK1 and prevents its activation by Raf, possibly
allowing Raf to interact with other effectors (Alessi et al., 1995). In systems with
high Raf kinase activity (Ras G12V, Raf-BxB CAAX transfected cells), PD098059
127
Integrin Affinity Modulation by Ras Signalling Molecules
may not inactivate all endogenous MEK and therefore low level MEK activity may
be sufficient to mediate integrin suppression. In cells treated with PD098059 (Figure
4.3A), ERK1/2 phosphorylation was completely inhibited, however ERK1/2
phosphorylation below our level of detection cannot be ruled out. Results with a
constitutively active ERK2 construct are described in Chapter5. The possibility of a
MEK/ERK independent pathway downstream of Raf is described further in
Chapter5. As with results in Chapter3, MKP-1 expression can still reverse integrin
suppression, an ERK-like, protein sensitive to MKP-1 dephosphorylation may
therefore act downstream ofRaf signalling.
The Ras (G12V, E37G) mutant retained its ability to activate the RalGEFs and in
turn to activate Ral. Expression of active RalA (23V) however was insufficient to
mediate integrin suppression. Active Ral has been poor in replicating the biological
effects of RalGEFs and Ras (G12V, E37G) (Peyssonnaux et al., 2000; White et al.,
1996; Wolthuis et al., 1997). It has been proposed that the GTPase deficient RalA
(23V) does not mimic the actions of endogenous active Ral as hydrolysis of GTP
may be important to activate Ral effectors (Wolthuis et al., 1997). Alternatively
RalGEFs may activate Ral-independent pathways that may mediate integrin
suppression (Wolthuis et al., 1997). The effects of RalGEFs can be inhibited by
dominant negative Ral (Urano et al., 1996; Wolthuis et al., 1997), RalA (28N) had
no effect on integrin suppression. Thus, integrin suppression by Ras (G12V, E37G)
may not necessarily require RalGEF or Ral activity. RalGEF and Ral independent
effects from Ras (G12V, E37G) have also been suggested during skeletal
myogenesis (Ramocki et al., 1998).
Phospholipase Cs has recently been identified as a novel Ras effector (Kelley et al.,
2001; Lopez et al., 2001; Song et al., 2001). PLCs activity was stimulated by
expression of Ras (G12V, E37G) and therefore, effects attributed to Ras (G12V,
E37G) will need to take into account of PLCs activation (Kelley et al., 2001).
Whether PLCs plays a role in Ras (G12V, E37G)-mediated integrin suppression is
currently under study. A PLC inhibitor, U-73122, was shown to inhibit H-Ras-
mediated adhesion of Baf3 (haematopoietic cell line) to fibronectin. While H-Ras
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G12V has been shown to activate (3i integrin affinity in these cells, integrin affinity
was not assessed in the presence of the PLC inhibitor (Liu et al., 1999; Shibayama et
al., 1998; Shibayama et al., 1999). To address the role of PLCs activation, Ras
(G12V, E37G) transfected cells will be treated with U-73122. It should be noted that
no data is currently available on the sensitivity of the inhibitor on the PLC epsilon
isoform. Alternatively, the Ras (G12V, D38N) effector mutant specifically activates
PLCs (Kelley et al., 2001) allowing the role of PLCs to be determined.
PI3-kinase has been implicated in integrin affinity modulation. Activation of LFA-1
(cclP2) and anbp3 has been observed with active forms of PI3-kinase (Nagel et al.,
1998; Zhang et al., 1996b). Expression of Ras (G12V, Y40C) in T-cells caused LFA-
1 activation and an increase in binding to ICAM-1 (Tanaka et al., 1999). While
expression of Ras (G12V, Y40C) produced inconsistent results towards integrin
affinity, active PI3-kinase failed to act upon the chimeric integrin. Inhibition of PI3-
kinase activity with LY294002 did not affect Ras G12V-mediated integrin
suppression in a,p-py cells (Sethi et al., 1999). The variable nature of Ras (G12V,
Y40C)-mediated integrin suppression remains to be clarified; PI3-kinase activity can
modulate protein translation through p70 S6-kinase (Dufner and Thomas, 1999) that
may explain the poor expression of Ras (G12V, Y40C) compared to the other Ras
mutants. The mechanism by which Ras (G12V, Y40C) may mediate integrin
suppression remains unclear.
The Ras effectors mutants have implicated several pathways in mediating integrin
suppression. Of these effectors, only Raf has been shown to directly modulate
integrin affinity. We therefore cannot rule out the possibility that overexpression of
the three Ras effector mutants could all lead to Raf activation. While cross talk
between the different pathways has not been reported, overexpression of the Ras
effector mutants may lead to activation of endogenous Ras (Peyssonnaux et al.,
2000). Such a feedback mechanism however, would lead to Raf activation and
subsequently ERK1/2 phosphorylation with all three effector mutants. The
differential ERK1/2 phosphorylation pattern with the Ras effector mutants suggests
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that a global Raf activation may not account for suppression by all the effector
pathways.
Growth factors stimulate Ras activation within minutes of treatment (Gibbs et al.,
1990). Acute stimulation of Ras activity does not appear to mediate integrin
suppression as serum treatment of a,p-py cells has no effect on affinity (data not
shown) and that Hughes et al. (1997) has shown that integrin suppression occurs
approximately 3 hours following Raf activation (Hughes et al., 1997). The events
occurring during this 3 hour lag phase remain to be determined.
Ras effectors other than those previously mentioned have been identified (reviewed
in Campbell 1998). The RasGAP pi20 may act upon the actin cytoskeleton through
Rac while MEKK1 can activate JNK (Leblanc et al., 1998; Russell et al., 1995; Yan
et al., 1994). Both Rac and JNK have been shown not to affect integrin affinity in
aP-py cells (Hughes et al., 1997). Other effectors include the atypical PKC^, AF-6
and Rinl (Diaz-Meco et al., 1994; Han and Colicelli, 1995; Kuriyama et al., 1996).
PKC^ has been shown to be required for cytokine stimulated neutrophil adhesion to
fibrinogen. This integrin-dependent increase in adhesion was suggested to be a result
of avidity modulation of the integrins (Laudanna et al., 1998). AF-6 co-localises with
ZO-1 at cell-cell contacts, binding to which is disrupted in the presence of active
Ras. The resulting decrease in AF-6 and ZO-1 at cell-cell contact sites may explain
the loss of cell-cell contacts in Ras transformed cells (Yamamoto et al., 1997). Rinl,
identified by its ability to suppress Ras G12V in yeast (Colicelli et al., 1991) is
phosphorylated by the tyrosine kinase c-Abl and the oncogenic fusion protein
Bcr/Abl (Han et al., 1997). Co-expression of Rinl with Bcr/Abl potentiates the
oncogenic activity of the Bcr/Abl tyrosine kinase in haematopoietic cells, though this
did not require interaction with Ras. Rinl may therefore act as an effector for Ras
and activated tyrosine kinases (Afar et al., 1997). Bcr/Abl expression in
haematopoietic cells can activate VLA-5 (aspi) integrin affinity; the role of Rinl
was not addressed in this paper (Bazzoni et al., 1996). Any one of these effectors
could mediate integrin suppression by Ras G12V; it will be interesting to determine
their effect on integrin affinity in a,p-py cells.
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R-Ras can reverse Ras G12V-mediated integrin suppression at a point downstream of
ERK1/2 activation (Oertli et al., 2000; Sethi et al., 1999). The ability ofR-Ras G38V
to reverse integrin suppression by all three effector mutants suggests that R-Ras may
act at a point where these pathways converge. As yet, known effectors of R-Ras have
not been shown to modulate integrin affinity, the mechanism of action is therefore
unclear. R-Ras is believed to antagonise the suppression pathway rather than a direct
activation of the integrin since R-Ras G38V has not been shown to activate the
chimeric integrin in a[3-py cells (Sethi et al., 1999).
Ras transformation of cells has often been associated with a change in cell
morphology through re-organisation of the actin cytoskeleton by the Rho family of
proteins (Khosravi-Far et al., 1995). Integrin suppression did appear to play a role for
changes in cell morphology, with cells with suppressed integrins having a rounder
morphology than control cells. Cells transfected with Ras (G12V, Y40C) were
indistinguishable from control transfected cells. Cell morphology of Ras (G12V,
E37G) cells was slightly rounder than control cells this may be a result of the
suppressed integrins in these cells. Neurite-like extensions are often observed in Ras
transfected neuronal cell lines e.g. PC 12 undergoing cell differentiation (Guerrero et
al., 1986; Elagag et al., 1986). The presence of such extensions in Ras (G12V, T35S)
transfected cells may suggest a similar type of differentiation. Neurite-like extensions
by Ras (G12V, T35S) have been observed in transfected non-neuronal cell lines
(Khosravi-Far et al., 1996).
In summary integrin suppression by Ras can be reproduced by some of the Ras
G12V effector mutants. Integrin suppression can occur by both Raf-dependent and
Raf-independent pathways downstream of Ras.
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RESULTS: CHAPTER 5
Integrin Suppression by Raf-BxB T481A
5.1 Introduction
Signalling by Raf is responsible for many of the biological effects attributed to
activate Ras. Three isoforms of Raf have been identified and knockout studies in
mice have suggested that each have isoform specific in vivo functions (reviewed in
Hagemann 1999). Common to each isoform is their ability to activate MEK1/2 and
subsequently ERK1/2. Activation of ERK1/2 mediates many of the effects of active
Raf, including transcriptional changes, cell cycle control and cell transformation
(Campbell et al., 1998).
Recent in vivo studies have called into question the importance of Raf-1 as an in vivo
/ • FF/FFMEK activator. Raf-E" mice died during embryogenesis, while Raf-1 mice
(mutation of Raf-Tyr340/341, lacks activity towards MEK) survived to adulthood. Cells
derived from either strain had normal ERK1/2 activity suggesting that MEK
activation by Raf-1 is not essential for development (Ehiser et al., 2001). The ability
of activated Raf to mediate cellular responses in a MEK and ERK1/2 independent
manner have been previously described. Differentiation of hippocampal neuronal
cells required Raf but not MEK activity (Kuo et al., 1996). Activation of p70 S6
kinase by active Raf was not prevented by co-expression of dominant negative ERK1
or MKP-1 (Lenormand et al., 1996) in CCL39 cells. The interaction of Raf-1 with
apoptosis signal-regulating kinase 1 (ASK1) led to an increase in cell survival by a
MEK-ERK independent mechanism (Chen et al., 2001). Raf-dependent integrin
suppression in the absence of ERK1/2 phosphorylation (Figure 4.4) indicates that
Rafmay mediate suppression through effectors other than MEK 1/2.
Several proteins have been described that have been shown to bind to Raf in addition
to Ras and MEK (reviewed in Kolch 2000). Candidate Raf effectors have been
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identified including the well described MEK1 protein. Raf phosphorylates cdc25A;
the increase in phosphatase activity allowed dephosphorylation of the cyclin
dependent kinases and cell cycle progression (Galaktionov et al., 1995).
Phosphorylation of the retinoblastoma tumour suppressor protein (Rb) by Raf
relieved the inhibitory action of Rb on cell cycle progression at the Gi/S boundary
(Wang et al., 1998). An interaction between Raf and the anti-apoptotic protein Bcl-2
has been described, leading to localisation of Raf to the mitochondria. Mitochondrial
targeted Raf was shown to lead to an increase in BAD phosphorylation (Wang et al.,
1996). An ankyrin repeat protein, Tvl-1 was identified as a substrate for Raf
phosphorylation, Tvl-1 expression was also shown to potentiate stimulated Raf
activity (Lin et al., 1999). Integrin suppression by Raf may reflect activation of a
novel effector by Raf.
Mutagenisis of Raf-BxB, a constitutively active variant of Raf (Stanton, Jr. et al.,
1989), yielded a Raf mutant unable to bind to MEK (Pearson et al., 2000).
Substitution of threonine at position 481 for alanine generated a Raf-BxB mutant that
was unable to bind to both MEK1 and MEK2 in a yeast two-hybrid system.
Immunoprecipitated Raf-BxB T481A was able to phosphorylate saturating amounts
of a MEK substrate in vitro, indicating that Raf kinase activity was not significantly
affected (Pearson et al., 2000). In this chapter we have used the Raf-BxB T481A
mutant to study integrin suppression in the absence of ERK1/2 phosphorylation.
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5.2 Effect of Raf-BxB T481A mutant on integrin affinity
The downstream Ras effector, Raf-1 has previously been described to suppress the
chimeric integrin in ccf3-py cells (Figure 3.7). Expression of the Ras (G12V, T35S)
Ras effector mutant, displayed integrin suppression via a PD098059 insensitive
pathway (Figure 4.4). These results suggest that Raf may mediate integrin
suppression through a MEK independent pathway. Utilising a Raf-BxB mutant,
T481A, the role of MEK and ERK1/2 activation on integrin suppression was
determined.
5.2.1 Raf-BxB T481A expression leads to a loss in PAC1 binding
Cells transfected with the constitutively active Raf mutant, Raf-BxB CAAX,
displayed a loss in PAC1 binding and suppression of the active integrin. Figure 5.1A
shows that the Raf-BxB T481A mutant also leads to a loss of PAC1 binding
compared to control vector transfected cells. Representative dot blots show that 72%
of the highly transfected Raf-BxB T481A expressing cells were in the upper left
hand quadrant of the dot blot compared to 35% for control cells. Dot blots for Raf-
BxB CAAX and T481A displayed similar shifts in cell populations to the low PAC1
binding quadrant and as previously described, cells transfected to a lesser extent
displayed a reduced degree of integrin suppression.
Cell lysates from Raf transfected cells were probed for expression of the Raf
constructs. The Ha-tagged Raf-BxB CAAX protein ran with a mobility of
approximately 42-44 kDa (Figure 5.IB). The Ha antibody also detected a second
band with increased gel mobility. This band was not a degradation product of the
Raf-BxB CAAX protein as it was also present in Raf-BxB T481A and control vector
transfected cells. This non-specific Ha antibody interaction was occasionally
observed with high protein loading of the gels. The Raf-BxB T481A protein ran with
an estimated size of 37kDa and was detected with an anti-Raf antibody (E-10) that
recognises a C-terminal epitope (Figure 5.1C). Raf-BxB CAAX was not recognised
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Figure 5.1 Integrin affinity modulation by Raf-BxB mutants.
(A) Flow cytometry was performed on Raf-BxB transfected cells to determine
integrin affinity. Representative dot blots show PAC1 binding versus Tac binding of
Raf-BxB CAAX (lpg) and T481A (lpg) transfected cells. High Tac binding cells
are shown in red. The quadrant markers separate both high and low Tac and PAC1
binding. The percentage of high Tac binding cells in the upper left hand quadrant is
shown for each dot blot. Dot blots are representative of 3-5 experiments. (B) Cell
lysates from transfected cells were probed with the anti-Ha antibody and (C) Raf
antibody, E10. The western blots shown are representative of 4 experiments.
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by this antibody possibly due to the presence of the CAAX motif that may disrupt the
C-terminal epitope recognised by this antibody.
Inhibition of the chimeric integrin was examined by flow cytometry of Raf
transfected cells. Figure 5.2A shows that Raf-BxB T481A was able to inhibit PAC1
binding by 60.7 ± 4.6% relative to control vector transfected cells. Cells transfected
with either Ras G12V or Raf-BxB CAAX displayed inhibition of 67.8 ± 5.4% and
75.6 ± 6.5% respectively.
5.2.2 Raf-BxB T481A fails to activate ERK1 and 2
The T481A mutation of Raf-BxB has been described to prevent binding ofMEK1 to
Raf in vitro (Pearson et al., 2000). Cell lysates from aP-py cells transfected with
Raf-BxB T481A were analysed for the presence of phosphorylated ERK1 and 2.
Figure 5.2B shows that expression of Raf-BxB T481A failed to increase ERK1/2
phosphorylation compared to control vector transfected cells. Expression of either
Ras G12V or Raf-BxB CAAX in contrast produced a substantial increase in ERK2
phosphorylation. ERK2 expression levels in all transfected cells were similar and
independent of the Raf construct used (Figure 5.2C).
5.2.3 Raf-BxB T481A activates NF-kB
The T481A mutation uncouples MEK1 activation from the active Raf kinase. The
absence of ERK1/2 phosphorylation in Raf-BxB T481A transfected cells could be
the result of a failure of Raf to interact with its effectors. Pearson et al. (2000)
showed that the T481A mutant was still capable of activating NF-kB dependent
transcription, suggesting that Raf effector pathways other than MEK were still
activated. Extracting nuclear proteins from Raf transfected cells, NF-kB activity was
measured by electro-mobility shift assay (EMSA) with a [32P]-labelled NF-kB
oligonucleotide containing NF-kB DNA binding sites. Binding reactions performed
between the labelled NF-kB oligonucleotide and nuclear extracts from transfected
cells were resolved on a 6% non-denaturing polyacrylamide gel. Binding of the
nuclear extracts to labelled oligonucleotide (p65 and p50) was detected by
136












Figure 5.2 Effect of Raf-BxB T481A on integrin affinity and ERK1/2
phosphorylation.
(A) Integrin affinity was determined in Raf-BxB CAAX (lpg) and the T481A
mutant (lpg) transfected cells. Ras G12V (ljug) was transfected as a positive control.
Percentage inhibition was calculated by comparing the activation index in the
presence of Raf DNA to that of the control vector. The results shown are the mean ±
SEM of 3 independent experiments. (B) Cell lysates from transfected cells were
probed with the phospho-specific ERK antibody and (C) the ERK2 antibody. The
western blots are representative of 3 experiments.
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autoradiography. Figure 5.3A shows that NF-kB binding was increased in nuclear
lysates from Raf-BxB CAAX and T481A transfected cells compared to control
vector transfected cells (representative autoradiograph of three experiments). Ras
G12V transfected cells also displayed an increase in NF-kB activity.
Control EMSA reactions were performed (Figure 5.3B) to show that binding
reactions were specific for NF-kB. Nuclear extracts from Raf-BxB T481A were
incubated with either excess unlabelled NF-kB oligonucleotide or excess unlabelled
SP-1 oligonucleotide which does not bind NF-kB. the NF-kB oligonucleotide
eliminated NF-kB binding while the non-specific (SP-1) oligonucleotide had no
effect on NF-kB binding to the NF-kB specific oligonucleotide. In addition a
supershift reaction was performed. Nuclear extracts were incubated with the p65
antibody prior to the binding reaction. P65 is a subunit of NF-kB and a supershift
indicates that nuclear extracts specifically contain the p65 subunit. The other band is
thought to be the second subunit ofNF-kB. Other unlabelled bands present on the gel
are thought to be non-specific bands or are a result of protein breakdown.
Image quantification of phospho-images with ImageQuant software allowed a
numerical estimate of NF-kB activity. NF-kB activity was increased 4.2 ± 1.1 fold
over control vector transfected cells in Raf-BxB T481A transfected cells (Figure
5.4). A fold increase of 2.3 ± 0.9 and 3.0 ± 1.3 was observed for Raf-BxB CAAX
and Ras G12V transfected cells respectively. These results indicate that the Raf-BxB
T481A mutant is capable of activating NF-kB and possibly other signalling pathways
in the absence ofMEK activation.
5.3 Effect of constitutively active MEK1 on integrin affinity
Integrin suppression by Raf-BxB T481A suggests that suppression may occur in the
absence of MEK activation. Utilising an active MEK1 mutant (MEK1-DD, S218D
S222D), the requirement for MEK activation during Raf-mediated suppression was
determined.
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Figure 5.3 NF-kB binding by Raf-BxB T481A.
(A) NF-kB EMSA's were performed on nuclear extracts from Raf-BxB transfected
cells (lpg DNA). (B) Control NF-kB binding reactions were performed on the
nuclear extract from Raf-BxB T481A transfected cells. Binding reactions were
performed in the presence of either excess cold NF-kB oligonucleotide, the non¬
specific SP1 oligonucleotide or the p65 antibody. The supershifted NF-kB complex
is marked on the autoradiograph.








Figure 5.4 NF-kB activity in Raf-BxB transfected cells.
Autoradiographs of NF-kB activity of transfected cells (lpg) were subjected to the
ImageQuant analysis software. Densitometry performed on the p65/p50 subunit
bands are represented as the fold increase over control vector transfected cells. The
results shown are the mean ± SEM of three independent experiments.
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5.3.1 Active MEK leads to an increase in ERK1/2 phosphorylation
Expression of the Ha-tagged MEK1 in a.p-py cells (Figure 5.5A) revealed a single
protein band at 45kDa, detected with the anti-EIa antibody; Ras G12V was expressed
as a 23kDa protein. Probing lysates with the phospho-ERK specific antibody showed
that expression ofMEK1-DD resulted in a large increase in ERK1/2 phosphorylation
(Figure 5.5B). Phosphorylation of ERK1/2 in Ras G12V transfected cells produced a
more modest increase in phosphorylation compared to MEK1-DD. Total ERK levels
were unaffected by expression of either Ras G12V or MEKl-DD (Figure 5.5C).
5.3.2 MEK1 DD expression can mediate integrin suppression
Figure 5.6 showed that expression of MEKl-DD in ap-py cells caused integrin
suppression (53.5 ± 5.2%), similar to that with Ras G12V (69.5 ± 3.8%). The
involvement of MEK1 in integrin suppression is in contradiction to previous data
obtained with Raf-BxB T481A and PD098059 experiments that indicate that integrin
suppression is independent ofMEK and ERK1/2 activation.
5.4 Effect of constitutively active ERK2 on integrin affinity
Integrin suppression by Raf-BxB T481A indicates that Raf-mediated suppression
occurs via an ERKl/2-independent pathway. However, integrin suppression by
MEKl-DD suggests that activation of ERK 1/2 may contribute to integrin
suppression or that overexpression of the MEK protein can lead to phosphorylation
of other substrates that could mediate integrin suppression.
Expression of a constitutively active ERK construct in aP-py cells would determine
whether ERK activation is required for integrin affinity modulation. An ERK2-
MEK1 fusion construct generated by Robinson et al. (1998) produced an active
ERK2 protein capable of activating transcription factors Elk-1 and AP-1 and
phosphorylation ofmyelin basic protein (MBP) (Robinson et al., 1998).
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Figure 5.5 Effect of MEK1-DD expression on ERK1/2 phosphorylation.
Cell lysates from Ras G12V (lpg) and MEK1-DD (lpg) transfected cells were
probed with the (A) anti-Ha antibody. Separate blots were also probed with (B) the
phospho-specific ERK antibody and (C) the ERK2 antibody. The western blots
shown are representative of 2 experiments.













Figure 5.6 Effect ofMEK1-DD expression on integrin affinity.
Integrin affinity was determined in MEK1-DD transfected cells (lpg). Ras G12V
(lpg) was transfected as a positive control. Percentage inhibition was calculated by
comparing the activation index in the presence of test DNA to that of the empty
vector. The results shown are the mean ± SEM of 5 independent experiments.
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5.4.1 Active ERK2-MEK1 phosphorylates MBP
Cells transfected with a construct encoding myc-tagged wildtype ERK2-MEK1
fusion protein revealed a protein of approximately 95 kDa on western blots probed
with the anti-myc (9E10) antibody (Figure 5.7A). Increasing DNA transfected from
lpg to 3pg ofDNA increased expression of the fusion protein. Mutation of Lys52 to
Arg within ERK2 produces a protein that is phosphorylated by the linked MEK1 but
has no endogenous ERK2 kinase activity i.e. kinase dead (Robinson et al., 1998).
Transfection of this kinase-dead fusion protein also revealed a protein of 95 kDa,
however, expression of this construct was greater than that of the wildtype construct.
Increasing the quantity of wildtype ERK2-MEK1 DNA beyond 3pg failed to
increase expression of the construct to levels equivalent to that of the kinase dead
mutant.
ERK2 activity was assayed by immunoprecipitation of the myc-tagged ERK2-MEK1
fusion proteins with the anti-myc (9E10) antibody and MBP used as a substrate.
Figure 5.7B shows myelin basic protein (MBP) phosphorylation represented as a fold
increase above control pCMV5 vector, by the ERK2-MEK1 fusion proteins.
Wildtype ERK2-MEK1 increased MBP phosphorylation by 2.6 ± 0.7 and 6.1 ± 1.6
fold with 1 and 3pg DNA respectively. Transfection of 3pg of wildtype ERK2-
MEK1 DNA caused a significant increase (P<0.05) in MBP phosphorylation
compared to control cells. Immunoprecipitation of the kinase-dead ERK2-MEK1
fusion protein failed to increase MBP phosphorylation over control vector levels (0.6
± 0.2 for lpg and 0.2 ± 0.2 fold for 3pg DNA) that were not significantly different
(P>0.05). Reducing ERK2-MEK1 kinase-dead expression levels to that similar of the
wildtype fusion proteins also failed to increase MBP phosphorylation (data not
shown). This data indicates that the wildtype ERK2-MEK1 protein is catalytically
active in a(3-py cells and acts as a constitutively active kinase within aP-py cells.
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Figure 5.7 Effect of expression of ERK2-MEK1 fusion proteins on MBP
phosphorylation.
(A) Cell lysates from ERK2-MEK1 transfected cells (1-3jixg DNA) were probed with
the anti-myc (9E10) antibody. The western blots shown are representative of 3
experiments. (B) Kinase activity of immuno-precipitated fusion proteins was
assessed by MBP phosphorylation. The results, which are expressed as fold increase
over control vector transfected cells (3pg), are the mean ± SEM of three independent
experiments carried out in duplicate. Statistical analysis was performed by one-way
ANOVA test, asterisk indicates significant difference (P<0.05) compared to control
transfected cells.
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5.4.2 Active ERK2-MEK1 does not suppress integrins
Expression of wildtype ERK2-MEK1 in a(3-py cells yields a constitutively active
kinase capable of phosphorylating MBP. Integrin affinity was assessed in cells
expressing either active ERK2 or the kinase-dead mutant. Transfection of the
pCMV5 empty vector caused a small suppressive effect in aP-py cells (15.7 ± 4.0%)
(Figure 5.8). Expression of wildtype ERK2-MEK1 with 1 or 3pg of DNA in aP-py
cells did not suppress the chimeric integrin beyond that of the pCMV5 control vector
(10 ± 3.8% and 0.02 ± 7.1% respectively). The kinase-dead ERK2-MEK1 fusion
protein was also unable to suppress the chimeric integrin (4.7 ± 10.2% and -2.5 ±
10.1% respectively for 1 and 3pg of DNA). Compared to either control or empty
vector transfected cells, expression of ERK2-MEK1 fusion proteins did not cause
any significant difference (P>0.05) in percentage inhibition.
This data indicates that while expression of a constitutively active ERK2 in ap-py
cells is capable of phosphorylation of MBP, no effect on integrin affinity was
observed.
5.5 Effect of MKP-1 on Raf-BxB T481A
Integrin suppression by Ras G12V was reversed by co-transfection of MKP-1
(dephosphorylates Thr/Tyr residues in MAP kinase proteins) (Figure 3.11). A similar
reversal of integrin suppression was also observed with the Ras (G12V, T35S)
mutant (Figure 4.6). This data suggests that integrin suppression by the Raf effector
arm downstream of Ras may be sensitive to MKP-1 expression. Raf-BxB T481A
suppresses integrins in the absence of ERK1/2 phosphorylation. Co-expression of
MKP-1 with Raf-BxB T481A was performed to determine whether an ERK-like
activity other than ERK1/2 was responsible for Raf-BxB T481A suppression.
5.5.1 MKP-1 prevents ERK1/2 phosphorylation by Raf
Cell lysates from co-transfections with Raf and MKP-1 were subjected to western
analysis for expression of the Raf and MKP-1 constructs. Ha-tagged Raf-BxB
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Figure 5.8 Effect of ERK2-MEK1 fusion proteins on integrin affinity.
Integrin affinity was determined in cells transfected with either the wildtype or the
kinase dead ERK2-MEK1 fusion proteins. Ras G12V (1 pig) was transfected as a
positive control, the ERK2-MEK1 empty vector (3pg) was transfected as a control
for the ERK2-MEK1 constructs. Percentage inhibition was calculated by comparing
the activation index in the presence of ERK2-MEK1 DNA to that of the control
vector (3pg). The results shown are the mean ± SEM of 3-5 independent
experiments. Statistical analysis was performed by one-way ANOVA test.
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CAAX was expressed as a single band at 42-44kDa and expression was unaffected
by co-transfection of MKP-1 (Figure 5.9A). Expression of Raf-BxB T481A was
detected with the anti-Raf antibody and as previously described a band at 37kDa was
observed (Figure 5.9B). Co-transfection of MKP-1 did not affect expression of Raf-
BxB T481A. The myc-tagged MKP-1 was probed with the anti-myc (A 14) antibody,
the anti-myc (9E10) antibody previously used for other myc-tagged proteins failed to
recognise either MKP-1 or Raf-BxB T481A proteins (Figure 5.9C). MKP-1 was
expressed as a 39kDa protein, a small reduction in MKP-1 expression was observed
in Raf-BxB T481A co-transfections compared to expression in control vector or Raf-
BxB CAAX co-transfections. The anti-myc (A 14) antibody also detected the myc-
tagged Raf-BxB T481A protein at 37kDa.
Cell lysates from co-transfections with Raf and MKP-1 were probed with the
phospho-specific ERK antibody (Figure 5.9D). As previously observed, Raf-BxB
CAAX expression produced an increase in ERK2 phosphorylation compared to
control lysates. Raf-BxB T481A expression did not increase ERK2 phosphorylation
above control vector transfected cells. Co-expression of MKP-1 in all three
transfections prevented ERK2 phosphorylation. Low level phosphorylation was
occasionally observed in MKP-1 co-transfections upon long film exposure times.
ERK2 expression levels were unaffected by Raf or MKP-1 expression in a(3-py cells
compared to control cells (Figure 5.9E).
5.5.2 MKP-1 expression inhibits Raf-mediated integrin suppression
MKP-1 co-expression prevented the increase in ERK2 phosphorylation by Raf-BxB
CAAX and basal ERK2 phosphorylation by Raf-BxB T481A. The ability ofMKP-1
to inhibit integrin suppression by Ras G12V and the Ras (G12V, T35S) mutant
indicated that MKP-1 expression might also inhibit integrin suppression by Raf.
Expression of Raf-BxB CAAX or Raf-BxB T481A both increased integrin
suppression compared to that observed with Ras G12V (Figure 5.10). Co-
transfection ofMKP-1 with empty vector produced a small increase in PAC1 binding
(-8 ± 15.1% inhibition), this was previously observed in Ras G12V-MKP-1 co-
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Figure 5.9 Effect of MKP1 co-expression on Raf-BxB mediated ERK1/2
phosphorylation.
Lysates from cells co-transfected with Raf-BxB (lpg) and MKP-l/empty vector
(lpg) were probed with (A) anti-Ha antibody, (B) Raf antibody (E10) and (C) the
anti-myc (A 14) antibody. Lysates were also probed with (D) the phospho-specific
ERK antibody and (E) the ERK2 antibody. The western blots shown are
representative of 3 experiments.





Figure 5.10 Effect of MKP1 expression on integrin affinity in Raf-BxB co-
transfected cells.
Integrin affinity was determined in Raf-BxB transfected cells (CAAX or T481A,
lpg) co-transfected with either MKP1 or control vector (lpg). Percentage inhibition
was calculated by comparing the activation index in the presence of test DNA to that
of the control vector in the absence of MKP-1. The results shown are the mean ±
SEM of 3 independent experiments.
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transfections (Figure 3.11). Expression of MKP-1 with Raf-BxB CAAX (1.6 ±
15.5% inhibition) produced a 97% reduction in integrin suppression compared with
Raf-BxB CAAX alone (53.6 ± 19.3%). Co-transfection of MKP-1 with Raf-BxB
T481A (58.9 ± 8.4%) produced a similar reduction in integrin suppression. A 91 %
reduction was observed in MKP-1 and Raf-BxB T481A co-transfectants (5.2 ±
10.0%).
The ability ofMKP-1 to reverse integrin suppression by both Raf constructs suggests
that ERKl/2-independent integrin suppression by Raf-BxB T481A may require a
MKP-1-sensitive ERK-like kinase activity.
5.6 Effect of R-Ras G38V on integrin suppression by Raf
T481A
The active R-Ras small GTP binding protein (R-Ras G38V) has been shown to
reverse integrin suppression caused by Ras G12V, Raf-CAAX and Raf-BxB (Sethi et
al., 1999). It was shown that R-Ras G38V can also reverse integrin suppression by
the Ras effector mutants (Figure 4.11). We hypothesised that integrin suppression by
Raf-BxB T481A should also be reversed by R-Ras G38V.
5.6.1 Effect of R-Ras G38V on ERK activation
Lysates from cells transfected with Raf mutants and R-Ras G38V were analysed for
expression of the transfected constructs. Figure 5.11A shows that the Ha-tagged Raf-
BxB CAAX construct was expressed as previously observed and that co-transfection
of R-Ras G38V did not affect expression. Expression of Raf-BxB T481A was also
unaffected by R-Ras G38V expression (Figure 5.1 IB). The myc-tagged R-Ras G38V
was expressed as a 25kDa protein and was expressed at similar levels in all co-
transfections performed (Figure 5.11C).
Cell lysates from co-transfections between Raf and R-Ras G38V were probed with
the phospho-specific ERK antibody (Figure 5.1 ID). Raf-BxB CAAX expression
produced an increase in ERK2 phosphorylation compared to control lysates while
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Figure 5.11 Effect of R-Ras G38V expression on Raf-BxB mediated ERK1/2
phosphorylation.
Cells transfected with either Raf-BxB CAAX (lpg) or Raf-BxB T481A (1 pig) were
co-transfected with R-Ras G38V or empty vector (lpg). Lysates were probed with
(A) anti-Ha antibody, (B) anti-Raf E10 antibody or (C) anti-myc (9E10) antibody.
Lysates were also probed with the (D) phospho-specific ERK antibody and (E) the
ERK2 antibody. The western blots shown are representative of 3 experiments.
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Raf-BxB T481A expression did not increase ERK2 phosphorylation above control
vector transfected cells. Co-expression of R-Ras G38V with either control vector or
Raf-BxB CAAX produced no detectable change in ERK2 phosphorylation. A slight
increase in ERK2 phosphorylation was observed in co-transfections between Raf-
BxB T481A and R-Ras G38V. The phosphorylation of ERK2 in these transfections
was always below that observed with Raf-BxB CAAX. ERK2 expression levels were
unaffected by Raf or MKP-1 co-expression in aP-py cells compared to control cells
(Figure 5.1 IE).
5.6.2 R-Ras G38V reverses Raf-mediated integrin suppression
Expression of either Raf-BxB CAAX (53.6 ± 19.3%) or Raf-BxB T481A (58.9 ±
8.4%) in ap-py cells both suppressed integrins (Figure 5.12). This suppression by the
Raf constructs was similar to that observed with Ras G12V. Co-transfection ofR-Ras
G38V expression with Ras G12V empty vector produced a small activation of the
integrin (-7 ± 10.0%) compared to control vector alone. Co-expression of Raf-BxB
CAAX with R-Ras G38V reduced integrin suppression from 53.6 ± 19.3% to 2 ±
11.1%, a reduction of 96 % in integrin suppression. R-Ras G38V was also capable of
reversing integrin suppression by Raf-BxB T481A. Integrin suppression fell from
58.9 ± 8.4 to 6.1 ± 9.1%, a reduction of 90% in integrin suppression.
These results suggest that the ERK1/2 independent integrin suppression pathway of
Raf-BxB T481A is still sensitive to R-Ras G38V expression.
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Figure 5.12 Effect of R-Ras G38V expression on integrin affinity in Raf-BxB
transfected cells.
R-Ras G38V (lpg) was co-transfected together with Raf-BxB CAAX and the T481A
mutant (lpg) and integrin affinity was determined in these cells. Percentage
inhibition was calculated by comparing the activation index in the presence of test
DNA to that of the control vector in the absence of R-Ras. The results shown are the
mean ± SEM of 3 independent experiments.
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5.7 Discussion
The results presented in this chapter show that a Raf-BxB mutant unable to induce
ERK1/2 activation was capable of integrin suppression. This suppression was not
dependent on ERK2 activation but was sensitive to MKP-1 co-transfection.
Expression of a constitutively active R-Ras construct was also able to reverse the
suppressive effects of Raf-BxB T481A and Raf-BxB CAAX.
Pearson et al. (2000) have shown that the Raf-BxB T481A mutant does not increase
ERK1/2 phosphorylation. The absence of ERK1/2 phosphorylation in transfected
a.p-py cells with Raf-BxB T481A was in correlation with observations in both
HEK293 and PC12 cells (Pearson et al., 2000). It was shown that the T481A mutant
retained its ability to activate NF-kB signalling, measured by an increase in NF-kB
translocation to the nucleus. The ability of Raf-BxB T481A to mediate NF-kB
dependent transcription agrees with a previous report that inhibition of the Raf-
ERK1/2 cascade with PD098059 or a dominant negative MEK did not affect Raf
stimulated NF-kB dependent transcription (Baumann et al., 2000). NF-kB dependent
transcription is not believed to be responsible for Raf-mediated integrin suppression.
Hughes et al. (1997) have shown that an estradiol-activated Raf protein was able to
mediate a loss in PAC1 binding in the presence of either cyclohexamide or
actinomycin D (Hughes et al., 1997). This suggests that Raf-mediated suppression
occurs in the absence of de novo protein synthesis and mRNA transcription.
Ramos et al. (1998) have previously reported that expression of an active MEK2
construct could suppress integrins (Ramos et al., 1998). The ability of a
constitutively active MEK1 construct to suppress integrins in aP-py cells contradicts
the previous data with Raf-BxB T481A and PD098059 experiments which have
indicated that MEK and ERK1/2 were not required for integrin suppression.
Lenormand et al. (1996) have shown that an active MEK1 construct led to an
increase in p70 S6K activity in CCL39 cells, similar to that observed with an active
Raf construct. However, Raf-mediated activation of p70 S6K activity was not
reduced by co-expression of a dominant negative ERK1 or MKP-1. The authors
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suggested that stimulation of p70 S6K activity by Raf was independent of ERK1/2
activation and that the effect of active MEK was due to the triggering of an autocrine
loop subsequent to the persistent activation of the ERK1/2 cascade (Lenormand et
al., 1996). The large increase in ERK1/2 phosphorylation observed in MEK1-DD
transfected cells (Figure 5.5) is consistent with previous use of active MEK
constructs, Mansour et al. (1994) observed an 85-fold increase in ERK2
phosphorylation by an active MEK1 construct (Mansour et al., 1994). MEK1 is
highly specific for ERK1/2 and has not been shown to phosphorylate any other
member of the MAP kinase superfamily (Dhanasekaran and Premkumar, 1998).
Expression of an active MEK1 in HEK 293 and COS cells resulted in the
hyperphosphorylation of Raf and an increase in Raf kinase activity (Zimmermann et
al., 1997). The ability of MEK1 to stimulate Raf activity in cells could explain the
ability of MEK1-DD to suppress integrins. Preliminary experiments in a.p-py cells
show that MEK1-DD can indeed stimulate endogenous Raf activity. The kinase
responsible for Raf phosphorylation downstream of MEK remains to be identified,
although phosphorylation was shown to be independent of Src activity (Zimmermann
et al., 1997).
The wildtype ERK2-MEK1 fusion protein expressed in HEK 293 cells caused an
increase in MBP phosphorylation and induced Elk-1 dependent transcription
(Robinson et al., 1998). This ability of wildtype ERK2-MEK1 to phosphorylate
MBP was reproduced in ap-py cells, suggesting that this construct is constitutively
active in a.p-py transfected cells. Endogenous ERK, upon activation by MEK
translocates to the nucleus (Chen et al., 1992; Lenormand et al., 1993; Sanghera et
al., 1992) where it is known to phosphorylate several transcription factors (Su and
Karin, 1996). The majority of wildtype ERK2-MEK1 however remains in the
cytoplasm due to a leucine-rich nuclear export sequence in MEK1, mutation of these
residues to alanine increases localisation of this protein into the nucleus (Robinson et
al., 1998). This nuclear localised ERK2-MEK1 was not used in these experiments as
it is proposed that Ras G12V-mediated integrin suppression does not require de novo
transcription or translation and that cytoplasmic signalling downstream of Ras is
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sufficient for integrin suppression (Hughes et al., 1997). Cytoplasmic ERK1/2 can
phosphorylate cytoplasmic substrates; p90RSK activation by ERK (Sturgill et al.,
1988) allows its translocation into the nucleus where it too stimulates several
transcription factors (Chen et al., 1992; Chen et al., 1993). Cytoplasmic
phospholipase A2 (cPLA2) (Lin et al., 1993; Nemenoff et al., 1993) and myosin
light chain kinase (MLCK) (Morrison et al., 1996) are also activated by ERK1/2
phosphorylation. Both cPLA2 and MLCK are potential candidates as effectors
modulating integrin affinity. Production of arachidonic acid by cPLA2 (Kramer and
Sharp, 1997) is required for oqibP3 activation in platelets (Shattil and Brass, 1987),
MLCK modulates actin-myosin contraction (Kamm and Stull, 2001) and changes
within the cytoskeleton may affect integrin affinity. Cytochalasin D, an inhibitor of
actin polymerisation, produced a modest increase in oqibP3 affinity in platelets
(Bennett et al., 1999).
The inability of the constitutively active ERK2 to mediate integrin suppression
suggests that ERK 1/2 and its effectors, including cytosolic phospholipase A2
(cPLA2), myosin light chain kinase (MLCK) and p90 are probably not involved in
integrin affinity modulation (Klemke et al., 1997; Milella et al., 1997; Sturgill et al.,
1988). While wildtype ERK2-MEK1 is sufficient for MBP phosphorylation (Figure
5.7) and increase transcription (Robinson et al., 1998), the presence of the fused
MEK1 protein may hinder interactions of ERK2 with its effectors. Wildtype ERK2-
MEK can phosphorylate p90RSK, although phosphorylation of cPLA2 and MLCK has
not been shown (Robinson et al., 1998). As such, a role for cPLA2 and MLCK
activation cannot be ruled out until inhibitor studies are performed e.g. MAFP
(cPLA2 inhibitor) (Lio et al., 1996) and ML-9 (MLCK inhibitor) (Saitoh et al.,
1986). However, the inability of active ERK2 to suppress integrins does fit with the
premise that Ras and Raf-mediated suppression is independent ofERK 1/2 activation.
A described in chapter 3, MKP-1 is a broad spectrum phosphatase, that is known to
act on ERK1/2, JNK and p38 MAP kinase (Chu et al., 1996). The ability of MKP-1
to reverse integrin suppression by Ras-BxB T481A (Figure 5.10) suggests that a
member of the MAP kinase superfamily can mediate integrin suppression. The data
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within this thesis indicates that this MAP kinase is not ERK1 or ERK2. Co-
expression ofMKP-3 (Pystl) and Raf-BxB T481A produced similar results to that of
MKP-1 (preliminary data). MKP-3 preferentially dephosphorylates MAP kinases
with the TEY phosphorylation motif present in ERK1/2, with very low activity
toward JNK (TPY) and p38 MAP kinase (TGY) (Groom et al., 1996; Muda et al.,
1996). The increased specificity of MKP-3 indicates that a MAP kinase with a TEY
motif i.e. an ERK family member is downstream of the Raf effector pathway that
mediated integrin suppression. Possible candidate ERKs includes ERK5 and p97
ERK5-related protein.
ERK5 a protein approximately twice the size of the other ERK proteins (Lee et al.,
1995b; Zhou et al., 1995) has shown kinase activity in response to activated Ras and
Raf (English et al., 1999). MEK5 the upstream activator of ERK5 can associate with
Raf and activated Raf to a greater extent, however direct activation ofMEK5 by Raf
has not been shown (English et al., 1995). Both MKP-1 and MKP-3 are able to
dephosphorylate ERK5. However, the ability of PD098059 and U0126 to inhibit
ERK5 phosphorylation by acting upon MEK5 argues against a possible role ofERK5
in Raf-mediated integrin suppression (Kamakura et al., 1999).
Janulis et al. (2001) have recently identified a novel p97 ERK5-related protein by
affinity purification. This protein associates with and was activated by Raf, but the
MEK inhibitors PD098059 and U0126 did not inhibit activation of p97 (Janulis et
al., 2001). Cross-reaction of phospho-specific ERK5 antibodies with phosphorylated
p97 suggests that the activation loop TEY motifmay be present in p97 and therefore
susceptible to dephosphorylation by MKP-1 and MKP-3 action. Of the remaining
identified ERK proteins, none have been reported to interact with Raf.
A constitutively active form of R-Ras has been shown to reverse Ras G12V-
mediated integrin suppression (Sethi et al., 1999) and that of the Ras G12V effector
mutants (Figure 4.11). R-Ras G38V can also reverse integrin suppression by Raf-
BxB CAAX and Raf-BxB T481A (Figure 5.12). The mechanism of R-Ras reversal is
currently unclear; Sethi et al. (1999) have proposed that R-Ras signals may act at a
point downstream of ERK 1/2. The ability of R-Ras G38V to reverse Raf-BxB
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T481A-mediated suppression suggests that the novel Raf effector pathway is also
sensitive to R-Ras signalling.
GTP loaded R-Ras can bind to Raf-1, however Raf activity is not increased by R-Ras
(Marte et al., 1997). This is reflected in the inability of R-Ras G38V to affect
ERK1/2 phosphorylation in transfected cells (Sethi et al., 1999) and (Figure 5.11).
As the two Raf constructs used here lack the N-terminal Ras binding domains and
thus cannot bind to R-Ras. Reversal of Raf-mediated integrin suppression therefore
cannot be attributed to R-Ras sequestering Raf away from its effectors. Until
effectors of R-Ras and Raf-BxB T481A are identified the mechanism by integrin
suppression is reversed remains undetermined.
In summary it has been shown that integrin suppression by a Raf-BxB mutant can
occur in the absence of ERK1/2 activation. Suppression is sensitive to co-expression
of MKP-1 but does not occur in the presence of a constitutively active ERK2.
Signalling by a novel Raf effector other than MEK may be responsible in activating
an ERK-like kinase that mediates integrin suppression by Raf-BxB T481A.
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RESULTS: CHAPTER 6
Search for Novel Integrin Affinity Modulators
6.1 Introduction
Ras-mediated integrin suppression appears to utilise several effector pathways. The
precise association between effectors and integrins is currently unclear. Several
proteins have been identified that can bind integrin cytoplasmic tails (reviewed in
Liu 2000), only cytohesinl however, has been shown to link P2 integrin affinity and
the Ras effector, PI3-kinase (Nagel et al., 1998).
Model organisms have often been used to study complex biological processes. The
power ofDrosophila genetics has allowed rapid identification of loci associated with
integrin-mediated adhesion. Currently, 5a and 2p subunits have been identified in
Drosophila; mutations in which reveal that integrins are required for both embryonic
and larval development. Several phenotypes are observed with integrin mutations,
including defects in muscle contraction and attachment to the epidermis, gut
morphogenesis and epithelial cell layer adhesion (reviewed in Brown 2000).
Deletion of the anb cytoplasmic tail generates a constitutively active integrin capable
of binding PAC1 in CHO cells (O'Toole et al., 1991). A similar deletion of the
cytoplasmic domain of the aPS2 subunit produced abnormal and delocalised muscle
attachments. Muscle attachment to the epidermis is normally restricted to the muscle
end and mediated by the aps2Pps integrin. Integrin activation, (normally restricted to
the muscle tip) is hypothesised to mediate these ectopic attachments. Modulation of
drosophila integrin affinity may therefore play an important role during development
(Martin-Bermudo et al., 1998).
The wing blister phenotype is associated with a loss of integrin-mediated adhesion
between merging epidermal layers. Genetic screens performed by Prout et al. (1997)
and Walsh et al. (1998) have identified several novel loci required for integrin
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adhesion (Prout et al., 1997; Walsh and Brown, 1998). In collaboration with Dr. N.
Brown (Cambridge, UK) we have obtained genes encoding cassowary (Cass) and
Auk. Neither gene altered integrin expression level and sequence information
suggests that they are both cytoplasmic proteins. It can be speculated that these
proteins may have a role in affinity modulation.
Expression cloning screening strategies have been successful in identifying proteins
that modulate integrin affinity. CD98 can reverse trans-dominant suppression by pi
tails while PEA-15 can reverse Ras G12V-mediated integrin suppression (Fenczik et
al., 1997; Ramos et al., 1998). Small cell lung cancer (SCLC) is a highly metastatic
tumour and in vitro, cells grow as free floating aggregates. Suppression of integrin
affinity may explain the in vitro growth characteristics of these cells. To date,
oncogenic Ras mutations have not been identified in SCLC tumours and therefore a
novel effector may mediate integrin suppression in these cells (Suzuki et al., 1990).
The aim of this part of the study was to use alternative methods to identify proteins
involved in integrin affinity modulation.
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6.2 Cloning of Drosophila genes into a mammalian
expression vector
The drosophila genes encoding Cassowary (Cass) and Auk have been implicated in
integrin-mediated adhesion between the dorsal and ventral layers of the adult wing
(Walsh and Brown, 1998). To determine whether they play a role in modulating
affinity of drosophila integrins, we sought to express these genes in aP-py cells.
6.2.1 High fidelity PCR of Cass and Auk
Both drosophila genes provided by Dr. N. Brown (Cambridge, UK) were cloned into
vectors unsuitable for mammalian cell expression. Cass was cloned in the Bluescript
cloning vector and Auk in the pWRhpA drosophila vector. In order to clone these
genes into a suitable mammalian expression vector, high fidelity PCR was performed
using Stratagene's Pfu Turbo DNA polymerase. Primers were designed to
incorporate unique restriction sites in order to facilitate subsequent sub-cloning steps.
PCR cycle conditions were optimised as described in Materials and Methods and
PCR products were amplified as shown in Figure 6.1. The Cass gene was amplified
as a 1.6kb product (Figure 6.1A) and the Auk gene as a 2.6kb product (Figure 6.IB).
No PCR products were observed in reactions performed in the absence of template
DNA in both Cass and Auk PCR reactions.
6.2.2 Cloning of genes into the pCMV-Tag3B expression vector
Ethanol precipitated PCR products were subjected to poly-A tail reactions and cloned
into a pGEMT vector using the Promega Rapid ligation kit. Ligations were
transformed into competent DH5a E.coli and screened by blue/white selection.
Figure 6.2 shows restriction digests of ligations with appropriate restriction enzymes
of amplified DNA from white colonies on the ligation plates. Clones that contained
inserts of the correct size were subjected to automated fluorescence sequencing.
DNA sequencing showed that Cass clone 14 and Auk clone 13 contained inserts with
identical DNA sequence to that of template DNA.
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Figure 6.1 High fidelity PCR of the drosophila genes, cass and auk.
High fidelity PCR was performed on 25ng of template DNA for (A) cass and (B)
auk. The negative control PCRs contained no template DNA. PCR products (5pl)
were resolved on 1% agarose gels.
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Figure 6.2 Restriction digest of cass and auk ligations into the pGEMT T-vector.
Mini-prepped DNA from (A) cass ligations (1-15) were digested with BamHl and
Hind III and (B) auk ligations (1-15) were digested with EcoRI and Hind III
restriction enzymes and resolved on a 1% agarose gel against a lkb DNA ladder. The
white markers indicate the 3kb pGEMT vector and the cass/auk inserts.
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Inserts from Cass-14 and Auk-13 clones were subsequently sub-cloned into the
mammalian expression vector pCMV-Tag3B. Figure 6.3 shows restriction digests of
amplified DNA from colonies from the ligation plates. The Cass ligation reaction
only produced one colony, however, this was positive for the insert. This single Cass
clone and Auk clone 4 were amplified and used in subsequent expression studies.
6.2.3 Expression of Cass and Auk in a(3-py cells
The pCMV-Tag3B expression vector contains a N-terminal myc epitope such that
fusion proteins can be detected with the anti-myc (9E10) antibody. Cells transfected
with Cass or Auk-3B expression vector were lysed and cell lysates were resolved by
10% SDS-PAGE. Following western blotting Figure 6.4 shows that the nitrocellulose
membrane probed with the anti-myc antibody detected expression of both Cass and
Auk proteins. No expression was observed from the Tag-3B control vector
transfected cells. The myc-tagged Cass protein was expressed as a single 62kDa
protein, while Auk was detected with an electrophoretic mobility of approximately
115kDa. Both myc-tagged proteins were also detected with a second anti-myc (A14)
antibody. Utilising the Compute Mw tool on the ExPasy proteomics server at the
Swiss Institute of Bio-informatics the predicted molecular weight of myc-tagged
Cass and Auk was determined. Predicted molecular weights were 60kDa and 96kDa
for myc-Cass and myc-Auk respectively.
6.2.4 Cellular localisation of Cass and Auk proteins
The presence of the myc-tag on the proteins allowed immuno-fluorescence to be
performed on transfected cells. Cells were grown on glass coverslips and transfected
with Cass-3B, Auk-3B or empty vector DNA. After 48h, the coverslips were stained
with the anti-myc (9E10) antibody and visualised by fluorescence microscopy.
Phase microscopy of cells transfected with Cass-3B or Auk-3B DNA showed cells
with similar morphology to that observed with the empty vector control (Figure 6.5).
Cells displayed the flat spread morphology observed with untransfected cells or cells
transfected with the control vector.
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Figure 6.3 Restriction digest of cass/auk ligations into the pCMV-Tag3B
expression vector.
Mini-prepped DNA from (A) cass ligations were digested with BamHl/Hind III and
(B) auk ligations with EcoRI/Hind III restriction enzymes and resolved on a 1%
agarose gel against a lkb DNA ladder. The markers indicate the 4.3kb pCMV-Tag3B
vector and the cass/auk inserts.
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Figure 6.4 Expression of Cass/Auk in aP-py cells.
Cells were transfected with either Cass-3B, Auk-3B expression vectors or 3B control
vector (lpg). Western blots of cell lysates were probed with the anti-myc (9E10)
antibody. The blots shown are representative of 3 experiments.
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Fluorescence microscopy of empty vector transfected cells showed no staining with
the anti-myc antibody. Cells transfected with Cass-3B showed a high level of Cass
expression in a highly localised area. Merging both phase and fluorescence
microscopy images of the cells showed that expression appeared to be localised
within the nucleus of the transfected cells. Expression of the Cass protein was not
observed outside the nucleus. In contrast, the Auk protein was expressed at a low
level in a[3-py cells and expression was diffuse within the cell, furthermore the
merged image did not show expression to be localised to a specific area of the cell.
6.3 Effect of Cass expression on integrin affinity
6.3.1 Cass does not suppress integrins
The Cass protein was shown to be expressed in aP-py cells both by western analysis
and by immuno-fluorescence. Figure 6.6A shows that expression of the Cass protein
was optimal with transfection of lpg of Cass-3B DNA, transfection with DNA
quantity above lpg resulted in lower expression which may be due to sub-optimal
DNA/lipid ratios. The decrease in expression with increasing Cass-3B DNA was not
due to DNA quantity, as all transfections were adjusted to 5 jug of total DNA with the
empty control vector.
Cells transfected with Cass-3B DNA were also assessed for integrin affinity
modulation by flow cytometry. Figure 6.6B shows that transfection of increasing
Cass-3B DNA into aP-py cells did not cause any significant change (P>0.05) in
integrin affinity compared to the empty 3B control vector. Cells transfected with Ras
G12V DNA produced a characteristic loss in PAC1 antibody binding with an
inhibition of 61.4 ± 2.9%.
6.3.2 Cass cannot reverse Ras G12V-mediated integrin suppression
Transfection of Cass-3B DNA into aP-py cells did not significantly affect integrin
affinity. It was shown that R-Ras G38V is capable of reversing Ras G12V-mediated
integrin suppression, however transfection of R-Ras G38V DNA alone does not
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Figure 6.5 Immunofluorescence of cass/auk expression.
Cells transfected with Cass, Auk or empty vector (lpg) were permeabilised and
stained with the anti-myc (9E10) antibody with an Alexa-green 488 secondary
antibody. Panels show a phase contrast image (left) a fluorescence image (middle),
and a merged image of the cells (right). Scale bar represents 100pm.









aO/ Q7 & cass (pg DNA)
1
% '%°/ cass ^9 DNA)
Figure 6.6 Effect of Cass expression on integrin affinity.
(A) Lysates from cells transfected with increasing cass DNA were probed with the
anti-myc (9E10) antibody. Total DNA quantity was adjusted to 5pg in all
transfections with the empty 3B control vector. The western blots shown are
representative of 3 experiments. (B) Integrin affinity was determined in cells Ras
G12V (lpg) was transfected as a positive control for suppression. Percentage
inhibition was calculated in reference to cells transfected with control vector. The
results shown are the mean ± SEM of three independent experiments. Statistical
analysis was performed by one-way ANOVA test.
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significantly affect affinity modulation (Figure 4.11). We therefore sought to
determine whether Cass-3B expression could affect integrin suppression by Ras
G12V.
Cass-3B was co-transfected with Ras G12V DNA in aP-py cells and expression of
both proteins were analysed by western blots (Figure 6.8). Cass was expressed as a
62kDa protein at similar levels in both control and Ras G12V co-transfectants
(Figure 6.7A). A decrease in Ras G12V expression was observed in co-transfections
with either the control 3B vector or Cass-3B vector. In the presence of Cass-3B
DNA, expression of Ras G12V was reduced compared to that in the presence of
control 3B vector (Figure 6.7B).
Figure 6.7C shows that the reduction in Ras G12V expression in co-transfections
with the control 3B vector did not affect integrin suppression (67.6 ± 1.3% and 66.9
± 2.4% respectively). As with previous experiments Cass expression did not affect
integrin affinity, however in co-transfections with Ras G12V a slight reduction in
integrin suppression was observed (55.0 ± 3.3%), this difference was statistically
significant (P<0.05), however, the decrease in Ras G12V expression in these cells
may explain the fall in percentage inhibition.
6.4 Effect of Auk expression on integrin affinity
6.4.1 Auk expression does not affect integrin affinity
Similar to the experiments performed with Cass, Auk-3B was transfected into a(3-py
and both expression and integrin affinity were determined. Figure 6.8A shows that
the Auk protein was expressed in ap-py cells. Expression was detected with the anti-
myc (A 14) antibody rather than the 9E10 clone. Results with the A14 antibody were
more robust than with the 9E10 antibody. Transfection with 2pg of Auk-3B gave a
marginal increase in expression to that observed with 1 pg.
While Ras G12V suppressed integrins in transfected a,p-py cells (66.2 ± 1.3%), Auk
did not affect integrin affinity compared to the empty 3B vector (Figure 6.8B).
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Figure 6.7 Effect of co-expression of cass on Ras G12V mediated integrin
suppression.
Lysates from cells co-transfected with Ras G12V (lpg) and cass (lpg) or empty 3B
vector (lpg) were probed with (A) anti-myc (9E10) antibody or (B) anti-Ha
antibody. The blots shown are representative of 3 experiments. (C) Integrin affinity
was determined in transfected cells. Percentage inhibition was calculated in reference
to control vector. The results shown are the mean ± SEM of three independent
experiments. Statistical analysis was performed by one-way ANOVA test, asterisk
indicates significant difference (P<0.05).
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Figure 6.8 Effect of auk expression on integrin affinity.
(A) Lysates from cells transfected with increasing auk DNA were probed with the
anti-myc (A14) antibody. Total DNA was adjusted to 2pg with the empty 3B control
vector. The blots shown are representative of 3 experiments. (B) Integrin affinity was
determined in cells transfected with increasing auk DNA. Ras G12V (1 pig) was
transfected as a positive control for suppression. Percentage inhibition was calculated
in reference to control vector. The results shown are the mean ± SEM of three
independent experiments. Statistical analysis was performed by one-way ANOVA
test.
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Transfection of Auk (2jug) suppressed integrins by 8.8 ± 6.4% compared to 7.2 ±
5.2% for control 3B vector (2pg). Transfection of Auk DNA did not significantly
increase (P>0.05) percentage inhibition.
6.4.2 Auk expression does not affect Ras G12V-mediated
suppression
The effect of Auk expression on Ras G12V-mediated integrin suppression was
determined in co-transfections between Auk and Ras. Figure 6.9A shows that Auk
was expressed in co-transfections containing either control or Ras G12V DNA.
Similar to the observations with Cass and Ras co-transfections, Ras G12V expression
was reduced in the presence of control 3B DNA (Figure 6.9B). A further decrease in
expression was not observed with Auk-3B co-transfections.
Co-transfection of either control 3B or Auk-3B with Ras G12V DNA did not affect
integrin suppression mediated by Ras G12V. Figure 6.9C shows that the percentage
inhibition in the presence of Ras G12V/control 3B was 59.4 ± 4.6 compared to 56.6
± 5.6 when Auk-3B was co-transfected. The difference in percentage inhibition
between Ras G12V transfected cells co-expressing Auk and control 3B vector were
not significantly different (P>0.05). These results suggest that the Auk protein does
not modulate the affinity of either the native chimeric integrin or the Ras G12V
suppressed integrin.
6.5 Genetic screen of a SCLC cDNA expression library
In an attempt to identify novel components of the inside-out pathway involved in
integrin affinity modulation a genetic strategy was adopted. Fenczik et al. (1997)
have successfully used this strategy to identify CD98 from a CHO-K1 cDNA library
that was able to reverse pi tail integrin suppression. Ramos et al. (1998) showed that
PEA-15 from a CHO-K1 cDNA library was able to reverse Ras G12V-mediated
integrin suppression. A small cell lung carcinoma (SCLC) cDNA expression library
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Figure 6.9 Effect of co-expression of auk on Ras G12V mediated integrin
suppression.
Lysates from cells co-transfected with Ras G12V (lpg) and Auk (2pg) or empty
vector (2pg) were probed with (A) anti-myc (A 14) antibody or (B) anti-Ha antibody.
The western blots shown are representative of 3 experiments. (C) Integrin affinity
was determined in co-transfected cells. Percentage inhibition was calculated in
reference to control vector. The results shown are the mean ± SEM of three
independent experiments. Statistical analysis was performed by one-way ANOVA
test.
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(H33) was obtained from the MRC Human Genome Mapping Project and used to
screen for genes capable of integrin suppression.
The library was amplified in commercially competent TOP10/P3 E.Coli (Invitrogen)
in order to maximise the number of clones recovered. The cDNA library cloned in a
pCDM8 expression vector contains a CMV promoter and polyoma T antigen origin
of replication to facilitate autosomal replication in the ap-py cells. Figure 6.10 shows
an Xhol restriction digest of the SCLC library and pCDM8 empty vector. The Xhol
restriction site flanks the insert cloning site and digestion of the pCDM8 vector
produced a band of 4.0kb. Digests of the SCLC library showed the pCDM8
backbone at 4.0kb together with two major bands at 2.5kb and 12.0kb. A DNA smear
was also observed stretching from this 12.0kb band to approximately 500bp. A
similar restriction pattern was also observed with digestion of a macrophage cDNA
library with the Xhol enzyme.
6.5.1 Screening of the SCLC library transfected cells
Preliminary experiments were performed to titrate both antibody dilutions and DNA
quantities for the large number of cells used during the cell sort. Topro3 used for cell
viability staining during affinity determination experiments was replaced with the 7-
AAD viability stain due to the absence of an FL-4 channel on the cell sorter. Test
sorts were performed with Ras G12V a known suppressor of integrin affinity to
optimise both the cell sorting instrument settings (PMT voltages, compensation and
sort gates) and to validate the HIRT extraction protocol to rescue transfected
plasmids. From these tests sorts we were able to obtain colonies from the sort gate
that were transfected with Ras G12V DNA.
Cells transfected with the SCLC cDNA library were sorted according to the previous
test experiments. Using Ras G12V transfected cells as a positive control, the sort gate
contained a large number of cells with reduced PAC1 binding compared to the
pCDM8 control vector (Figure 6.11). Cells transfected with the library displayed a
similar profile as that observed with the pCDM8 control vector. As a result of the
large number of cells used in the sorting process, only a fraction of the analysed cells
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Figure 6.10 Digest of H33 SCLC cDNA expression library.
H33 SCLC expression library DNA (lpg) was digested with 10 units Xhol
restriction enzyme; the empty pCDM8 vector (50ng) was also digested. Digests were
resolved on a 1% agarose gel containing ethidium bromide.
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Control Ras G12V Library
PAC1 Binding
Figure 6.11 Expression of H33 SCLC cDNA library in aP-py cells.
Cells were transfected with pCDM8 control vector (4pg), Ras G12V (2pg) or H33
SCLC library (4pg). After 48 hours, cells were stained for Tac expression and PAC1
binding. Tac positive cells are shown in red and the sort gate in the upper left
quadrant represents cells that were collected by the cell sorter.
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H33 Library Sort Pools
Figure 6.12 Screen of library pools for effects on integrin affinity.
Integrin affinity was determined in cells transfected with DNA (4ju.g) isolated from
library pools. Each pool contained transformed bacterial cultures from 10 separate
colonies from the initial H33 library sort. The results represent data accumulated
from 6 separate experiments with percentage inhibition calculated in reference to the
pCDM8 empty vector.
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are shown in this dot blot. Hirt extraction was performed on the cells collected from
the sort to extract the transfected plasmids within these cells. Plasmid DNA was
digested with the Dpnl restriction enzyme prior to transformation of TOP10/P3
E.Coli.
One hundred and fifty three colonies were obtained during this transformation. These
colonies were cultured and used to generate screening pools. Individual cultures were
pooled into groups of 10 and amplified to enable plasmid purification. DNA pools A-
O were transfected into aP-py cells and their effect on integrin affinity was
determined (Figure 6.12). In reference to the pCDM8 control vector, DNA pools A-
O did not significantly alter the integrin affinity of the chimeric integrin. Cells were
responsive to suppressive signals as Ras G12V was able to reduce PAC1 binding in
all the screening experiments.
The expression cloning strategy has previously been successful in identifying novel
components of integrin affinity modulation. In our hands, the screen failed to identify
genes from the SCLC library that may be involved in integrin suppression.
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6.6 Discussion
In this chapter we have cloned and expressed two drosophila genes identified from a
genetic screen in a.p-py cells. Proteins, cassowary and auk failed to modulate the
affinity of the native chimeric integrin and were not capable of reversing Ras G12V-
mediated integrin affinity. Screening of a SCLC cDNA expression library also failed
to identify genes involved in integrin suppression.
Integrins and integrin-mediated adhesion have been shown to be crucial for
drosophila development (Brown, 2000; Gotwals et al., 1994). Genetic screens in
drosophila have identified several novel mutants that display the blistered wing
phenotypes associated with a loss of integrin-mediated adhesion (Prout et al., 1997;
Walsh and Brown, 1998). Several of these mutants have been identified and cloned
including cass, auk and kakapo. Kakapo encodes a cytoskeletal adapter protein
related to plectin or dystrophin. The protein appears to be required to maintain
epidermal adhesion to the muscle through interactions with integrins and the actin
and microtubule cytoskeleton (Gregory and Brown, 1998). Unlike kakapo, sequence
analysis of cass and auk failed to identify any significant regions of interest towards
integrin-mediated adhesion.
Cass and auk were both expressed in ap-py cells as 62 and 115kDa proteins. The
size of the cass protein was comparable to the predicted mass of myc-tagged cass
(60kDa). A 20kDa discrepancy was observed between the predicted weight of auk
(96kDa) and that observed in transfected ap-py cells. The size discrepancy may
reflect post-translational modifications, approximately seven O-GlcNac
glycosylation sites were predicted to exist on the auk protein.
Expression of Cass or Auk failed to effect integrin affinity. The localisation of Cass
to the nucleus may explain the inability of Cass to interact with the inside-out
signalling pathway. The same explanation cannot be used for Auk as it appears to be
expressed diffusely throughout the cell.
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Sequence analysis of Cass revealed that orthologues exist in several species
including humans called anti-apoptosis clone 11 (AAC-11). A truncated form of
AAC-11 (lkb) was initially identified by its ability to protect fibroblast from growth
factor withdrawal induced apoptosis, full length AAC-11 did not protect against
apoptosis (Tewari et al., 1997). AAC-11 contains a C-terminal leucine zipper motif
but lacks a DNA-binding domain that appears to be required for the anti-apoptotic
effects. The leucine zipper motif is not well conserved in the Cass sequence. The role
of Cass in drosophila cell apoptosis is currently being investigated by Dr. N. Brown
(Cambridge). AAC-11 has also been shown to be up-regulated in metastatic cervical
tissue compared to normal tissue. Over-expression of AAC-11 in cervical cell lines
altered matrix metalloproteinase (MMP) expression, increased soft agar colony
formation, invasion into matrigel and increased cell adhesion to laminin (Kim et al.,
2000). The ability ofAAC-11 to alter MMP expression may reflect a role of AAC-11
in transcription regulation. The localisation of Cass to the cell nucleus in a.p-py cells
may explain the ability of AAC-11 to regulate gene expression. As the authors did
not examine integrin levels in transfected cells, AAC-11 may also alter integrin
expression levels. The chimeric integrin contains the cytoplasmic domain of the
(X6aPi laminin receptor. Cass did not affect the affinity of this integrin, therefore the
increase in adhesion to laminin may be through changes in integrin expression levels,
avidity changes or through other laminin receptors. AAC-11 has recently been shown
to be a marker of increased tumour aggressiveness in non-small cell lung cancer
patients (Sasaki et al., 2001). Cass/AAC-11 does not appear to have a direct role in
modulating integrin affinity, however its role in apoptosis and tumour biology merits
further study.
Auk has shown sequence similarity to proteins of the La family, a family of possible
RNA binding proteins. The RNA binding domain within these proteins is not
conserved in Auk indicating that Auk may not play a role in RNA binding. Neither
Cass or Auk genes have any recognisable protein kinase domains, protein interaction
domains (SH2/SH3) or lipid binding regions, their direct role in cell signalling is
therefore debatable. Their role in integrin-mediated adhesion may therefore rely on
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protein-protein interactions with other proteins. Several of the mutants identified in
the initial screen remain to be cloned; it will be interesting to determine whether
these proteins have any role in integrin affinity modulation.
An alternative approach to identify genes involved in affinity modulation was to
perform a genetic screen of a SCLC expression library. Unfortunately the screen
failed to identify any genes that could mediate integrin suppression. Only 150 clones
were obtained from the E.coli transformation by the Hirt plasmid extract. This was a
small number considering that 50,000 events were collected within the sort gate.
While event number does not exactly correlate with cell number, it does suggest that
a significant proportion of cells collected may not have contained any library
plasmid. The Dpnl digestion step also drastically reduces the number of colonies
obtained. The Dpnl restriction site requires DNA methylation; plasmids that have
replicated in the a,p-py cells lose this methylation and are therefore resistant to
digestion. This step removes plasmids that fail to replicate in aP-py cells including
the Tac-a.5 reporter construct and should reduce background noise within the screen.
If a large proportion of the collected cells contain plasmids that have not replicated
this may explain the small number of colonies recovered. To address these problems,
we can increase the sort gate to increase the number of cells collected or use other
expression libraries. A second screen is currently underway in the laboratory; a PMA
treated macrophage library is being screened for genes that can reverse Ras G12V
suppression. Increasing the sort gates, a greater number of colonies were obtained;
the colonies have been pooled and amplified. Screening of the pools by flow
cytometry is currently underway, positive pools have been identified and are under
further study (R. Buttery, University ofEdinburgh personal communication).
In summary we have cloned and expressed two drosophila genes into aP-py cells,
unfortunately these genes had no affect on integrin affinity. We have also performed
a genetic screen of a SCLC cDNA expression library. Screening of this library, did
not identify any genes that could suppress integrins.
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DISCUSSION: CHAPTER 7
Concluding Remarks and Future Work
Integrin affinity modulation is essential to the function of integrins. A
conformational change arises through intracellular signals acting upon the
cytoplasmic tails of integrins (Ginsberg et al., 1992). H-Ras (Ras G12V) can
suppress a constitutively active integrin in CHO cells (Hughes et al., 1997). The aim
of this thesis was to elucidate the mechanism of Ras G12V-mediated integrin
suppression.
Ras effector mutants revealed that suppression occurred through Raf-dependent, (Ras
(G12V, T35S)) and Raf-independent, (Ras (G12V, E37G)) pathways. Integrin
suppression by Ras (G12V, Y40C) is currently under further study. Figure 7.1 shows
the proposed mechanism of integrin suppression downstream of Ras signalling.
Activation of RalGEFs by Ras (G12V, E37G) was not responsible for suppression;
however, activation of Raf by Ras (G12V, T35S) did facilitate integrin suppression.
Stimulation of ERK1/2 activity by Raf signalling was not required for suppression,
as a constitutively active ERK2 failed to suppress integrins, while the Raf-BxB
T481A mutant mediated suppression in the absence of MEK activation. Sensitivity
of Raf-mediated integrin suppression to MKP-1 and MKP-3 expression implicated
an ERK-like protein with a TEY consensus sequence.
Both H-Ras and R-Ras can modulate integrin affinity. With identical effector
domains and a high degree of sequence identity adjacent to the effector domain
suggests that both H-Ras and R-Ras may share common effectors, although R-Ras
specific effectors that have yet to be identified may mediate unique R-Ras functions.
H-Ras has recently been localised to lipid-raft microdomains within the plasma
membrane (Prior et al., 2001), microdomain localisation of R-Ras has not been
reported. The hypervariable sequence of H-Ras was essential for targeting to the
lipid-rafts, K-Ras4B, which contains a polybasic lysine motif, was excluded from
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Figure 7.1 Proposed pathway of Ras G12V-mediated integrin suppression.
Ras G12V and Ras effectors mutants are shown in the black lined boxes. Red boxes
denote proteins that can mediate integrin suppression. The pink box indicates the
proposed ERK-like protein. For clarity, Ras effectors AF6, PKCC and MEKK1 have
not been shown. PD — PD098059 (MEK1 inhibitor).
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lipid-rafts and localised to the bulk plasma membrane. The differential microdomain
localisation of the Ras isoforms may contribute to the varying ability of the Ras
isoforms to activate Raf-1 and PI3-kinase (Voice et al., 1999; Yan et al., 1998). It
will be interesting to determine whether K-Ras4B is as potent as H-Ras in
modulating integrin affinity.
Substitution of the H-Ras hypervariable sequence with that of R-Ras drastically
reduced the transforming ability of this chimeric protein (Lowe et al., 1988). H-Ras
and R-Ras chimeras have also shown that sequences within the C-terminus are
important for specifying the unique effects on integrin affinity by H-Ras and R-Ras
(personal communications P. Hughes, Scripps Research Institute, USA and J. Love,
University of Edinburgh, UK). The chimeras have also revealed that H-Ras can
mediate integrin suppression in the absence of ERK1/2 activation in correlation with
data in this thesis. Membrane localisation of these chimeras may provide clues to
explain the unique properties ofH-Ras and R-Ras towards integrin affinity.
Hughes et al. (1997) have shown that activation of endogenous Ras with active Src
can mediate integrin suppression. Ras activation by growth factors has yet to be
described to modulate integrin affinity. One can speculate that integrin suppression is
a regulated cellular process and that Ras activition e.g. during cell cycle progression,
may not always correlate with integrin suppression. Whether spatial and temporal
Ras activation regulates the ability of Ras to mediate integrin suppression remains to
be determined.
Integrin suppression by the Raf-independent, Ras (G12V, E37G) pathway was not
blocked by a dominant negative Ral construct although Ral activity was completely
inhibited. Ras effectors phospholipase Ce and Rinl bind to Ras G12V and of the
three effector mutants, preferentially bind to Ras (G12V, E37G) (Han et al., 1997;
Kelley et al., 2001). Future work with Ras (G12V, E37G) must therefore take into
account these effector pathways in addition to RalGEFs.
The relevance of PLCs activation on integrin affinity could be determined both
pharmacologically and by gene expression studies. A PLC inhibitor, U-73122 has
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been shown to inhibit Ras G12V stimulated adhesion of a haematopoietic cell line to
fibronectin (Shibayama et al., 1999), whether this inhibitor is active towards PLCs
has not been determined. The Ras effector mutant Ras (Q61L, D38N) can
differentiate between activation of RalGEFs and PLCs (Kelley et al., 2001), a similar
mutation in the Ras G12V background would enable the significance of PLCs
activation to be determined, alternatively PLCs mutants that fail to interact with Ras
could be used. PLCs also contains a cdc25 homology domain (GEF activity) that can
activate Rapl; deletion of this region prevents Rapl activation (Jin et al., 2001) and
could be used to dissect a possible role ofPLCs towards integrin affinity.
The biological role of Rinl is currently unclear, isolated Ras binding domains (RBD)
of Rinl can inhibit Ras induced transcription, though this was not reproduced with
full length Rinl (Han et al., 1997). Rinl A, which lacks the RBD, would enable
activation of Rinl to be studied further.
Raf-dependent integrin suppression is independent of MEK and ERK1/2 activation.
The ability of MEK to mediate integrin suppression is a result of a feedback
activation of Raf (Zimmermann et al., 1997); MEK1-DD (active construct) can
increase Raf activity in ap-py cells (J. Love personal communication). A growing
body of evidence supports the existence ofMEK independent pathways downstream
of Raf and alternative Raf effectors (Chapter5). The ability ofMKP-1 (Chapter5) and
MKP-3 (preliminary results) to reverse Raf-mediated suppression indicates that a
TEY containing ERK protein may mediate suppression. Possible candidates include
ERK5 (English et al., 1999) and p97 ERK5-related protein (Janulis et al., 2001),
cloning of the latter is of particular interest as the characteristics of this protein
closely fit with the current data of Raf-mediated integrin suppression. Screening of
novel Raf phosphorylation targets may also provide an insight into the mechanism of
integrin suppression (W. Kolch, personal communication). An in-gel kinase assay
may enable the detection of the novel ERK activity stimulated by Raf-BxB T481A.
This thesis has concentrated on the mechanism underlying Ras G12V-mediated
integrin suppression. The cellular consequence of such integrin suppression, however
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remains to be answered. Ras expression can modulate integrin-dependent cellular
functions including fibronectin matrix assembly (Brenner et al., 2000), adhesion
(Shibayama et al., 1999) and migration (Voice et al., 1999). Cell morphology,
altered upon Ras effector mutant expression may partially correlate with integrin
suppression although cytoskeletal changes are also required (Chapter4). Fibronectin
matrix assembly was inhibited by Ras transformation (Brenner et al., 2000), whether
the Ras effector mutants E37G and T35S have a similar effect will be interesting to
determine. Voice et al. (1999) has shown that the Ras isoforms differ in their ability
to stimulate cell mobility (Voice et al., 1999) possibly due to differential stimulation
of Ras effector pathways; changes in effector pathway utilisation by the Ras effector
mutants may also modulate cell mobility. Mobility changes of transfected cells could
be assessed by both migration in Boyden chambers or via time-lapse microscopy
(LaFlamme et al., 1994). Cell migration across a matrix requires the transient
adhesion and de-adhesion of the cell at the leading and trailing edge respectively
(Lauffenburger and Horwitz, 1996). These changes are in part mediated by the
cycling of focal adhesions during cell migration (Petit and Thiery, 2000). Spatial
changes in integrin affinity between the leading edge and the trailing edge could be
assessed by confocal microscopy with the PAC1 antibody. Integrin suppression at
the trailing edge could allow retraction of the cell and similarity integrin activation at
the leading edge may provide the traction required for migration. Redistribution of
integrin affinity modulators may contribute to the spatial changes in integrin affinity,
confocal microscopy would show whether Ras proteins concentrate to the trailing
edge of a cell during migration.
Ras G12V stimulates adhesion of haematopoietic cells to fibronectin through
activation of Pi integrins; this contradicts the ability of Ras G12V to suppress
integrins in ap-py cells. The inability of Ras G12V to activate resting anbP3 in CHO
cells (Sethi et al., 1999), suggests that affinity modulation by Ras expression may
dependent on cell type and on the integrin affinity state. Adhesion of Ras G12V
transfected aP-py cells on fibrinogen (by chimeric integrin) would determine
whether Ras-mediated integrin suppression affects cell adhesion.
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This current study has furthered our understanding of Ras-mediated integrin
suppression; future work may allow the identification of potential targets for
therapeutic intervention. Such developments may allow the regulation of integrin-
dependent processes. Platelet aggregation could be modulated to prevent excessive
and damaging arterial obstructions, leucocyte infiltration could be restricted during
chronic inflammatory diseases and possibly reduce tumour metastasis by inhibiting
tumour cell detachment at the primary tumour mass.
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